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ABSTRACT 
 
Mitochondrial dysfunction, which is consistently observed in Down syndrome 
(DS), is suspected to worsen mental retardation and congenital cardiopathies in 
DS subjects, as well as to determine other phenotypic abnormalities, such as 
Alzheimer's disease, type 2 diabetes, obesity, and hypertrophic cardiopathy.  
As the heart is one of the main targets of DS, we have analyzed gene 
expression of DS fetal hearts demonstrating a global downregulation of nuclear 
encoded mitochondrial genes (NEMGs) together with the upregulation of 
clusters of extracellular matrix proteins (ECMs). A mitochondrial dysfunction 
was found associated with NEMG downregulation in DS fetal fibroblasts (DS-
HFFs).  
Based on these previous results, this doctorate thesis was aimed: 
• to identify Hsa21 genes responsible for either NEMG downregulation 
or ECM upregulation; 
• to develop strategies to counteract the negative effects triggered by 
NEMG dysregulation in DS; 
• to investigate how NEMG downregulation or ECM upregulation might 
affect cardiac phenotype. 
Performing a meta-analysis on public expression data we identified two genes 
mapping to chromosome 21 (Hsa21), namely NRIP1/ RIP140 (nuclear receptor 
interacting protein 1) and RUNX1 (Runt related transcription factor 1), as good 
candidates for NEMG downregulation and ECM upregulation, respectively. 
These genes are overexpressed in DS cells and in heart tissue.  
NRIP1 negatively regulates PGC-1α, a master regulator of the mitochondrial 
function. We attenuated by siRNA NRIP1 expression in a cell model of DS 
demonstrating an inverse correlation between NRIP1 and PGC-1α expression, 
together with an improvement of mitochondrial function in silenced cells. We 
therefore developed a strategy to correct mitochondrial alterations in DS by 
pharmacologically stimulating the activity of the NRIP1 targets PGC-1α and 
PPARs. To this aim we supplemented cultures of DS-HFFs with drugs 
affecting PGC-1α, namely Metformin and Pioglitazone, to evaluate their 
modulatory impact on mitochondrial function.  
We found both strategies effective in rescuing mitochondrial function in terms 
of oxigen consumption, ATP production and mitochondrial biogenesis. 
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1. INTRODUCTION 
 
 
1.1 The Down syndrome 
 
Down Syndrome (DS) is caused by a complete or partial trisomy of 
chromosome 21 (TS21) (Fig. 1). It occurs with an incidence of 1/700 newborns 
and it is characterized by a complex phenotype in which over 80 features occur 
with various degrees of expression and frequency (Epstein et al. 1991). 
Constant clinical features in DS subjects are: mental retardation, short stature 
and muscular hypotonia. Congenital cardiac defects (CHDs) are observed in ~ 
50% of cases. 
The life expectancy of DS subjects is less than 50-60 years. Starting from the 
age of 40 years DS subjects may suffer from Alzheimer’s Disease (AD) (Cork, 
1990). In addition diabetes, obesity and cardiac hypertrophy are important 
complications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 DS karyotype. The presence of three copies of chromosome 21 causes DS. 
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1.2 DS is a major cause of congenital heart defects 
 
DS is known to be a major cause of CHDs and the most frequent cause of 
atrioventricular septal defects (AVSDs) (Barlow et al. 2001). The most 
common CHDs in DS subjects are: atrioventricular canal defect (AVCD), 
ventricular septal defect (VSD) and tetralogy of Fallot (TOF) (Park et al. 
1977). Most of them derive from the abnormal development of the endocardial 
cushions (Ferencz et al. 1989; Park et al. 1977). Defects of the outflow tract are 
also frequent. The high CHD incidence in DS suggests that the overexpression 
of genes mapping on Hsa21 alters the normal development of the heart either 
directly or influencing the expression of genes mapping to other chromosomes. 
1.2.1 Down Syndrome Congenital Heart Disease Critical Region 
Despite a large amount of studies, the molecular alterations that cause the DS 
phenotype are still elusive. Several attempts to identify the Hsa21 genes that 
contribute to the DS phenotype have led to identify a Down Syndrome Critical 
Region (DSCR) which spans approximately 5.4 Mb in band 21q22.3 (Fig. 2) 
(Korenberg et al. 1994; Delabar et al. 1993; McCormick et al. 1989; Rahmani 
et al. 1989). The DSCR hypothesis predicts that a gene, or some genes, in this 
region are sufficient to produce the specific DS features when present in three 
copies. Testing this hypothesis in mice Olson et al. (2004) found that trisomy 
of DSCR alone is necessary but not sufficient for brain DS phenotypes in 
trisomic mice. These results suggest that the origins of trisomic phenotypes are 
even more complicated than formerly assumed and that they probably involve 
multiple gene interactions (Olson et al. 2007).  
Similar efforts have been made to identify a critical region for Down Syndrome 
Congenital Heart Disease (DS-CHD) by studying subjects with partial Hsa21 
trisomies (Fig. 2) (Korenberg et al. 1990) and mouse models (Fig. 3) (Liu et al. 
2014; Liu et al. 2011; Barlow et al. 2001), with conflicting results. 
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Fig. 2 DSCR (dark) (Korenberg et al. 1990);  DS-CHD (red) (Liu et al. 2011; Barlow et al. 
2001); new DS-CHD (green) (Liu et al.2011). 
 
1.2.2 CHDs in mouse models of DS 
Hsa21 presents high sequence omology of about 30 Mb with mouse 
chromosome 16, including part of DSCR. Other syntenic regions are localized 
on murine chromosomes 10 and 17. Many mouse models have been generated 
carrying three copies of Hsa21 syntenic regions of different sizes. Ts65Dn is 
the most widely used model from this group (Reeves et al. 1995). It is trisomic 
for ~13.4 Mb of the Hsa21 syntenic region on Mmu16, which contains 
approximately 99 orthologs of Hsa21 genes and exhibits some phenotypic 
features comparable to DS. Less than 8% of Ts65Dn mice develop septal 
defects, which increase their post-natal mortality (Moore, 2006). Unfortunately 
this mouse model is also trisomic for 5.8 Mb region on Mmu17, which is not 
syntenic to Hsa21 and may contribute to the cardiovascular phenotype (Liu et 
al. 2011).  
In another mouse model, Dp(16)1Yu/+, the trisomic region spans from 21q11 
band to 21q22.3 band thus including part of DS-CHD region. These transgenic 
mice develop congenital cardiopathy, atrioventricular septal defects including 
Tetralogy of Fallot and atrioventricular canal defect, with a similar percentage 
to that found in DS individuals (Li et al. 2007). 
Liu et al. (2011), using a model derived from the Dp(16), identified a 5.4 Mb 
genomic region associated to congenital heart defects similar to that observed 
in DS-CHD. This region spans from Tiam1 and Kcnj6 and includes 52 Hsa21 
8 
 
orthologs genes and one miRNA. More recently the authors further narrowed 
the region to 3.7 Mb (Liu et al. 2014). This region spans from Ifnar1 and Kcnj6 
and includes 35 Hsa21 orthologs genes (Fig. 3, model 8). The CHD frequency 
was lower than that observed in human DS subjects. 
Some models have been designed, carrying the entire Hsa21 or fragments of it 
(O’Doherty et al. 2005, Shinohara et al. 2001). The Tc1 model was obtained 
introducing into the mouse genome Hsa21 traits with only two small deletions 
including about 8% of Hsa21 genes. This mouse model shows craniofacial 
anomalies and cardiac alterations, typical of DS. The morphogenetic defects 
include ventricular and atrioventricular septal defect, that are due to an 
incomplete fusion of endocardial cushions (Dunlevy et al. 2010). The main 
problem of this model is that Hsa21 sequences are frequently lost during cell 
divisions producing a mosaic condition. 
 
 
 
Fig. 3 Synteny of different mouse models with Hsa21. Mouse models: 1, Dp(10)1Yey/+; Dp 
(16)1Yey/+; Dp(17)1Yey/+. 2, Dp(17)1Yey/+. 3, Dp(10)1Yey/+. 4, Dp (16)1Yey/+. 5, 
Ts65Dn. 6, Dp(16)2Yey/+. 7, Dp(16)3Yey/+. 8, Dp(16)4Yey/+. 9, Ts1Rhr (Liu et al. 2014) 
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1.3 Atrioventricular valve development during cardiogenesis 
 
In the vertebrate embryo, the heart is the first organ to become functional; its 
development starts at gastrulation with the formation of precardiac mesoderm 
(Fig. 4). Cells composing this middle embryonic germ layer then migrate 
anterolaterally to establish bilateral primary heart fields. The two heart fields 
eventually combine to form the cardiac crescent and, as the mesodermal cells 
differentiate into myocardial and endocardial progenitors, the primary heart 
tube (Abu-Issa and Kirby, 2007). The two poles of the linear tube soon receive 
contributions from a second cardiogenic population; this population of cells is 
termed the Second Heart Field (SHF) and its addition leads to pronounced 
elongation of the linear tube (Zaffran and Kelly, 2012; Snarr et al. 2007). 
The primary heart tube has an outer myocardial layer and an inner endocardial 
layer of cells separated by the cardiac jelly (Fig. 5) (Armstrong and Bischoff, 
2004). Cardiac jelly is composed primarily of proteoglycan 
glycosaminoglycans of which hyaluronan and chondroitin sulfates are the 
major components (Person et al. 2005).  
 
 
Fig. 4 Schematic representation of cardiogenesis. In the early steps of heart development, 
the precardiac mesodermal cells form two endothelial tubes, which join to form a primitive 
cardiac tube. As the cardiac tube extends, the primitive heart forms a loop. During the looping 
heart, atrioventricular valves and atrial and ventricular septa form. At last the heart with 4 
chambers forms.  
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Fig. 5 Schematic representation of the cardiac jelly. In the cardiac primitive tube, the 
cardiac jelly, an acellular and extracellular matrix-rich space, separates the outer myocardial 
layer and the inner endocardial layer of cells. 
 
 
After the heart tube begins rightward looping, the myocardium of specific 
regions of the primary heart tube, the atrioventricular (AV) junction and the 
ventricular outflow tract (OFT) upregulat secretion of ECM, which causes the 
cardiac jelly to swell into the lumen of the heart tube, forming primordial 
structures termed ‘‘endocardial cushions’’ (Combs and Yutzey, 2009; Person et 
al. 2005). Stimulated by local signals, a subset of AV and OFT endocardial 
cells loose cell–cell contact, resulting in their delamination into the cardiac 
jelly and their adoption of a migratory, mesenchymal-like phenotype. This 
phenotype is retained during the population of cardiac jelly of the AV and OFT 
cushions. The process whereby subsets of AV and OFT endocardial cells 
transform into a mesenchymal phenotype has been called an endocardial-to-
mesenchymal transition (EMT), which determines the anatomical placement 
where the valves will form within the primary heart tube. This EMT results in 
the mesenchymalization of the two major endocardial cushions of the AV 
canal: the superior (ventral) endocardial cushion that is associated with the 
inner curvature of the looped heart and the inferior (dorsal) endocardial 
cushion that forms along its outer curvature. The two major cushions then 
expand and eventually fuse, separating the heart into left and right AV orifices 
(Fig. 6). Following development of the major endocardial cushions, the lateral 
cushions appear later as lateral swellings of mesenchyme at the junction 
between the atria and ventricles (de Lange et al. 2004; Wessels et al. 1996). 
Each of the four cushions plays an important role in AV valvuloseptal 
development; the superior and inferior AV cushions contribute to the aortic 
leaflet of the mitral valve and the septal leaflet of the tricuspid valve. The 
lateral cushions also make significant contributions to the AV valves; the right 
lateral cushion contributes to the anterosuperior and inferior leaflets of the 
tricuspid while the left lateral cushion is involved in formation of the mural 
leaflet of the mitral valve (Snarr et al. 2008). 
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Fig. 6 Schematic representation of the atrioventricular canal from endocardial cushions 
 
 
1.4 Hsa21 genes are overexpressed in DS 
 
High-throughput technologies measuring thousands of transcripts in human DS 
cells (Conti et al. 2007; FitzPatrick et al. 2002) and in tissues from mouse 
models of DS (Dauphinot et al. 2005; Amano et al. 2004; Lyle et al. 2004; 
Kahlem et al. 2004) reported a global overexpression of triplicated genes in a 
dosage-dependent manner. Interestingly, these studies indicated that only a 
subset of Hsa21 genes is consistently overexpressed in comparision to euploid 
controls, and that the increase in expression may differ from the expected ~1.5 
fold (Conti et al. 2007; Mao et al. 2005; FitzPatrick et al. 2002). Also, the set 
of overexpressed Hsa21 genes differs across the trisomic cell types (Li et al. 
2006). These findings indicate that other factors (e. g. developmental stage, 
tissue specific differences) also affect gene expression (Sommer and Henrique 
Silva 2008). Hsa21 gene expression may be regulated by dosage compensation 
or other mechanisms such that only a subset of those genes is expressed at the 
expected 50% increased levels in agreement with the above hypothesis. 
It was hypothesized that, since Hsa21 encodes a number of transcription 
factors, coregulators and factors performing post-translational modification, 
including phosphorylation, dephosphorylation and sumoylation, the altered 
levels of these factors may contribute to the DS phenotype by perturbation of 
downstream gene expression (Gardiner et al. 2006). 
The immediate conclusion of all these studies is that Hsa21 trisomy causes an 
overexpression of Hsa21 genes as a primary dosage effect.  This produces, as 
secondary effect, the dysregulation of genes mapping on different 
chromosomes and as final effect the DS phenotype (Fig. 7). 
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Fig. 7 Primary and secondary effects of TS21. Three copies of Hsa21 may cause a 50% 
increase in the expression of trisomic genes as primary dosage effect. The dysregulation of 
Hsa21 genes may cause alteration of disomic gene expression as secondary effects. Both 
primary and secondary effects will finally result in developmental defects and phenotypic 
alterations. 
 
 
As the heart is one of the main DS targets, a gene expression profiling of fetal 
heart tissue by microarray technology was performed in 2007 (Conti et al. 
2007). This study analyzed 15 fetal hearts at 18-22 weeks of gestation divided 
into 3 groups: 5 DS with CHDs, 5 without CHDs and 5 euploid samples. The 
analysis demonstrated that Hsa21 genes were globally upregulated by ~1.5 fold 
and 441 genes, mapping to other chromosomes, were significantly 
dysregulated in trisomic heart samples (Fig. 8). Functional class scoring and 
gene set enrichment analyses of the differentially expressed genes, revealed a 
high prevalence of genes encoding mitochondrial enzymes (NEMGs) among 
downregulated genes, and genes encoding extracellular matrix (ECM) proteins 
among the overexpressed genes (Tab. S1 and S2, appendix 1). Indeed, 65 out 
of 600 NEMGs mainly involved in all the respiratory complexes and 
mitochondrial functions were downregulated and 40 out of 700 ECM genes 
were upregulated (Fig. 9). 
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Fig. 8 Volcano plot of differentially expressed genes between trisomic and non-trisomic 
hearts (Conti et al. 2007). 
 
14 
 
Fig. 9 Genes and gene pathways affected by Hsa21 trisomy. Pathway analysis was 
performed with Pathway Miner software on the 473 genes dysregulated in trisomic samples. 
The most affected pathways are: Oxidative Phosphorylation (cluster 1), containing 16 genes 
downregulated in trisomic samples, Focal Adhesion (cluster 2), containing at least 7 genes 
upregulated in trisomic samples, and a network of Cell Adhesion genes (cluster 2), 
upregulated in trisomic samples. Upregulated genes in clusters 2 and 3 are mostly ECM genes. 
Green indicates downregulated genes (darker green = more downregulated); red indicates 
upregulated genes (darker red = more upregulated) (Conti et al. 2007). 
 
 
 
1.5 Mitochondrial dysfunction is associated to DS 
 
TS21 has been associated to mitochondrial dysfunction in several DS cell types  
(Busciglio et al. 1995; Roat et al. 2007) and in mouse models (Shukkur et al. 
2006; Shuchman et al. 2000), suggesting that a mitochondrial dysfunction 
affects the DS phenotype. Data from functional studies suggest that TS21 alters 
the mitochondrial function (Gardiner, 2003).  DS has been associated to 
oxidative stress, increase of ROS production, altered intracellular calcium 
homeostasis, increase of apoptosis, decrease of protein level of complexes I, III 
and V in cerebellar and brain regions (Bambrick et al. 2008). Complex I was 
also deficient in mouse models of trisomy of chromosome 16. Impaired 
mitochondrial function, indicated by reduced mitochondrial redox activity and 
membrane potential, has been observed in DS astrocytes and in primary 
cultures of DS fibroblasts (Arbuzova et al. 2002; Busciglio et al. 2002). 
Deregulation of Ca2+ homeostasis and Ca2+ mediated signaling has been 
described in cells derived from DS patients and in mouse models of DS 
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(Yamato et al. 2009; Caviedes et al. 2006) since mitochondria function as a 
Ca2+ buffer. It has also been reported that the brain of the DS mouse model 
Ts1Cje has decreased mitochondrial membrane potential and ATP production 
(Shukkur et al. 2006). Recently it has been reported that both fetal and adult 
fibroblasts with TS21 show a drastic reduction in catalytic efficiency for the 
proteins involved in ATP production, such as increased levels of ANT (adenine 
nucleotide translocator), AK (adenylate kinase) and a drastic reduction in the 
catalytic efficiency respiratory chain complex I, which contributes to ROS 
overproduction in DS mitochondria (Valenti et al. 2010). These events were 
correlated with changes in the cAMP/PKA signaling pathway, which is known 
to affect the abundance of the transcriptional coactivator PGC-1α/PPARGC-1α 
(peroxisome proliferator activated receptor gamma coactivator 1α) (Valenti et 
al. 2011). A decrease in basal levels of cAMP has been reported also in the 
hippocampus of the mouse model of DS, Ts65Dn, due to the altered basal 
activity of adenylate cyclase (Siarey et al. 2006).  
Even though these results are indicative of widespread mitochondrial 
dysfunction in DS, few studies investigate the basis of mitochondrial 
dysfunction at the transcriptional level. Furthermore, no hypotheses have been 
formulated about the mechanisms by which trisomy of Hsa21 genes might 
induce such a dysfunction. 
Mitochondrial function was investigated also in human fetal fibroblasts with 
TS21 (DS-HFFs), in our laboratory (Piccoli et al. 2013). Oxygen consumption 
rate (OCR) was decreased in trisomic fibroblasts (Fig. 10A). Electron 
microscopy of trisomic fibroblasts revealed that a significant number of 
mitochondria had an abnormal morphology, showing an increased size, 
irregular shape, evident breaks, mainly of inner membranes. In addition, the 
mitochondria showed alterations in the pattern of cristae where some were 
broadened and arranged concentrically or oriented parallel to the long axis of 
the organelle (longitudinal cristae) (Fig. 10B). Finally confocal microscopy 
analysis of ROS production, showed a significative increase of ROS in 
fibroblasts with Ts21 (Fig. 10C). Beside the upregulation of Hsa21 genes and 
the downregulation of NEMGs, a significant mitochondrial dysfunction was 
found that was more severe in fibroblasts from cardiopathic trisomic fetuses 
(CDS-HFFs) when compared with controls. 
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Fig. 10 Mitochondrial function analysis in fibroblasts. A) OCRs normalized to cell number 
were assessed by high-resolution oxymetry in intact cells. A comparative analysis between five 
different euploid (N-HFFs) and eight different trisomic (DS-HFFs) samples is shown; a 
distinction of the DS-HFFs between non-cardiopathic (NCDS-HFFs, n = 4) and cardiopathic 
(CDS-HFFs, n = 4) fetuses-derived fibroblasts is also reported. The endogenous OCR were 
measured under resting conditions (OCRRR), in the presence of oligomycin (OCROL) and in the 
uncoupled state in the presence of FCCP (OCRUNC). B) Electron micrographs of normal 
mitochondria in N-HFF and morphologically abnormal mitochondria in DS-HFF 
(mitochondria with concentric cristae) C) Confocal microscopy analysis of ROS production in 
DS live fibroblasts. Representative LSCM imaging of the DCF-related fluorescence of euploid 
(N-HFFs) and DS (NCDS-HFFs and CDS-HFFs) fibroblasts (Piccoli et al. 2013). 
 
 
One possible interpretation of these results is that a more pronounced pro 
oxidative state could induce a more severe cardiac phenotype, a concept that 
could be extended to other phenotypic traits. This study, together with the 
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previously cited one (Conti et al. 2007), suggests that the dysregulation of 
NEMGs is probably the basis of mitochondrial dysfunction in DS.  
Mitochondrial alterations and oxidative stress are common features, also of 
neurodegenerative diseases, such as Alzheimer’s Disease (AD), Parkinson’s 
Disease and Huntington’s Disease. Development of the DS brain is associated 
with decreased neuronal number and abnormal neuronal differentiation, indeed 
adults showed that DS cortical neurons, as well as fibroblasts with DS, exhibit 
a three to four fold increase in intracellular ROS, that causes neuronal 
apoptosis (Busciglio et al. 1995) (Fig. 11). In addition both DS neurons and 
astrocytes showed an abnormal pattern of protein processing as for amyloid β 
precursor protein (APP), consistent with chronic energy deficits (Busciglio et 
al. 2002). In DS astrocytes and neuronal cultures there is also a substantial 
alteration of the mitochondrial morphology, which exhibits increased 
fragmentation (Helguera et al. 2012) and a reduced mitochondrial redox 
activity and membrane potential (Arbuzova et al. 2002; Busciglio et al. 2002). 
 
 
Fig. 11 NL and DS astrocytes labeled with MitoTracker Green and MitoSOX. 
Simultaneous staining allows the visualization of superoxide production (mtsox, red) in live-
cell mitochondria (mtgr, green) (Busciglio et al. 1995). 
 
 
Proteomic approach demonstrated a significant reduction of mitochondrial 
respiratory enzymes in different brain regions from patients with DS and AD 
(Kim et al. 2000).  
Further evidence for mitochondrial dysfunction was found in brain of the 
Ts1Cje (Sago et al. 1998), mouse model for DS, that shows decreased ATP 
levels, a decreased in mitochondrial membrane potential and an increased 
oxidative stress (Shukkur et al. 2006).  
The identification of a molecular basis responsible for the deficiency of the 
OXPHOS in DS cells could provide an explanation for some clinical 
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characteristics of the syndrome. Indeed, genetic defects involving nuclear or 
mitochondrial OXPHOS enzymes are characteristic of clinical manifestations, 
including developmental delay, hypotonia, ophthalmoplegia, muscle weakness 
and cardiomyopathy, clinical signs present, although with variable severity in 
subjects affected by DS (Epstein, 1995). Although all these data are indicative 
of widespread mitochondrial dysfunction, the cause of this aspect of the disease 
is still unclear and remains to be investigated whether and how the alterations 
in the pathways/biomolecules of mitochondrial energy metabolism are 
involved in the pathogenesis of the syndrome.  
1.5.1 Structure and function of mitochondria 
Mitochondria are intracellular organelles present in the cytoplasm of all 
eukaryotic cells. The overall volume of mitochondria is high in tissues and 
organs with high metabolic activity such as brain, retina, skeletal muscle, heart, 
kidney, and endocrine glands. The overall volume of mitochondria further 
increases in cells with enhanced energy demands, as in hyperactive skeletal 
muscle or in cardiac myocyte hypertrophy. Mitochondria are variable in size 
from 0.5 to 10 µm, with an average diameter approximately of 1 µm. The 
shape and number of these organelles are regulated by fission and fusion 
processes, which vary depending on the function of the cell and tissue. 
Mitochondria are surrounded by outer and inner membranes that are consistent 
with their symbiontic origin. The outer membrane is smooth and permeable to 
molecule of molecular mass up to approximately 5 KDa, whereas the inner 
envelope is highly folded and structured in cristae and offers the major 
permeability barrier to ions and molecules that traverse to the inner 
mitochondrial compartment by active transport. The two envelopes enclose an 
intermembrane space and an area inside the inner membrane, called matrix, 
where the basic mitochondrial macromolecular syntheses (DNA replication, 
transcription, and translation) take place. As the result of mitochondrial 
endosymbiotic origin, the organelles have its own genetic system with several 
bacteria-like features including a compact double stranded circular DNA 
genome of 16,5 Kb (mtDNA), which is self-replicating and maternally 
inherited (Fig. 12). Only 13 mitochondrial genes encode proteins, all of which 
are involved in electron transport and oxidative phosphorylation (Douglas, 
2005). 
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Fig. 12 Human mitochondrial DNA (mtDNA). The mtDNA consists of 16,568 base pairs 
and was the first entire genome sequenced in 1981. It encodes 22 tRNA, the 12 S and the 16 S 
rRNA, and 13 peptides forming with the 74 nuclear-encoded polypeptides the five respiratory 
chain complexes. The regulatory region is a non-coding sequence, or three stranded D-loop of 
nearly 600 base pairs. It contains the promoters of the heavy and light strands (HSP and LSP 
respectively), and the origin of replication of Purine-rich Heavy strand (OH). Transcription is 
polycistronic, and translation uses a specific code different from the universal. Replication is 
asymmetric, starting with the synthesis of the Heavy strand until the origin of the Light strand 
(OL) located about 2/3 from OH from which synthesis proceeds counter-clockwise. Thus, the 
Heavy strand is single stranded during about half of the replication cycle, which lasts about 2 
hours. ND1-6: NADH dehydrogenase subunits, COX1-3: Cytochrome c oxidase subunits, 
ATP6 and ATP8: subunits of ATP synthase, Cyt b: Cytochrome b (Shokolenko et al. 2011). 
 
 
The main function of mitochondria is the production of energy, in the form of 
adenosine triphosphate (ATP), by the oxidative phophorylation (OXPHOS) 
process (Fig. 13). Mitochondrial OXPHOS constitutes the major cellular ATP 
producing mechanism under aerobic conditions.  During OXPHOS process 
most ATP molecules are produced in cellular respiration. Five multiprotein 
enzyme complexes (I–V) and two electron carriers, coenzyme Q and 
cytochrome C, which act as electron acceptors, compose the Electron Trasport 
Chain (ETC), present in the inner mitochondrial membrane. Electrons are 
carried by two main molecules (NADH and FADH2), from glycolysis and the 
Krebs cycle, to the ETC to finally combine with oxygen in redox reactions. 
These redox reactions release energy, which is used to form ATP by ATP 
synthase, in a process called chemiosmosis. During OXPHOS the charged 
molecules are processed within the five ETC complexes to finally combine 
with oxygen to release the energy needed to make ATP. Complex I is called 
NADH ubiquinone oxidoreductase and it can be inhibited by rotenone; 
complex II is called succinate ubiquinone reductase and it can be inhibited by 
malate which competes with the substrate; complex II is called cytocrome bc1 
or ubiquinone cytocrome c oxidoreductase and it can be inhibited by antimycin 
and/or myxothiazol; complex IV is called cytocrome oxidase and it can be 
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inhibited by potassium cyanide (KCN); finally, there is the ATP synthase 
enzyme. 
 
 
Fig. 13 The OXPHOS process. Schematic representation of the complexes activity during the 
OXPHOS. The transition of the electrons is accompanied by a translocation of protons across 
the mitochondrial membrane. This phenomenon produces a chemical gradient (Phi) and an 
electrical gradient (Δψ). 
 
 
In addition to ATP synthesis, mitochondria also play central role in cellular 
Ca2+ homeostasis (Gunter et al. 2004), through its accumulation and release, as 
a result of physiologic stimuli. An important role in calcium signaling is 
covered by calcineurin/NFAT signaling pathway. NFAT is a Ca2+/calcineurin 
(CaN) dependent transcription factor that has been implicated in the 
development and function of various organ systems, including the immune, 
endocrine, and cardiovascular systems (Crabtree and Olson, 2002). NFAT is 
exquisitely sensitive to the duration of the Ca2+ signal, which is explained by 
its activating mechanisms. In resting cells, phosphorylated NFAT resides in the 
cytosol. It is dephosphorylated by CaN in response to an increase in [Ca2+]i, 
resulting in unmasking of its nuclear localization signal (NLS) and its import 
into the nucleus.  
The mitochondria are the major site for the production of ROS due to the 
highly propensity for aberrant release of free electrons. Increased production of 
ROS damages cell membranes through lipid peroxidation and further 
accelerates the high mutation rate of mtDNA. ROS are a variety of molecules 
and free radicals (chemical species with one unpaired electron) derived from 
molecular oxygen with the ability to react with reduced compounds. They 
comprise superoxide (O2--•), hydrogen peroxide (H2O2), and the highly reactive 
hydroxyl radical (•OH), although cells can also form minor amounts of singlet 
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oxygen. The initial product of the electron transport chain is O2--•, which is 
quickly transformed into H2O2 by the enzyme superoxide dismutase (SOD). 
H2O2 can be reduced to water by catalase or glutathione peroxidase or can be 
converted into •OH in presence of reduced transition metals (reduced copper or 
iron). The main source of O2--• are respiratory complexes I and III located at 
the inner mitochondrial membrane (Camello-Almaraz et al. 2006; Chen et al. 
2003). 
1.5.2 Molecular basis of mitochondrial dysfunction in DS 
The limited coding capacity of mtDNA necessitates that nuclear genes specify 
most proteins of the respiratory apparatus. Indeed most of the OXPHOS 
subunits are encoded by the nuclear genome. Some NEMGs act exclusively 
within the mitochondria to regulate the control of mitochondrial transcription 
and translation, others govern the expression of nuclear genes required for 
mitochondrial metabolism and organelle biogenesis. With only 13 OXPHOS 
polypeptides encoded by mtDNA, most of the OXPHOS subunits (at least 70) 
are encoded by the nuclear genome. The transcriptional regulatory network 
controlling the expression of nuclear and mitochondrial genes includes nuclear 
respiratory factors NRF1 and NRF2 and mitochondrial transcription factor A 
(TFAM or mtTFA). NRF1 transcriptionally controls many genes involved in 
mitochondrial function and biogenesis, genes involved in assembly of the 
respiratory apparatus, constituents of the mtDNA transcription and replication 
machinery, mitochondrial and cytosolic enzymes of the heme biosynthetic 
pathway (Huo and Scarpulla, 2001). It is interesting to note that NRF1 was 
found downregulated in DS fetal hearts. 
TFAM binds to the mtDNA at multiple sites and functions in both mtDNA 
maintenance and transcription initiation (Scarpulla et al. 2011).  
NRF1 is a binding partner for the transcriptional coactivator PGC-1α that 
coactivates numerous transcription factors, including nuclear receptors such as 
PPARγ and PPARα, and ERRα (estrogen receptor α), exerting the final effect to 
promote mitochondrial biogenesis and to regulate mitochondrial respiratory 
capacity (Scarpulla et al. 2012; Scarpulla et al. 2011; Leone et al. 2005) (Fig. 
14). PPARα (peroxisome proliferator activated receptor α) was the first NR 
(nuclear receptor) shown to be involved in the transcriptional control of 
mitochondrial metabolism. It is known to coordinately regulate nuclear genes 
encoding mitochondrial FAO enzymes. PPARα is a member of a family of 
related NRs including the ubiquitously expressed PPARβ (also known as 
PPARδ) and PPARγ, an adipose enriched transcription factor involved in 
adipocyte differentiation and the target of the insulin sensitizing 
thiazolidinediones. 
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Fig. 14 Regulatory network governing mitochondrial functions orchestrated by PGC-1α. 
Interactions among some key participants in the transcriptional network regulating 
mitochondrial biogenesis are depicted schematically. The diagram summarizes the regulation 
of PGC-1α by transcriptional and post-transcriptional pathways and its interactions with some 
of its target transcription factors involved in metabolic regulation. Potential suppression of 
glycolysis through NRF1 control of VHL expression and negative is also shown (Scarpulla et 
al. 2011). 
 
 
PGC-1α function has been investigated in several specialized cell types and 
transgenic mouse models, demonstrating its role in the regulation of 
mitochondrial oxidative metabolism. Forced overexpression studies conducted 
in cultured adipocyte lines (Puigserver et al. 1998), cardiac myocytes (Lehman 
et al. 2000) and in conditional, tissue specific, transgenic mice (Russell et al. 
2004), have shown that PGC-1α is capable of driving virtually all aspects of 
mitochondrial biogenesis, including activation of respiratory chain and FAO 
genes, increased mitochondrial number, and augmentation of mitochondrial 
respiratory capacity. Indeed PGC-1α  knockout mice manifest a reduction of 
mitochondrial number and of respiratory capacity in skeletal muscle (Leone et 
al. 2005).  
PGC-1α transcription and activity are positively regulated by Ca2+ signaling. 
Interestingly PGC-1α was found hypoexpressed both at the transcriptional and 
protein level in trisomic human heart and fibroblasts with TS21 (Fig. 15) 
(Piccoli et al. 2013; Conti et al. 2007). 
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Fig. 15 Expression analysis of the PGC-1α. A) Expression analysis of the PGC-1α by qRT-
PCR. The values, means + SEM, of the DS samples are normalized to that of the euploid 
fibroblasts. B) Analysis of the PGC-1α protein. Western blotting of PGC-1α on total cellular 
protein extracts from euploid and DS samples. To compare different electrophoretic runs, the 
densitometric value (normalized to tubulin) of the euploid sample BIO-23 was taken as an 
internal reference (Piccoli et al. 2013). 
 
 
PGC-1α is activated via post-transcriptional phosphorylation by AMPK or by 
deacetylation via SIRT1 in response to nutrient deprivation (Jager et al. 2007). 
Induction or activation of the coactivator can enhance mitochondrial biogenesis 
and oxidative function through the coactivation of multiple transcription 
factors involved in respiratory gene expression. PGC-1α activation may also 
promote an antioxidant environment by coactivating ERRα to induce SIRT3, a 
mitochondrial sirtuin that has been implicated in ROS detoxification. In 
addition, AMPK promotes autophagy through direct phosphorylation of ULK1 
or via suppression of the TORC1 kinase complex. 
Hsa21 genes that regulate mitochondrial biogenesis and function have been 
identified. The kinase DYRK1A and DSCR1/RCAN1 (Bushdid et al. 2003) were 
considered to be involved in mitochondrial dysfunction in DS. RCAN1 and 
DYRK1A genes are localized on Hsa21 and their overexpression, through the 
downregulation of NFATc genes (Fig. 16), might result in the depression of 
PGC-1α expression. Indeed in human DS fetal fibroblasts (DS-HFFs) and DS 
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hearts, NFATc3 and NFATc4 were significantly downregulated while DYRK1A 
and DSCR1/RCAN1, involved in regulating the levels of NFATc 
phosphorylation, were upregulated (Piccoli et al. 2013; Conti et al. 2007). 
DYRK1A and DSCR1/RCAN1 play key roles in the calcineurin/NFAT pathway, 
which affects mitochondrial activity and morphology during heart development 
(Arron et al. 2006). Moreover DSCR1/RCAN1 regulates mitochondrial 
function, increases susceptibility to oxidative stress in mammalian cells (Peiris 
et al. 2014), and modulates NRF2 (O'Leary et al. 2004), a NEMG transcription 
factor. 
 
 
Fig. 16 Calcineurin/NFAT signaling. The entry of calcium ions into the cell activates the 
enzyme calcineurin to remove phosphate groups (P) from NFATc factors in the cytoplasm, 
allowing NFATc to enter the nucleus and to activate its target genes. However, once in the 
nucleus, NFATc can be phosphorylated, and so returns to the cytoplasm. Arron et al. and 
Gwack et al. (2006) implicated the DSCR1 and DYRK1A proteins in regulating the levels of 
NFATc phosphorylation. 
 
 
1.6 Pharmacological approaches for improving DS phenotype 
 
Over the last several years, interesting results have been obtained testing drugs 
to rescue, or partially rescue, DS relevant deficits in learning and memory and 
abnormalities in cellular and electrophysiological features seen in the Ts65Dn 
mouse (Gardiner, 2014). These results suggest that some level of amelioration 
or prevention of cognitive deficits in people with DS may be possible. 
The first demonstration of L/M (learning and memory) rescue in Ts65Dn used 
estrogen and was reported more than 10 years ago. The choice of estrogen was 
based on the observation of premature menopause and early onset cognitive 
decline in women with DS. Another drug that was effective was minocycline, a 
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derivative of tetracycline. In addition to antibiotic properties, minocycline is of 
interest because it is considered to have neuroprotective effects, modulating the 
activity of interleukin 1 beta (inflammation) and inhibiting caspases 
(apoptosis). 
A GABA receptor (GABAAR) antagonist, pentylenetetrazole (PTZ), was 
tested for its efficacy in L/M rescue. The proposal of PTZ for clinical trials in 
DS has been controversial because it is a known convulsant. Since DS subjects 
are at increased risk of seizures, they could be more sensitive to PTZ. 
Moreover, this drug is not currently US Food and Drug Administration (FDA) 
approved. To lessen the probability of negative side effects in people with DS, 
other more specific GABAAR antagonists are now being studied. 
Memantine is an uncompetitive antagonist of the N-methyl-d-aspartate 
(NMDA) receptor and has been shown to rescue L/M in mouse models of AD. 
It is also currently approved by the US FDA for use in moderate to severe AD. 
The mechanism of action of memantine has known relationships with proteins 
encoded by Hsa21. There are nine Hsa21-encoded proteins, all trisomic in the 
Ts65Dn, which directly or indirectly interact with the NMDAR (Siddiqui et al. 
2008). Among these is the regulator of CaN, RCAN1 that in turn is 
phosphorylated by the Hsa21 kinase DYRK1A. RCAN1 activity is further 
modulated by levels of reactive oxygen species that are affected by the Hsa21 
proteins, the superoxide dismutase (SOD1), the amyloid precursor protein 
(APP), and the transcription factor BACH1. Activity of CaN is also influenced 
by the expression level of the Hsa21 calmodulin-binding protein, PCP4. Costa 
et al (2008) were the first to propose and test memantine in Ts65Dn. They 
showed that acute injection of memantine rescued L/M deficits. Thus, unlike 
GABAAR antagonists, memantine does not produce lasting positive effects. 
There is extensive evidence in DS about of the potential efficacy of fluoxetine, 
the serotonin reuptake inhibitor. It had been shown previously in rodents that 
chronic treatment with fluoxetine, and other antidepressants, stimulates the 
production of new neurons and their incorporation into functional networks 
(Malberg et al. 2000). The first Ts65Dn study with fluoxetine demonstrated 
that adult neurogenesis is indeed impaired in untreated mice, and that 2 weeks 
of fluoxetine injections rescued this deficit (Clark et al. 2006). Most recently, 
fluoxetine has been used in prenatal treatment. Pregnant Ts65Dn mice were 
injected daily with 10 mg/kg fluoxetine (lower dose) from embryonic day 10 to 
birth (Guidi et al. 2014). When tested at P45, learning was normal. Prenatal 
fluoxetine treatment also rescued the abnormalities in neurogenesis seen in 
untreated Ts65Dn, both at birth and at 45 days.  
Lithium is a common treatment for mood disorders that has been in use since 
the 1970s. Lithium has neuroprotective properties and has also been shown to 
increase adult neurogenesis in both controls and Ts65Dn mice. It has been 
demonstrated that when younger (~5-month-old) male Ts65Dn mice were 
treated for 1 month with lithium, a complete rescue of neurogenesis was seen 
(Contestabile et al. 2013).  
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Brains from individuals with DS and the Ts65Dn mice have small cerebella 
and reduced granule cell density. Roper et al (2006) first showed that an 
agonist of sonic hedgehog, SAG 1.1, rescued decreased cell numbers in the 
granule cell layer of the cerebellum. This work was particularly important 
because the correction, measured at P6, was obtained with a single injection of 
SAG 1.1 at P0.  
EGCG (epigallocatechin-3-gallate) is a catechin found in green tea. It is a 
highly specific inhibitor for two Hsa21 kinases, DYRK1A and the MAPKAPK5. 
Reduction of activity of DYRK1A by EGCG in the Ts65Dn occurs in the 
context of elevated expression of other multiple Hsa21 genes. Decreasing 
DYRK1A expression in the presence of elevated expression of these Hsa21-
encoded substrates and functional interactors could cause additional 
imbalances relevant to DS phenotypic features. It is unlikely that the benefits 
of EGCG treatment in the Ts65Dn are limited to inhibition of the activity of the 
DYRK1A kinase. EGCG has been shown to be a powerful antioxidant and 
antitumor agent. It is currently in clinical trials for obesity, several types of 
malignancy, Huntington’s disease, Fragile X, and AD, as well as for DS. 
Oxidative stress and mitochondrial dysfunction are both considered hallmarks 
of DS tissues and contributors to neurological phenotypes across the DS 
lifespan (Lott et al. 2012; Coskun et al. 2012). Cortical neurons derived from 
DS fetal brains show elevated levels of reactive oxygen species, and survival is 
enhanced by treatment with antioxidants (Busciglio et al. 1995). Several Hsa21 
genes, among them SOD1, BACH1, ETS2, and S100B, are known to contribute 
to the regulation of oxidative stress when overexpressed (Sturgeon et al. 2012). 
Consistent with these observations, it was shown that levels of oxidative stress 
are elevated in the brains of adult Ts65Dn, and when male Ts65Dn mice were 
fed a diet high in vitamin E (0.4 g per kg) from the age of 4 months to ~8 
months and 10 months, the levels of oxidative stress were decreased. In an 
attempt to prevent the developmental consequences of elevated oxidative 
stress, pregnant Ts65Dn female mice and their offspring were treated with a 
vitamin E-enriched diet and it has been observed an improvement of learning 
(Lockrow et al. 2009). 
Some protocols are being developed to improve oxidative imbalance in DS 
using antioxidants such as the coenzyme Q10 (Tiano et al. 2011; Miles et al. 
2007). 
Considerable evidence has accumulated to suggest that prenatal and perinatal 
supplementation with choline can have long-term benefits for L/M (McCann et 
al. 2006) including the enhancement of adult neurogenesis (Glenn et al. 2007). 
Several clinical trials for cognitive deficits in DS have been completed recently 
and/or in progress. The efficacy of folate supplementation was tested in a larger 
trial where infants with DS, aged 3–30 months, received leucovorin (folinic 
acid) or placebo daily for 12 months (Blehaut et al. 2010). The choice of folate 
was based on the fact that seven Hsa21 genes are involved in folate 
metabolism, and evidence for their elevated expression and resulting perturbed 
concentrations of folate pathway components have been observed in DS. While 
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only a small effect was seen with folate, this effect was significantly increased 
in children who were also receiving thyroxine for hypothyroidism. Only two of 
the seven genes predicted to affect folate metabolism are trisomic in the 
Ts65Dn mice, making it an inadequate model for preclinical evaluations of 
folate-related supplements. The Hsa21 connection to the thyroid hormone may 
involve NRIP1, which is also not trisomic in the Ts65Dn mice (Park et al. 
2009). A larger trial with folate plus thyroxine is in progress. 
Although some therapeutic protocols had shown positive outcomes in Ts65Dn 
mice, the clinical trials did not shown the expected results, and were also 
expensive in terms of time and resources. While prevention of cognitive 
deficits is an important goal, prenatal treatments come with their own more 
stringent and challenging requirements for safety demonstrations. The details 
of the Ts65Dn experiments used in preclinical evaluations are important; 
different drugs rescued L/M in different tasks, or they produced only partial 
rescue, with and without attendant rescue of neurogenesis. This suggests that 
combinations of drugs may be both necessary and advantageous. This approach 
is common in cancer therapy and viral infections, and recent methods for the 
rapid identification of optimally effective combinations of drugs could be 
easily applied to in vitro DS systems (Jaynes et al. 2013; Honda et al. 2013).  
 
1.7 Drugs affecting the PGC-1α pathway 
 
PGC-1α is an important regulator of the mitochondrial biogenesis and can be 
activated via the PPAR, AMPK or Sirt1 pathway, either through increased 
expression (PPARs, AMPK) or through post-translational modification (PTMs, 
AMPK, Sirt1) (Wenz et al. 2008). Several substance and drugs that activate 
PPARs, AMPK and Sirt1 are established. Recent studies have demonstrated 
that the activation of the PGC-1α pathway has a potential therapeutic benefit in 
muscular and neurodegenerative disorders associated with mitochondrial 
dysfunction in cellular and murine models (Noe et al. 2013; Dillon et al. 2012; 
Dumont et al. 2012; Johri et al. 2012; Yatsuga and Suomalainen, 2012; 
Viscomi et al. 2011; Wenz et al. 2008). In some cases, this benefit led to an 
improve of mitochondrial processes such as OXPHOS or fatty acid oxidation, 
while in other cases no significant effect was observed (Hofer et al. 2014).  
Counteracting mitochondrial dysfunction in DS might provide the basis for 
clinical trials aimed at improving the pathological phenotypes that characterize 
DS or alleviate and prevent some of its related pathologies, including 
neurodegeneration, diabetes, obesity, and hypertrophic cardiopathy, thus 
providing a better quality of life for DS individuals and their families.  
Our results (Izzo et al. 2014; Piccoli et al. 2013) indicate that the dysregulation 
of NRIP1 plays a key role in the mitochondrial dysfunction observed in DS and 
suggest that the NRIP1-PGC-1α axis might represent a potential therapeutic 
target for restoring altered mitochondrial function in this syndrome. 
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Several clinical trials on the effects of antioxidant nutrients or vitamins (Lott et 
al. 2012; Tiano et al. 2011; Ellis et al. 2008; Miles et al. 2007) concluded that 
although antioxidant supplementation is safe, it neither improves cognitive 
performance nor prevents dementia in DS patients. 
New therapies can be proposed based either on direct inhibition of NRIP1 by 
specific RNAi or indirectly through the use of drugs, affecting genes involved 
in the same dysregulated pathways. 
A possible therapeutic approach in DS could be based either on PGC-1α 
activators, which have been tested in other disease mouse models (Jager et al. 
2007; Rodgers et al. 2005), or on PPARγ agonists, which attenuate 
mitochondrial dysfunction in AD mouse models (Yamaguchi et al. 2012; 
Bastin et al. 2008). Such drugs are already routinely used in clinical practice 
for the treatment of metabolic syndromes, type 2 diabetes, and 
neurodegenerative diseases such as AD (Marciano et al. 2014; Watson et al. 
2005). 
What is puzzling is that although drugs capable of modulating the activity of 
PGC-1α and/or the downstream PPAR proteins are available, no therapeutic 
approaches have ever been undertaken to correct the overall mitochondrial 
dysfunction in DS patients. In effect, PGC-1α activity is mainly controlled by 
PPARs, AMP-activated kinases (AMPKs) and the NAD-dependent deacetylase 
SIRT1 (Canto and Auwerx, 2009). Direct phosphorylation by AMPK promotes 
PGC-1α dependent induction at the PGC-1α promoter level (Jager et al. 2007); 
similarly, SIRT1 stimulates PGC-1α activity through deacetylation, thereby 
inducing mitochondrial biogenesis (Rodgers et al. 2005). Pharmacological 
activators for these proteins, such as metformin, via AMPK induction, as well 
as resveratrol, via SIRT1 induction, have been tested in other disease mouse 
models (Dong et al. 2007; Jager et al. 2007; Lagouge et al. 2006). A recent 
study indicates that metformin promotes neurogenesis and enhances spatial 
memory formation in normal adult mouse. 
Other pharmacological activators include thiazolidinediones, pioglitazones, and 
bezafibrates. In brief, thiazolidinediones selectively stimulate PPARγ. 
Pioglitazone attenuates mitochondrial dysfunction in animal models of central 
nervous system injury, improving the mitochondrial ability to produce ATP 
and rates of oxygen consumption (Sauerbeck et al. 2011; Nicolakakis et al. 
2008). Finally, bezafibrate, a PPAR pan-agonist typically used to treat human 
hyperlipidemia (Yatsuga and Suomalainen, 2012), also stimulates the 
mitochondrial respiratory chain, mitochondrial biogenesis, and fatty acid 
oxidation both in vitro and in vivo (Yamaguchi et al. 2012; Johri et al. 2011; 
Bastin et al. 2008). Hofer et al. (2014) performed a comprehensive analysis of 
the effects of potential PGC-1α activating drugs. The authors pharmaceutically 
targeted the PPARs (bezafibrate, rosiglitazone), AMPK (AICAR, metformin) 
and SIRT1 (resveratrol) pathways in HeLa cells, neuronal cells and PGC-1α-
deficient MEFs demonstrating tissue-specific effects of these drugs in 
modulating mitochondrial processes and cellular stress programs. All the 
observed effects were clearly dependent on PGC-1α modulation. 
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Not all analyzed drugs activate the PGC-1α pathway or alter mitochondrial 
protein levels. However, they all affect supramolecular assembly of OXPHOS 
complexes and OXPHOS protein stability.  
 
1.8 A novel approach to assess mitochondrial respiration: XFe 
Analyzer 
 
Glycolysis and oxidative phosphorylation are the two major energy-producing 
pathways in the cell.  
XFe 96 Extracellular Flux Analyzer (Seahorse Bioscience) simultaneously 
interrogate these major energy producing pathways of the cell mitochondrial 
respiration and glycolysis in a microplate, in real-time. The XFe 96 Analyzer 
determines in vitro oxygen consumption rate (OCR), and extracellular 
acidification rate (ECAR), in order to assess cellular functions such as 
oxidative phosphorylation and glycolysis. The measurement of cellular 
bioenergetics on live cells enables time-resolved analysis and testing of 
multiple conditions per assay well. By incorporating automated compound 
addition and solid-state fluorescence sensors in a microplate format, XF 
technology provides the tools to:  
• Simultaneously measure oxygen consumption rate (OCR) and 
extracellular acidification rate (ECAR) in all assay wells.  
• Rapidly detect cellular responses to substrates, inhibitors, and other 
perturbants.  
• Test more conditions with the same amount of sample, maximizing the 
value of each experiment.  
• The XFe 96 Extracellular Flux Analyzer, XF stress test kits, reagents, 
consumables, and software tools work together to simplify the 
measurement of cellular metabolism. 
The XF Cell Mito Stress Test is the standard assay for measuring 
mitochondrial function in cells. The XF Cell Mito Stress Test Kit makes it easy 
to measure the four key parameters of mitochondrial function in a microplate: 
basal respiration, ATP turnover, proton leak, and maximal respiration, 
revealing critical information not evident in basal metabolism measurements 
alone, by directly measuring the OCR of cells. The XF Cell Mito Stress Test 
uses modulators of respiration that specifically target components of ETC in 
the mitochondria to reveal key parameters of metabolic function. The 
modulators (oligomycin, FCCP, and a mix of rotenon and antimycin A) are 
serially injected to measure ATP production, maximal respiration, and non-
mitochondrial respiration, respectively (Fig. 17). Each modulator targets a 
specific component of the ETC. Oligomycin inhibits ATP synthase (complex 
V) and the decrease in OCR following injection of oligomycin correlates to the 
mitochondrial respiration associated with cellular ATP production. Carbonyl 
cyanide – 4 (trifluoromethoxy) phenylhydrazone (FCCP) is an uncoupling 
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agent that collapses the proton gradient and disrupts the mitochondrial 
membrane potential. As a result, electron flow through the ETC is uninhibited 
and oxygen is maximally consumed by complex IV. The FCCP stimulated 
OCR can then be used to calculate spare respiratory capacity, defined as the 
difference between maximal respiration and basal respiration. Spare respiratory 
capacity is a measure of the cell’s ability to respond to increased energy 
demand. The third injection is a mix of rotenon, a complex I inhibitor, and 
antimycin A, a complex III inhibitor. This combination shuts down 
mitochondrial respiration and enables the calculation of non-mitochondrial 
respiration driven by processes outside the mitochondria.  
 
Fig. 17 XF Cell Mito Stress Test profile of the fundamental parameters of mitochondrial 
function: basal respiration, ATP turnover, proton leak, maximal respiration, and spare 
respiratory capacity. 
 
The XF analyzer also provides a standard and comprehensive method to assess 
the three key parameters of glycolytic function: Glycolysis, Glycolytic 
Capacity, and Glycolytic Reserve (Fig. 18). Initially, cells are incubated in the 
glycolysis stress test medium without glucose and ECAR is assessed. The first 
injection is a saturating concentration of glucose (10 mM). Glucose is taken up 
by the cells and catabolized through the glycolytic pathway to lactate, 
producing ATP and protons. The extrusion of protons into the surrounding 
medium produces a rapid increase in ECAR. This glucose-induced response is 
reported as the rate of glycolysis (or Glycolytic Flux) under basal conditions. 
The second injection is oligomycin that inhibits mitochondrial ATP production 
and thus shifts the energy production to glycolysis, with the subsequent 
increase in ECAR revealing the maximum glycolytic capacity of the cells. The 
final injection is 2-DG, a glucose analog, which inhibits glycolysis through 
competitive binding to glucose hexokinase, the first enzyme in the glycolytic 
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pathway. The resulting decrease in ECAR further confirms that the ECAR 
produced in the experiment is due to glycolysis.  
 
 
 
 
Fig. 18 XF Glycolysis Stress Test Kit profile of the fundamental parameters of cellular 
glycolysis: glycolysis, glycolytic capacity, and glycolytic reserve capacity. 
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2. AIMS OF THE STUDY 
 
The main objective of this PhD project was to understand the molecular 
mechanisms implicated in some traits of the DS phenotype, especially cardiac 
and neurological defects, in order to develop strategies for prevention and/or 
therapeutic treatments. 
Mitochondrial alterations, consistently observed in DS subjects and in DS 
mouse models, have been proposed to contribute to the severity of DS 
anomalies. In human cells and tissues from DS fetuses it was demonstrated that 
NEMGs (nuclear encoded mitochondrial genes) are globally downregulated, 
while ECM (extracellular matrix) genes are upregulated in comparison with 
euploid samples (Piccoli et al. 2013; Conti et al. 2007).  
A mitochondrial dysfunction was found associated with NEMG 
downregulation and a more pronounced pro-oxidative state was demonstrated 
in DS fibroblasts from fetuses with congenital cardiopaty (Piccoli et al. 2013). 
These results are in line with the hypothesis that mitochondrial dysfunction 
might worsen the DS cardiac phenotype. 
The project that our research group carried out was aimed at investigating 
whether NEMG downregulation or ECM upregulation might affect cardiac 
phenotype, to identify Hsa21 genes responsible for either NEMG 
downregulation or ECM upregulation, and to develop strategies to counteract 
the negative effects triggered by NEMG dysregulation in DS. 
Through a metaanalysis of public expression data NRIP1/RIP140 (Nuclear 
receptor interacting protein 1) was identified as the potential repressor of 
NEMGs expression, and RUNX1 (Runt related transcription factor 1) as the 
potential candidate for ECM upregulation. 
A strategy to counteract mitochondrial dysfunction in DS has been developed 
starting from the following considerations: 
1) The co-repressor gene NRIP1 negatively regulates the mithocondrial 
function possibly by repressing the activity of PGC-1α, a master regulator of 
mitochondrial biogenesis (Izzo et al. 2014; Chen et al 2012; Powelka et al. 
2006, Scarpulla et al. 2012; Scarpulla et al. 2011).  
2) PGC-1α is downregulated in DS fetal fibroblasts and heart tissue (Piccoli et 
al. 2013; Conti et al. 2007). 
The rationale of therapeutic strategies is therefore to repair mitochondrial 
dysfunction in DS through the restoration of the NRIP1/ PGC1-α axis.  
To meet our objectives, we have transiently silenced NRIP1 gene in DS-HFFs 
to evaluate its possible implication in the regulation of PGC-1α expression and 
in mitochondrial dysfunction. The final aim of silencing experiments was to 
verify whether NRIP1 inhibition in DS cells was able to rescue the 
mitochondrial function. DS-HFF samples in which NRIP1 gene was found 
overexpressed have been selected.  
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In order to evaluate the effect of NRIP1 silencing on mitochondrial function a 
phenotypic mitochondrial analysis in silenced cells versus control cells was 
carried out.  
After demonstrating that NRIP1 attenuation in DS cells is able to rescue 
mitochondrial function, the next aim of this project was to counteract 
mitochondrial dysfunction by pharmacologically targeting the genes controlled 
by NRIP1, namely PGC-1α and PPAR genes. Among the possible therapeutic 
agents we have chosen two drugs: metformin (an activator of PGC-1α) and 
pioglitazone (an agonist of PPARγ). These two drugs are already used in the 
clinical practice for the treatment of metabolic syndromes. 
DS-HFF cultures were treated with these drugs in order to evaluate their 
efficiency in increasing PGC-1α expression and ATP production and in 
globally ameliorating the mitochondrial function. To evaluate the drug effect 
on mitochondrial phenotype the same parameters described above for NRIP1 
silencing were chosen.  
As the chosen drugs are already registered for human therapeutic use, should 
any of them demonstrate to be effective it can be immediately translated in 
human therapeutic protocols. 
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3. MATERIALS AND METHODS 
  
Samples 
The local Institutional Ethics Committee approved all experimental protocols.  
Primary lines of skin fibroblasts (HFFs) from fetuses at 18-22 gestational 
weeks were obtained from the "Telethon Bank of Fetal Biological Samples" at 
the University of Naples Federico II. Eight lines of fetal fibroblasts were from 
euploid fetuses (N-HFF) and ten from DS fetuses (DS-HFF) with and without 
cardiopathy (CDS-HFF and NCDS-HFF respectively) (Tab. 1) Fibroblasts 
were cultured in T25 flasks (BD Falcon) with Chang medium C (Irvine 
Scientific) supplemented with 1% penicillin/streptomycin (Gibco) at 37°C in 
5% CO2 atmosphere. All the analyses described throughout this study were 
carried out at cell culture passages 4-5. For silencing experiments 4 DS-HFF 
(BIO37, BIO55, BIO44 and BIO48) samples were used. For drug treatments 2 
DS-HFFs (BIO-45 and BIO-71) were used. 
 
TABLE 1 Primary lines of fetal skin fibroblasts used in the study. 
 
N-HFF 
 
 
DS-HFF 
 
 NCDS-HFF CDS-HFF 
BIO23 BIO37 
 
BIO36 
 
BIO27 BIO45 BIO44 
BIO29 BIO48 BIO55 
BIO30 BIO74 BIO71 
BIO75   
BIO80   
N-HFF (euploid samples); NCDS-HFF (trisomic samples from fetuses without cardiopathy); 
CDS-HFF (trisomic samples from fetuses with cardiopathy)  
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Transcription factors binding analysis of co-regulated genes 
Pscan software (http://www.beaconlab.it/pscan, [Zambelli et al. 2009]) was 
used to look for over-represented TF motifs in the list of genes dysregulated in 
DS fetal hearts. We considered enriched in targets, TF with adjusted P-values < 
0.05. 
 
Public data expression analysis 
The data set GSE 19836 series (De Cegli et al. 2010) from Gene Expression 
Omnibus repository (GEO (http://www.ncbi.nlm.nih.gov/geo) was reanalyzed 
to investigate the effects of Hsa21 gene overexpression over NEMG and ECM 
regulation. Clones of mouse embryonic stem cells in which 13 transcription 
factors (Aire, Bach1, Erg, Ets2, Gabpa, Nrip1, Olig1, Olig2, Pknox1, Runx1, 
Sim2, ZFP295, 1810007M14Rik), one transcriptional activator (Dscr1-Rcan1) 
and 6 protein kinases (DYRK1A, SNF1LK, Hunk, Pdxk, Pfkl, Ripk4) were 
individually induced, were transcriptionally profiled under inducing and non-
inducing conditions with Affymetrix Gene Chip Mouse 430_2. Specifically, 
RNAs from three induced mouse ESCs and three controls were profiled for 
each inducible Hsa21 gene (De Cegli et al. 2010). In our analysis, we used 
GeneSpring software vers. 11.5 Multi–Omic Analysis (Agilent technologies, 
Inc.) for data interpretation. We considered genes differentially expressed with 
a Fold change (LogFC) >0.3 and < -0.3 with P<0.05. Gene ontology (GO) 
functional class scoring of all the lists of significantly upregulated or 
downregulated genes was performed using the Web-based Gene Set Analysis 
Toolkit V2 (http://bioinfo.vanderbilt.edu/webgestalt/) (Zang et al. 2005, Wang 
et al. 2013). Special attention was given to mitochondria- and ECM-related 
categories and pathways. 
 
Comparison of lists of differentially expressed NEMGs: meta-analysis 
We compared three sets of gene expression data from different experiments, to 
identify genes consistently dysregulated across the three studies. The first set, 
SET1, included genes dysregulated by NRIP1 modulation in mouse adipocytes 
(Powelka et al. 2006). The second set, SET2, included genes upregulated after 
PGC-1α induction in SAOS2 cells (human osteoblast like cells) (Schreiber et 
al. 2004). The third set included mitochondria-related genes, downregulated in 
DS fetal heart tissue (Conti et al. 2007). The three sets were filtered according 
to the GO cell component category "mitochondrion" with Web-based Gene Set 
Analysis Toolkit V2. The resulting genes - 123 genes in SET1, 129 in SET2 
and 70 in SET3 - were intersected using the R software (http://www.R-
project.org/). A Venn diagram was built, which shows overlapping genes 
across the three sets. 
 
Transfection of siRNA (short interfering RNA) 
NRIP1 expression was attenuated transiently in 4 DS-HFFs lines using a 
specific pool of siRNAs for NRIP1 (ON-TARGETplus SMART-pool, 
Dharmacon). ON-TARGET plus SMART pool Non-targeting siRNAs control 
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(Dharmacon) was used as control (scrambled siRNA).The siRNAs were diluted 
in an appropriate buffer consisting of 20 mM KCl, 6 mM HEPES pH 7.5 and 
0.2 mM MgCl2, for a stock of 20 µM siRNA. INTERFERIN (Polyplus 
transfection) was used as transfection reagent, which avoids off-target effects. 
The trisomic fetal fibroblasts were transfected with two different 
concentrations of siRNAs, 5 nM and 20 nM. Each experiment was conducted 
in duplicate according to manifacturer’s protocols. 72 hours after transfection, 
the effects of NRIP1 siRNA mediated attenuation were evaluated. 
 
NRIP1 protein assay by immunofluorescence 
Cultured cells, grown on 12 mm diameter round glass coverslips, were fixed in 
3:1 methanol:acetic acid for 15 minutes, washed twice with PBS, and then 
incubated twice in 0.1 M Borate Buffer pH 8.5 for 10 minutes to neutralize the 
pH. After two washes with PBS, the cells were incubated with DNase 1:10 in 
RDD Buffer (Qiagen) at 37°C for 1 h and then treated with 2% BSA in PBS to 
block non-specific protein-protein interactions. The cells were then incubated 
with the antibody anti-NRIP1 (30 µg/ml, ab42126 Abcam, Cambridge Science 
Park, Cambridge, UK) overnight at + 4°C. The secondary antibody (green) was 
Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/200 dilution for 1 h. 
Cells were finally mounted in 50% glycerol in PBS. Immunofluorescence 
analysis was performed at a confocal laser-scanning microscope LSM 510 
(Zeiss, Gottingen, Germany) equipped with an Argon ionic laser whose λ was 
set at 488 nm, and an HeNe laser whose λ was set at 633 nm. Emission of 
fluorescence was revealed by a BP 505-530 band pass filter for Alexa Fluor 
488 and by a 615 long pass filter for DRAQ5. Images were acquired at a 
resolution of 1024 x 1024 pixels. Analysis of data was performed with ImageJ 
software, version 1.37. Fifty random single cells were analyzed for each 
imaging analysis. 
 
Laser scanning confocal microscopy live cell imaging of ROS production 
Cultured cells, grown for 72 hours on 25 mm diameter round glass coverslips 
in an Attofluor cell chamber (Molecular Probe, Leiden, NL), were incubated 
for 15 minutes at 37°C with 10 µM of 2,7-dichlorofluorescin diacetate (DCF-
DA) which is converted to dichlorofluorescein by intracellular esterases, for 
detection of H2O2, or with 5 µM of MitoSOX™ Red reagent (Life 
Technologies, Molecular Probes), a live-cell permeant which rapidly and 
selectively targets the mitochondria exhibiting red fluorescence when oxidized 
by superoxide. Manifacturer’s protocols were applyed. Immunofluorescent 
images were captured by a confocal laser scanner microscopy Zeiss LSM 510 
(Carl Zeiss, Gottingen, Germany), equipped with Argon ionic laser whose λ 
was set at 488 nm, an HeNe laser whose λ was set at 546 nm. Emission of 
fluorescence was revealed by BP 505-530 band pass filter for DCF and 560 
Long Pass for MitoSOX™ Red. Images were acquired in the green or in the 
red channels and than saved in LSM format. They were acquired with a 
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resolution of 1024 x 1024 pixel with the confocal pinhole set to one Airy unit. 
Analysis of data was performed with ImageJ software, version 1.37. Fifty 
random single cells were analyzed for each imaging analysis. 
 
MitoTracker immunofluorescence 
The MitoTracker® Red CMXRos (Molecular Probe) is a red-fluorescent dye 
that diffuses into the plasma membrane depending on the potential and 
accumulates in the mitochondria of living cells in active respiration. Cells were 
grown on 12 mm diameter round glass coverslips and then incubated with 150 
nM of MitoTracker® Red for 30 minutes. After incubation cells were fixed for 
20 minutes in PBS containing 4% paraformaldehyde (Sigma) and then washed 
once with PBS 1x. Nuclei were stained with the DNA intercalant DRAQ5 (Bio 
status, Alexis Corporation). Cells were finally mounted in 50% glycerol in 
PBS. Immunofluorescence analysis was performed with a confocal laser-
scanning microscope LSM 510 (Zeiss, Gottingen, Germany). The lambda of 
the two HeNe lasers was set at 546 nm and at 633 nm. Fluorescence emission 
was revealed by BP 560-615 band pass filter for MitoTracker® Red and by 
615 long pass filter for DRAQ5. Double staining immunofluorescence images 
were acquired separately in the red and infrared channels at a resolution of 
1024 x 1024 pixels, with the confocal pinhole set to one Airy unit, and then 
saved in LSM format. Fifty random single cells were analyzed for each 
imaging analysis using the ImageJ version 1.37. 
 
RNA extraction and quantitative real-time PCR  
Total RNA from each sample was extracted using TRIzol reagent (Gibco/BRL 
Life Technologies, Inc., Gaithersburg, MD) and was reverse transcribed using 
the iScript cDNA Synthesis kit (Bio-Rad Laboratories, Inc., Hercules, CA, 
USA). Real-time PCR was performed using iQ Supermix SYBR Green 2x on a 
Bio-Rad iCycler according to the manufacturer’s protocols. PCR reactions 
were performed in triplicate. Primer pairs (MWG Biotech, Ebersberg, 
Germany) were designed using the Primer 3 software 
(http://frodo.wi.mit.edu/primer3) to obtain amplicons ranging from 100 to 150 
base pairs. In order to test primer efficiency, serial dilutions of cDNAs 
generated from selected samples, that expressed target genes at a suitable level, 
were used to generate standard curves for each gene. Expression values were 
normalized either versus scrambled transfected cells or versus scrambled 
transfected euploid cells. ABELSON and GAPDH housekeeping genes were 
chosen as reference genes. 
 
mtDNA quantification 
To quantify the mtDNA content, we selected two genes: D-LOOP as the 
mitochondrial target and ACTIN as the nuclear target. Both targets were 
quantified by qRT-PCR using cDNA reverse-transcribed from RNA of three 
NRIP1-silenced trisomic samples and scrambled control. Normalization of 
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gene expression was obtained using ABL gene as housekeeping. The ratio 
between D-LOOP and ACTIN expression under each condition (NRIP1-
silenced or scrambled trisomic cells) was calculated.  
 
ATP measurements by chimeric photoprotein Luciferase ATP sensitive 
Cells were seeded on glass coverslips (13 mm diameter) for single sample 
luminescence measurements and allowed to grow until 50% confluence. The 
cells were then transfected with a cytosolic (untargeted) firefly luciferase 
(cytLuc) and a mitochondrially targeted luciferase (mtLuc). Cell luminescence 
was measured in a luminometer constantly perfused with KRB, supplemented 
with 1 mM CaCl2 and 20 mM luciferin. The light output of a coverslip of 
infected cells was in the range of 1.000-10.000 counts per second (cps) versus 
a background lower than 10 cps. All compounds employed in the experiments 
were tested for non-specific effects on the luminescence, but none was 
observed. 
Measurements of ATP and mitochondrial mass were performed in 
collaboration with Prof. Pinton’s Lab. 
 
Western Blot 
Cells were scraped into ice cold phosphate-buffered saline and lysed in a 
modified 10 mM Tris buffer pH 7.4 containing 150 mM NaCl, 1% Triton X-
100, 10% glycerol, 10 mM EDTA and protease inhibitor cocktail. After 30 
minutes of incubation on ice, the lysates were cleared via centrifugation at 
12,000 g at 4°C for 10 minutes. The protein concentration was determined by 
the Lowry procedure. Protein extracts (18 µg) were separated on 4-12% Bis-
Tris acrylamide Gel (Life Technologies, NP0323). Gel was then blotted onto 
nitrocellulose transfer membranes using a Bio-Rad apparatus. After transfer, 
the filters were blocked at room temperature for 1 h with 5% non-fat powdered 
milk in TTBS (150 mM NaCl, 20 mM Tris-HCl pH 7.5). After washing twice 
with TTBS (150 mM NaCl, 20 mM Tris-HCl pH 7.5, 0.1% Tween 20), filters 
were incubated overnight at 4°C with [GAPDH (Cell Signaling, 2118); 
LUCIFERASE (Invitrogen, 356700)]. The filters were washed extensively with 
TTBS and incubated for 1 h at room temperature with antirabbit peroxidase-
conjugated secondary antibody [Santa Cruz, sc-2004 (goat anti-rabbit) and sc-
2005 (goat anti-mouse)] plus a chemiluminescent substrate (Thermo Scientific, 
34080).  Results were normalized to GAPDH; indeed, equal loading of lanes 
was confirmed by incubation with an anti-GAPDH antibody. 
 
Treatment of DS-HFFs with drugs 
• Treatment with metformin 
Two DS-HFFs lines (BIO-37 and BIO-71) at P3 passage were thawed and 
cultured in T25 flask with Chang medium C supplemented with 1% 
penicillin/streptomycin at 37°C in 5% CO2 atmosphere. Metformin (Sigma-
Aldrich, D150959) was dissolved in water to prepare a stock of 100 mM, and 
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then was added at final concentrations within the range between 0.5 mM and 2 
mM. The cells were treated for 72h and subjected to changes every 24h, with a 
culture medium supplemented with the drug, while the control cells were 
supplemented with water. The experiments were performed in triplicate for the 
measurement of OCR and in duplicate for other measuraments. 
 
• Treatment with pioglitazone 
Two DS-HFFs lines (BIO-71 and BIO-45) were thawed and cultured in T25 
flask with Chang medium C supplemented with 1% penicillin/streptomycin at 
37°C in 5% CO2 atmosphere. Pioglitazone (Takeda Pharmaceuticals, Osaka, 
Japan) was dissolved in a DMSO solution to prepare a stock of 1 mM, and then 
was added to a final concentrations of 100 nM, 1 µM  and 2µM. The cells were 
treated for 48 and 72 hours, and subjected to changes every 24h, with a culture 
medium supplemented only with the drug, while the control cells were 
supplemented with DMSO. The experiments were performed in triplicate for 
the measurement of OCR and in duplicate for other measurements. 
 
Measurement of OCR in cell cultures 
Oxygen consumption rate (OCR) in adherent fibroblasts was measured with an 
XFe 96 Extracellular Flux Analyzer (Seahorse Bioscience, Billerica, MA, 
USA). Cells from 2 DS-HFFs lines (BIO-71 and BIO-37) were cultured in T25 
flasks and treated with different concentrations of the drug for 48 h, with 
culture medium supplemented with the drug and subjected to change every 24 
hour. After this time, approximately 22,000 cells/well were plated in a 
microplate of 96 wells. The plate was then incubated in CHANG medium C 
supplemented with the drug for 24h. At the end of 24h, the CHANG medium 
was removed from the plate and 175µl of the OCAR medium were added in the 
other half of the plate. The final volume of each well was 250µl. Finally the 
plate was incubated with the cells in an incubator without CO2 for 1h. 
Experiments were performed in duplicate according to manifacturer’s 
protocols. Each sample was plated in triplicate; for each well 12 measurements 
at different times, before and after the injection of inhibitors were carried out.  
These experiments were performed in collaboration with Prof. Matarese’s Lab.  
 
Measurement of mitochondrial mass 
The method to assess mitochondrial mass by confocal microscopy is based on 
the fluorescence of the mitochondrial network after the expression of a GFP 
specifically targeted to the mitochondria. DS-HFF cells and controls (BIO-45 
and BIO-71) were infected with adenovirus mtGFP in the culture medium, and 
incubated for a total of 48h after the addition of virus. Z-stack images were 
taken with a confocal system Nikon Eclipse Ti and analyzed by software 
NisElements Imaris 3.2 and 4.0. The software is able to provide, starting from 
the scanned image, the number of mitochondria per cell and the value of the 
mitochondrial mass; hence the value of the mitochondrial volume can be 
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obtained. Acquisitions Z-series were obtained using the software Huygens 
Essential 3.3. 
DS-HFF and N-HFF cell cultures were first infected with adenovirus mtGFP, 
incubated for 48 hours after the addition of virus, and finally treated with 
Pioglitazone at final concentration of 1µM for 48h. The control cells were 
treated with DMSO. The images were taken with a confocal system Nikon 
Eclipse Ti. 
 
Statistical analysis and softwares 
The Student t-test was applied to evaluate the statistical significance for 
differences in the measured data DS-HFFs vs N-HFFs, or in treated DS-HFFs 
vs untreated. The threshold for statistical significance (p-value) was set at 0.05. 
GeneSpring software vers. 11.5 Multi–Omic Analysis (Agilent technologies, 
Inc.) was used to identify differentially expressed genes with a Fold change 
(LogFC) >0.3 and < -0.3, P<0.05.  
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4. RESULTS 
4.1 Meta-analysis of public expression dataset 
 
To identify which Hsa21 gene might affect either NEMG or ECM expression, 
we screened the Gene Expression Omnibus repository 
(http://www.ncbi.nlm.nih.gov/geo) for gene expression data related to the 
modulation of Hsa21 genes. We selected the GSE19836 experiment (De Cegli 
et al. 2010), a dataset derived from the analysis of a mouse embryonic stem 
cells (ESC) bank in which 32 orthologs of human chromosome 21 genes, 
including transcription factors and protein kinases, were individually 
overexpressed in an inducible manner. 
 
NRIP1 overexpression negatively regulates NEMG expression 
We re-analyzed GSE19836 data focusing on the mitochondria-related 
categories and pathways dysregulated by the overexpression of each gene, i.e. 
we looked for Hsa21 genes that when overexpressed would induce NEMG 
downregulation. Among the 20 analyzed Hsa21 genes, only NRIP1, one of the 
7 genes considered "effective" for the expression perturbation in the 
manipulated cells (De Cegli et al. 2010), was able to cause NEMG 
downregulation when overexpressed. Our analysis showed that NRIP1 over-
expression caused a significant enrichment of NEMGs among the 298 
downregulated genes. The "Mitochondrion" was the most affected Cell 
Component Gene Ontology (GO) category (p<10-3), with a cluster of 37 
downregulated genes (Tab. 2). Motif enrichment analysis, by clustering 
downregulated genes based on their promoter regions, revealed a significant 
enrichment (p< 0.005) in genes with the ERRα motif. Twenty-five 
downregulated genes, instead of the expected 10, showed promoter regions 
around the transcription start site containing the ERRα motif.  
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TABLE 2 Mitochondria related genes downregulated after NRIP1 overexpression  
PROBE_SET GENE_SYMBOL DESCRIPTION 
1434866_x_at Cpt1a carnitine palmitoyltransferase 1a, liver 
1417956_at Cidea cell death-inducing DNA fragmentation factor, alpha 
subunit-like effector A 
1455106_a_at Ckb creatine kinase, brain 
1428145_at Acaa2 acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-
oxoacyl-Coenzyme A thiolase) 
1427342_at Fastkd1 FAST kinase domains 1 
1454674_at Fez1 fasciculation and elongation protein zeta 1 (zygin I) 
1428516_a_at Alkbh7 alkB, alkylation repair homolog 7 (E. coli) 
1421010_at Mobp myelin-associated oligodendrocytic basic protein 
1424562_a_at Slc25a4 solute carrier family 25 (mitochondrial carrier, adenine 
nucleotide translocator), member 4 
1450048_a_at Idh2 isocitrate dehydrogenase 2 (NADP+), mitochondrial 
1418091_at Tfcp2l1 transcription factor CP2-like 1 
1422703_at Gyk glycerol kinase 
1434499_a_at Ldhb lactate dehydrogenase B 
1423108_at Slc25a20 solute carrier family 25 (mitochondrial 
carnitine/acylcarnitine translocase), member 20 
1416457_at Ddah2 dimethylarginine dimethylaminohydrolase 2 
1429021_at Epha4 Eph receptor A4 
1451504_at Chchd3 coiled-coil-helix-coiled-coil-helix domain containing 3 
1433855_at Abat 4-aminobutyrate aminotransferase 
1451744_a_at Ptgr2 prostaglandin reductase 2 
1439947_at Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1 
1418709_at Cox7a1 cytochrome c oxidase, subunit VIIa 1 
1431980_a_at As3mt arsenic (+3 oxidation state) methyltransferase 
1425140_at Lactb2 lactamase, beta 2 
1419656_at Slc25a36 solute carrier family 25, member 36 
1427705_a_at Nfkb1 nuclear factor of kappa light polypeptide gene 
enhancer in B cells 1, p105 
1455991_at Ccbl2 cysteine conjugate-beta lyase 2 
1428140_at Oxct1 3-oxoacid CoA transferase 1 
1453738_at C330018D20Rik RIKEN cDNA C330018D20 gene 
1451084_at Etfdh electron transferring flavoprotein, dehydrogenase 
1456711_at 4932425I24Rik RIKEN cDNA 4932425I24 gene 
1417089_a_at Ckmt1 creatine kinase, mitochondrial 1, ubiquitous 
1418288_at Lpin1 lipin 1 
1416023_at Fabp3 fatty acid binding protein 3, muscle and heart 
1418640_at Sirt1 sirtuin 1 (silent mating type information regulation 2, 
homolog) 1 (S. cerevisiae) 
1434996_at Slc25a16 solute carrier family 25, member 16 
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1424056_at Usp48 ubiquitin specific peptidase 48 
1437974_a_at Hk1 hexokinase 1 
The analysis of differentially expressed genes in the in the GSE19836 experiment from GEO 
repository showed an enrichment of genes belonging to the cellular component 
“Mitochondrion” (GO:0005739). 
 
 
RUNX1 overexpression positively regulates ECM expression 
We re-analyzed the GSE19836 dataset focusing on ECM-related categories and 
pathways dysregulated by the overexpression of each gene, i.e. we looked for 
Hsa21 genes that when overexpressed would induce ECM gene upregulation. 
Only RUNX1 was able to cause ECM gene upregulation when overexpressed. 
Our analysis showed that RUNX1 overexpression caused a significant 
enrichment among the 573 upregulated genes (logFC>0.3, Adj.P-val <0.01). 
The “extracellular matrix” (GO:0031012) was the most affected Cell 
Component Gene Ontology category (P-val = 3.00 e-04), with a cluster of 32 
upregulated genes (Tab. 3). No other Hsa21 transcription factor or regulator 
under analysis showed a similar effect. 
 
 
TABLE 3 Extracellular Matrix genes upregulated after RUNX1 overexpression  
PROBE_SET GENE_SYMBOL DESCRIPTION 
1455965_at Adamts4 disintegrin-like and metallopeptidase (reprolysin type) 
with thrombospondin type 1 motif, 4 
1416298_at Mmp9 matrix metallopeptidase 9 
1416531_at Gsto1 glutathione S-transferase omega 1 
1419613_at Col7a1 collagen, type VII, alpha 1 
1450704_at Ihh Indian hedgehog 
1418910_at Bmp7 bone morphogenetic protein 7 
1418477_at Matn1 matrilin 1, cartilage matrix protein 
1424131_at Col6a3 collagen, type VI, alpha 3 
1437277_x_at Tgm2 transglutaminase 2, C polypeptide 
1419573_a_at Lgals1 lectin, galactose binding, soluble 1 
1426642_at Fn1 fibronectin 1 
1420569_at Chad Chondroadherin 
1415935_at Smoc2 SPARC related modular calcium binding 2 
1420855_at Eln Elastin 
1450673_at Col9a2 collagen, type IX, alpha 2 
1416589_at Sparc secreted acidic cysteine rich glycoprotein 
1460187_at Sfrp1 secreted frizzled-related protein 1 
1426231_at Vit Vitrin 
1419527_at Comp cartilage oligomeric matrix protein 
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1419091_a_at Anxa2 annexin A2 
1438312_s_at Ltbp3 latent transforming growth factor beta binding protein  
1449335_at Timp3 tissue inhibitor of metalloproteinase 3 
1417389_at Gpc1 glypican 1 
1416740_at Col5a1 collagen, type V, alpha 1 
1421279_at Lamc2 laminin, gamma 2 
1448870_at Ltbp1 latent transforming growth factor beta binding protein  
1452106_at Npnt Nephronectin 
1460227_at Timp1 tissue inhibitor of metalloproteinase 1 
1448598_at Mmp17 matrix metallopeptidase 17 
1420891_at Wnt7b wingless-related MMTV integration site 7B 
1422571_at Thbs2 thrombospondin 2 
The analysis of differentially expressed genes in the in the GSE19836 experiment from GEO 
repository showed an enrichment of genes belonging to the cellular component “extracellular 
matrix” (GO: 0031012). 
 
 
NRIP1 and PGC-1α modulation dysregulates the same NEMGs 
underexpressed in DS fetal hearts  
NRIP1 is a known repressor of the PGC-1α protein. To investigate whether the 
sets of genes regulated by NRIP1 and/or PGC-1α overlap the NEMGs 
downregulated in DS fetal hearts (Conti et al. 2007), we performed a meta-
analysis comparing three sets of gene expression data. 
SET1 included 123 genes which were both upregulated after NRIP1 silencing 
and downregulated after NRIP1 re-expression in mouse adipocytes (Powelka et 
al. 2006). SET2 included 129 genes, which were upregulated after PGC-1α 
induction in SAOS2 cells (human osteoblast-like cells) (Schreiber et al. 2004). 
SET3 included the 70 genes downregulated in DS fetal heart tissues (Conti et 
al. 2007) belonging to the ‘mitochondrion’ GO category. The comparison was 
aimed at identifying genes consistently dysregulated across these studies. The 
Venn Diagram in Figure 19 shows that the three sets of genes overlap each 
other for at least 25 genes. Fifteen genes are consistently dysregulated across 
all three experiments. Most of these genes are included in the electron transport 
chain, mainly in complex I, and in oxidative phosphorylation pathways. It is 
also interesting to note that 42 genes overlap between the sets of genes 
inversely regulated by NRIP1 and PGC-1a (SET1 and SET2), in agreement 
with the antagonistic functions of the two coregulators (Fritah et al. 2010). 
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Fig. 19 Venn Diagram comparing NEMGs downregulated in DS fetal hearts with those 
dysregulated by NRIP1 and/or PGC-1a. A) Twenty-five out of the 70 mitochondrial genes 
that are downregulated in DS fetal hearts (SET3) (Conti et al. 2007) overlap the list of NRIP1 
regulated genes (SET1) (Powelka et al. 2006) and 29 overlap the list of PGC-1a regulated 
genes (SET2) (Schreiber et al. 2004). B) List of mitochondria-related genes overlapping in the 
three sets of data. 
 
 
Promoter analysis of genes downregulated in DS fetal hearts shows enrichment 
for transcription factors repressed by NRIP1 
The promoter regions (-450bp to +50bp from transcription start site) of 
mitochondrial genes downregulated in DS fetal heart tissues (Conti et al. 2007) 
were analyzed in order to recognize DNA binding motifs for both NRF1 and 
ERRα matrices using PSCAN software (Zambelli et al. 2009). The list of 
downregulated genes was ranked according to the prediction of binding affinity 
of their promoter regions to NRF1 and ERRα binding sites with a cut-off of 
affinity score =0.80 and p-value <0.003. Interestingly, 40% of the 80 
mitochondrial genes downregulated in fetal hearts, have consensus DNA 
binding sites for the nuclear respiratory factor NRF1 in their 5’ flanking 
regions (Tab. 4); 20% of them show a high affinity for the estrogen-related 
receptor ERRα (Tab. 5).  
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TABLE 4 Mitochondrial genes downregulated in DS heart tissues with NRF1 binding site 
in their promoter regions.  
GENE NAME DESCRIPTION 
ECGF1 Endothelial Cell Growth Factor 1 
SCO2 SCO Cytochrome Oxidase Deficient Homolog 2 
PIN4 Protein (Peptidylprolyl Cis/Trans Isomerase) NIMA-Interacting, 4 
IDH3A Isocitrate Dehydrogenase 3 (NAD+) Alpha 
UQCRC1 Ubiquinol-Cytochrome C Reductase Core Protein 1 
NDUFB8 NADH Dehydrogenase (Ubiquinone) 1 Beta Subcomplex, 8, 19kDa 
RPL10 Ribosomal Protein L10 
ENDOG Endonuclease G 
SDHA Succinate Dehydrogenase Complex, Subunit A, Flavoprotein (Fp) 
UQCRC2 Ubiquinol-Cytochrome C Reductase Core Protein II 
ETFB Electron-Transfer-Flavo protein, Beta Polypeptide 
GLUD1 Glutamate Dehydrogenase 1 
NDUFAB1 NADH Dehydrogenase (Ubiquinone) 1, Alpha/Beta Subcomplex, 1, 8kDa 
CYCS Cytochrome C, Somatic1 
SDHB Succinate Dehydrogenase Complex, Subunit B, Iron Sulfur 
HSPA9 Heat Shock 70kDa Protein 9 
MRPL15 Mitochondrial Ribosomal Protein L151 
SLC25A12 Solute Carrier Family 25 (Aspartate/Glutamate Carrier), Member 12 
VDAC1 Voltage-Dependent Anion Channel 1 
HCCS Holocytochrome C Synthase 
IDH3B Isocitrate Dehydrogenase 3 (NAD+) Beta 
IDH2 Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial 
COX4NB ER Membrane Protein Complex Subunit 8 
COQ7 Coenzyme Q7 Homolog, Ubiquinone 
ETFA Electron-Transfer-Flavoprotein, Alpha Polypeptide 
GOT1 Glutamic-Oxaloacetic Transaminase 1, Soluble 
NDUFA13 NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex, 13 
NDUFS2 NADH Dehydrogenase (Ubiquinone) Fe-S Protein 2, 49kDa (NADH 
Coenzyme Q Reductase) 
PDHA1 Pyruvate Dehydrogenase (Lipoamide) Alpha 1 
DLAT Dihydrolipoamide S-Acetyltransferase 
GCSH Glycine Cleavage System Protein H (Aminomethyl Carrier) 
MOSC2 Mitochondrial Amidoxime Reducing Component 2 
AK2 Adenylate kinase 2 
NRF1 target genes are sorted with a cut-off affinity score =0.80 
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TABLE 5 Mitochondrial genes downregulated in DS heart tissues with ERRα binding site 
in their promoter regions.  
GENE NAME DESCRIPTION 
HSPA9 Heat Shock 70kDa Protein 9 
MOSC2 Mitochondrial Amidoxime Reducing Component 2 
SDHA Succinate Dehydrogenase Complex, Subunit A, Flavoprotein (Fp) 
TXN2 Thioredoxin 2 
MRPL35 Mitochondrial Ribosomal Protein L151 
BDH1 3-Hydroxybutyrate Dehydrogenase, Type 1 
NDUFB8 NADH Dehydrogenase (Ubiquinone) 1 Beta Subcomplex, 8, 19kDa 
COX7A2 Cytochrome C Oxidase Subunit VIIa Polypeptide 2 
SDHB Succinate Dehydrogenase Complex, Subunit B, Iron Sulfur 
DLAT Dihydrolipoamide S-Acetyltransferase 
NDUFAB1 NADH Dehydrogenase (Ubiquinone) 1, Alpha/Beta Subcomplex, 1, 8kDa 
COQ7 Coenzyme Q7 Homolog, Ubiquinone 
MRPS12 Mitochondrial Ribosomal Protein S12 
TIMM23 Translocase Of Inner Mitochondrial Membrane 23 Homolog 
ETFA Electron-Transfer-Flavoprotein, Alpha Polypeptide 
ATP5B ATP Synthase, H+ Transporting, Mitochondrial F1 Complex, Beta 
Polypeptide 
IDH3B Isocitrate Dehydrogenase 3 (NAD+) Beta 
ECI1 Enoyl-CoA Delta Isomerase 1 
MRPL15 Mitochondrial Ribosomal Protein L151 
ETFB Electron-Transfer-Flavo protein, Beta Polypeptide 
COX4NB ER Membrane Protein Complex Subunit 8 
CYCS Cytochrome C, Somatic1 
UQCRFS1 Ubiquinol-Cytochrome C Reductase, Rieske Iron-Sulfur Polypeptide 1 
SLC25A4 Solute Carrier Family 25 (Mitochondrial Carrier; Adenine Nucleotide 
Translocator), Member 4 
GOT1 Glutamic-Oxaloacetic Transaminase 1, Soluble 
PIN4 Protein (Peptidylprolyl Cis/Trans Isomerase) NIMA-Interacting, 4 
SCO2 SCO Cytochrome Oxidase Deficient Homolog 2 
NFS1 NFS1 Cysteine Desulfurase 
CKMT2 Creatine Kinase, Mitochondrial 2 
IMMT Inner Membrane Protein, Mitochondrial 
DLST Dihydrolipoamide S-Succinyltransferase (E2 Component Of 2-Oxo-
Glutarate Complex) 
MIPEP Mitochondrial Intermediate Peptidase 
COX10 Cytochrome C Oxidase Assembly Homolog 10 (Yeast 
ERRα target genes are sorted with a cut-off affinity score =0.80 
 
48 
 
Promoter analysis of genes upregulated in DS fetal hearts shows enrichment 
for the transcription factor RUNX1 
We performed a transcription factor-binding site (TFBS) analysis on the list of 
ECM genes upregulated in DS fetal hearts with the PSCAN software, in order 
to scan promoters of these genes for consensus sequences according to the 
JASPAR database. This analysis identified RUNX1 as a transcription factor 
with high binding specificity to ECM genes upregulated in DS hearts (Tab.6). 
About 60% of ECM genes overexpressed in DS hearts show consensus 
sequences for RUNX1. 
Molecular and functional studies are currently in progress in order to evaluate 
the effects of RUNX1 modulation on ECM gene expression and on cellular 
phenotype in euploid and trisomic fetal skin fibroblasts. 
 
TABLE 6 ECM genes upregulated in DS hearts with consensus sequence for RUNX1 
GENE NAME DESCRIPTION 
ECM2 extracellular matrix protein 2, female organ and adipocyte specific 
COL6A2 collagen, type VI, alpha 2 
GPC3 glypican 3 
APP amyloid beta (A4) precursor protein 
ADAMTS5 ADAM metallopeptidase with thrombospondin type 1 motif, 5 
ITGB4 integrin, beta 4 
COL18A1 collagen, type XVIII, alpha 1 
MMP11 matrix metallopeptidase 11 (stromelysin 3) 
FLRT2 fibronectin leucine rich transmembrane protein 2 
APP amyloid beta (A4) precursor protein 
COL3A1 collagen, type III, alpha 1 
DCN decorin 
ADAMTS7 ADAM metallopeptidase with thrombospondin type 1 motif, 7 
COLEC10 collectin sub-family member 10 (C-type lectin) 
WNT4 wingless-type MMTV integration site family, member 4 
HAPLN1 hyaluronan and proteoglycan link protein 1 
COL5A1 collagen, type V, alpha 1 
DCN Decorin 
C1QTNF3 C1q and tumor necrosis factor related protein 3 
LAMA4 laminin, alpha 4 
FBLN1 fibulin 1 
COL9A3 collagen, type IX, alpha 3 
APP amyloid beta (A4) precursor protein 
VCAN versican 
COL13A1 collagen, type XIII, alpha 1 
COL14A1 collagen, type XIV, alpha 1 
DTL denticleless E3 ubiquitin protein ligase homolog (Drosophila) 
ASPN Aspirin 
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4.2 OCR is decreased in DS-HFFs 
As preliminary experiments before testing the role of NRIP1 in causing the 
mitochondrial dysfunction in DS cells, we examined some features of the 
mitochondrial activity of the cell lines to be used thereafter. The first parameter 
we measured was the OCR. We compared two lines of trisomic fetal 
fibroblasts (DS-HFF) and two euploid lines (N-HFF) by XFe 96 Extracellular 
Flux Analyzer (Seahorse Bioscience, Billerica, MA, USA), a novel approach to 
evaluate mitochondrial respiration.  
After an OCR baseline measurement, oligomycin (OL), carbonyl cyanide 4- 
(trifluoromethoxy) phenylhydrazone (FCCP) and antinomycin/rotenon 
(ANT/ROT) solutions were sequentially added to each well to reach working 
concentrations and changes in the OCR were analyzed.  
The results of the XFe Analyzer measurements indicated a decrease of OCR by 
approximately 70% in DS-HFFs when compared to N-HFFs (Fig. 20). 
 
 
Fig. 20 XF Cell Mito Stress Test profile of the key parameters of mitochondrial 
respiration. (A) Sequential compound injections measure: basal OCR (injection 1-
oligomycin), ATP linked (injection 2 -carbonyl cyanide 4-trifluoromethoxy phenylhydrazone, 
FCCP) and maximal OCR (injection 3 -antinomycin/rotenone, ANT/ROT). (B) The XFe 
Analyzer showed a decrease of OCR by approximately 70% in DS-HFFs when compared to N-
HFFs. Values represent the average determination±SEM for DS-HFFs and N-HFFs carried out 
in triplicate. * p < 0.05. P-value was expressed for trisomic cells vs euploid cells. 
 
 
4.3 DS-HFFs show a very fragmented mitochondrial network 
 
In order to test whether a decreased mitochondrial biogenesis in DS-HFFs was 
associated to a variation of mitochondrial mass, parameters such as the 
number, volume and mitochondrial mass of individual cells were compared 
between DS-HFFs and N-HFFs. The trisomic and euploid cells were 
transfected with a mitochondrially targeted GFP (mtGFP) and incubated for 48 
hours. The analysis of mtGFP distribution by confocal microscopy showed that 
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there was a significant difference in the mitochondrial number and volume 
when comparing trisomic cells and controls: in particular, DS-HFF cells had a 
greater number of isolated mitochondria (Fig. 21A), and a smaller average 
mitochondrial volume (Fig. 21B). However, mitochondrial mass determination 
did not show significant differences between trisomic cells and euploid 
controls (Fig. 21C).  
 
Fig. 21 Mitochondrial morphology in DS-HFF and N-HFF. (A) The number of 
mitochondria was significantly higher in trisomic cells compared to controls. (B) The 
mitochondrial volume was significantly lower in trisomic cells compared to controls. (C) By 
comparing the values of the mitochondrial mass there were no significant differences between 
cells trisomic and euploid controls. * P <0.05. P-value was expressed for trisomic cells vs. 
euploid cells. 
 
 
Confocal microscopy images showed a mitochondrial network much less 
fragmented in control cells when (Fig. 22A) compared to DS-HFF cells (Fig. 
22B).  
 
 
Fig. 22 Mitochondrial network in DS-HFF and control cells. (A) Confocal microscopy 
images obtained with Nikon Eclipse Ti showed the mitochondrial network in euploid cells. (B) 
Mitochondrial network in trisomic cell. The mitochondrial network apparead more fragmented 
in trisomic cells respect to controls. 
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4.4 The Hsa21 gene NRIP1 is a major regulator of PGC-1α 
  
To test the hypothesis that NRIP1 overexpression perturbs mitochondrial 
function and that this effect is associated with PGC-1α downregulation, we 
performed silencing experiments of NRIP1 gene in DS-HFFs. We attenuated 
NRIP1 expression by either 5 or 20 nm siRNA in DS-HFFs. Seventy-two hours 
after transfection we performed qRT-PCR demonstrating a significant inverse 
correlation between NRIP1 silencing and PGC-1α upregulation in a siRNA 
dosage-dependent way (Fig. 23).  
 
 
 
Fig. 23 NRIP1 attenuation modulates PGC-1α expression in DS-HFFs. NRIP1 and PGC-1α 
expression levels in trisomic cells transfected with a scrambled siRNA and with a NRIP1-
specific SMART pool of siRNAs. A decrease in the NRIP1 expression level corresponds to an 
increase of PGC-1α expression level in a siRNA-dependent way. Values represent the average 
determination ± SEM for 4 NRIP1-silenced DS-HFFs carried out in triplicate.∗=p<0.05, 
∗∗=p<0.01. P-values express statistical significance for NRIP1-silenced versus scrambled 
comparisons. 
 
 
4.5 NRIP1 siRNA transfection decreases NRIP1 in the nucleus 
of DS-HFFs  
To have a deeper understanding of mechanisms by which NRIP1 exerts his 
repressive activity, we investigated the localization of NRIP1 protein by 
immunofluorescence methods demonstrating that the NRIP1 protein localized 
to the cell nucleus, both in euploid and in trisomic fibroblasts (Fig. 24). 
Fluorescent signal was more intense in nuclei of DS-HFFs (Fig. 24B) than in 
N-HFFs (Fig. 24A), indicating a higher concentration of the NRIP1 protein in 
trisomic cells. In these cells, some fluorescent signal was also present in the 
cytoplasm (Fig. 24B) likely due to the overexpression of the NRIP1 protein.  
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The attenuation of NRIP1 expression caused a decrease of the fluorescent 
signal in silenced versus scrambled DS-HFFs in a siRNA dosage-dependent 
way (Fig. 24). Quantitative evaluation of fluorescence intensities in euploid, 
trisomic and siRNA transfected cells (Fig. 24F) indicated that siRNA 
transfection reduced NRIP1 protein levels of trisomic cells down to the range 
of diploid cells or even lower (Fig. 24D and E). In particular, signal from 5 
nM NRIP1 siRNA transfected cells was comparable with euploid HFFs. 
 
Fig. 24 NRIP1 immunofluorescence in NRIP1-silenced DS-HFFs. Representative images of 
NRIP1 immunofluorescence analysis in A) euploid cells, B) trisomic cells and trisomic cells 
transfected C) with a scrambled siRNA, D) with 5 nM NRIP1 siRNA and E) 20 nM NRIP1 
siRNA. F) Semi-quantitative analysis of the immunodetected signals by the ImageJ software 
(means ± SEM of three assayed samples). Fifty randomly selected, different cells for each 
sample/experimental condition were analyzed. A decrease of the fluorescent signal is observed 
in silenced versus scrambled DS-HFFs. Signal from 5 nM NRIP1 siRNA transfected cells is 
comparable with euploid HFFs. Statistical significance: ∗∗=p<0.01 for trisomic versus euploid 
comparisons; #=p<0.05 for NRIP1-silenced versus scrambled comparisons. 
 
4.6 NRIP1 silencing improves mitochondrial function in DS-
HFFs  
To investigate whether NRIP1 affects mitochondrial function in DS possibly 
through the downregulation of PGC-1α and other NEMGs, we evaluated 
functional parameters in DS-HFFs after NRIP1 silencing compared to not 
silenced cells. We evaluated redox state of DS-HFF silenced cells by 
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measuring NEMGs expression, ROS production, mitochondrial activity, 
mitochondrial biogenesis and ATP production.  
 
 
 NRIP1 silencing affects NEMG expression in DS-HFFs 
To determine the effects of NRIP1 attenuation by siRNA on other 
mitochondria-related genes, we compared the expression of seven genes in 
silenced versus scrambled cells using qRT–PCR. Three genes, i.e. COX5A, 
NDUFA1 and NDUFS3, were chosen from the list of 15 genes that resulted 
consistently dysregulated across the three sets compared in the meta-analysis 
(Fig. 19). The fourth gene, NRF1, which is downregulated in DS hearts (Conti 
et al. 2007) and fibroblasts (Piccoli et al. 2013), was chosen because of its role 
both as a PGC-1α partner and as its target. Finally, three other genes, i.e. 
ANT1/SLC25A4, ANT2/SLC25A5 and ANT3/SLC25A6, which are 
downregulated in DS fetal fibroblasts (our unpublished data), were also chosen 
as PGC-1α targets (Schreiber et al. 2004). ANT1/SLC25A4 is downregulated in 
SET3 and after NRIP1 overexpression in the De Cegli’s dataset (Tab. 2) (De 
Cegli et al. 2010). The expression ratio of these genes in NRIP1-silenced DS-
HFFs versus scrambled transfected DS-HFFs demonstrated that five out of 
seven analyzed genes were significantly upregulated after NRIP1 attenuation 
by siRNA (Fig. 25). 
 
 
 
Fig. 25 Mitochondria-related gene expression in NRIP1-silenced DS-HFFs. Relative 
mRNA expression of seven mitochondria-related genes was measured in NRIP1-silenced DS-
HFFs versus scrambled transfected DS-HFFs. Five out of the seven genes show a significant 
increase in their expression level. Values represent the average determination ± SEM for three 
DS-HFFs samples carried out in triplicate. A pool of scrambled transfected euploid cells was 
used as calibrator. ∗=p<0.05. P-value expresses statistical significance for NRIP1-silenced 
versus scrambled comparisons. 
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NRIP1 silencing decreases mitochondrial ROS 
Since the mitochondrial respiratory chain is known to be the major source of 
ROS within the cell (Kussmaul and Hirst, 2006; Li and Trush, 1998), the 
intracellular redox state was assessed by confocal microscopy using DCF. The 
intensity of DCF was measured in silenced DS-HFFs compared either to non 
transfected DS-HFF or to N-HFF samples.  
Seventy-two hours after transfection with NRIP1 siRNA, trisomic cells showed 
a fluorescent signal of DCF up to 50% decreased in silenced DS-HFFs in a 
siRNA-dosage dependent way (Fig. 26).  
 
Fig. 26 Live cell imaging of confocal microscopy analysis of the DCF fluorescence in 
transfected DS-HFFs: A) scrambled, B) 5 nM NRIP1 siRNA and C) 20 nM NRIP1 siRNA. 
D) Semi-quantitative analysis of the DCF-related fluorescence by the ImageJ software (means 
± SEM of three assayed samples). Fifty randomly selected, different cells for each 
sample/experimental condition were analyzed. A significant decrease of DCF-related 
fluorescence is observed after NRIP1 attenuation in a siRNA-dependent way. Pixel intensity 
was measured in about 50 cells after NRIP1 silencing. ∗∗=p<10-4. P-value expresses statistical 
significance for NRIP1-silenced versus scrambled comparisons. 
55 
 
ROS production was also evaluated by confocal microscopy using a 
MitoSOX™ Red reagent, a fluorogenic dye specifically targeted to 
mitochondria in live cells. Oxidation of MitoSOX™ Red reagent by 
superoxide produces red fluorescence. This reagent is a live-cell permeant that 
is rapidly and selectively targeted to mitochondria. Our aim was to investigate 
whether this parameter is correlated to NRIP1 expression. MitoSOX™ 
fluorescent intensity was decreased in DS-HFFs silenced cells, thus suggesting 
that the decrease in ROS was in part associated to mitochondrial activity (Fig. 
27).  
 
 
 
Fig. 27 Intra-mitochondrial superoxide decrease in NRIP1-silenced DS-HFFs measured 
using Mitosox Red. Confocal microscopy live cell imaging of the MitoSOX Red fluorescence 
in transfected DS-HFFs: A) scrambled cells and B) 20 nM NRIP1 siRNA transfected cells. 
Note that the distribution of MitoSOX Red signal resem-bles the mitochondrial network. C) 
Semiquantitative analysis of the MitoSOX-related fluorescence by the ImageJ software (means 
± SEM of three assayed samples). Fifty randomly selected, different cells for each 
sample/experimental condition were analyzed. A reduction of the fluorescent signal over the 
mitochondrial network is detected. ∗∗=p<0.01. P-value expresses statistical significance for 
NRIP1-silenced versus scrambled comparisons. 
 
 
NRIP1 silencing increases mitochondrial activity  
In order to establish whether ROS decrease in NRIP1-silenced DS-HFFs 
depends on a rescue of respiratory chain complex activities, mitochondrial 
activity was evaluated using MitoTracker Red dye, a reagent that stains 
mitochondria in live cells according to their membrane potential. Mitotracker 
fluorescent intensity was increased in DS-HFFs silenced cells in a siRNA 
concentration dependent way, thus indicating an increase in respiratory activity 
(Fig. 28). 
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Fig. 28 Mitochondrial activity in DS NRIP1-silenced DS-HFFs. Confocal microscopy live 
cell imaging of the Mitotracker fluorescence in transfected DS-HFFs: A) scrambled cells and 
B) with 20 nM NRIP1 siRNA transfected cells C) Semi-quantitative analysis of the 
Mitotracker-related fluorescence by the ImageJ software (means ± SEM of five assayed 
samples). Fifty randomly selected, different cells for each sample/experimental condition were 
analyzed. An increase of Mitotracker-related fluores-cence is observed in NRIP1-silenced DS-
HFFs. ∗∗=p<0.005. P-value expresses statistical significance for NRIP1-silenced versus 
scrambled comparisons. 
 
 
NRIP1 silencing increases mtDNA content  
As an indirect measure of the mitochondrial biogenesis, we quantified by qRT-
PCR the gene expression of gene D-LOOP and ACTIN, mtDNA and nuclear 
DNA markers respectively, in NRIP1-silenced trisomic samples versus 
scrambled controls. The average ratio D-LOOP/ ACTIN indicated an increase 
of 2.5-fold in silenced trisomic cells, after NRIP1 attenuation by siRNA (Fig. 
29), thereby suggesting that mtDNA content increases after NRIP1 attenuation 
by siRNA and consequent PGC-1α overexpression. 
 
Fig. 29 mtDNA content in NRIP1-silenced DS-HFFs. Ratio between the mtDNA marker D-
LOOP and the nuclear DNA marker ACTIN was increasead after NRIP1 attenuation by siRNA. 
The ratio was calculated upon normalization to a reference gene (ABELSON) by qRT–PCR. 
Values represent the average determination ± SEM for three NRIP1-silenced trisomic samples 
carried out in triplicate. ∗=p<0.05. P-value expresses statistical significance for NRIP1-silenced 
versus scrambled comparisons. 
57 
 
NRIP1 silencing strongly increases cellular ATP content 
The universal energy carrier ATP defines the energy state in living cells and 
depends mainly on mitochondrial function (Bonora et al. 2012). In NRIP1-
silenced DS-HFFs, we investigated ATP concentration using a chimera of the 
ATP-sensitive photoprotein luciferase specifically targeted to mitochondria 
(mtLuc) to obtain a dynamic monitoring of [ATP]m. Luciferase has been 
widely employed to measure ATP content both in isolated mitochondria and in 
intact cells; its reaction with luciferin produces a flash of yellow green light 
with a peak emission at 560 nm, the intensity of which is proportional to the 
amount of substrates in the reaction mixture. Silenced DS-HFFs showed more 
than 50% increase of ATP content (Fig. 30), calculated by the luminescence 
values of the plateau generated after the addition of luciferin. Since basal ATP 
content is highly dependent on the abundance of transfected luciferase, we 
determined the exact amount of the luciferase transduced under our 
experimental conditions through an immunoblot assay. We found that the 
levels of luciferase protein transduced in NRIP1-silenced DS-HFFs were 
comparable with those detected in control cells transfected with the non-
targeting scrambled siRNA (Fig. 31). In parallel, NRIP1-silenced cells were 
slightly decreased in mitochondrial ATP production 72 hours after transfection. 
This was calculated by subtracting the basal cellular luminescence plateau, 
generated after the addition of luciferin, from the luminescence values of the 
second plateau, generated after the addition of the Ca2+ mobilizing agent 
histamine (Fig. 30).  
 
Fig. 30 Mitochondrial ATP measurement. A) The barplot of the mitochondrial ATP content 
and of the basal ATP content in scrambled and NRIP1 siRNA transfected DS-HFFs. B) The 
traces show mitochondrial [ATP]m changes elicited by mitochondrial [Ca2+] increase in cells 
perfused with 100 mM histamine as agonist. mtLuc luminescence data are expressed as a 
percentage of the initial value ± SEM. The traces are representative of four independent 
experiments. ∗=p<0.05, ∗∗=p<10-4. P-values express statistical significance for NRIP1-silenced 
versus scrambled comparisons. 
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Fig. 31 Luciferase expression following NRIP1 attenuation by siRNA. A) Representative 
immunoblot of luciferase protein in three NRIP1-silenced or scrambled DS-HFFs transfected 
with a luciferase-encoding plasmid specifically targeted to mitochondria (mtLuc) and cultured 
in complete medium for 72 h. B) Quantification of luciferase accumulation by the 
LUCIFERASE/GAPDH ratio. 
 
4.7 Drug testing in DS-HFFs cultures  
The mitochondrial rescue obtained by NRIP1 silencing, possibly mediated by 
restoring PGC-1α levels, suggested the possibility to pharmacologically induce 
PGC-1α activity in DS-HFFs. Two drugs have been tested: Metformin and 
Pioglitazone. Metformin, usually used to treat type 2 diabete, activates the 
AMPK pathway in liver and muscles, affecting mitochondrial biogenesis and 
function. Pioglitazone interacts with PPARγ, a nuclear receptor regulating the 
transcription of genes involved in glucidic and lipidic metabolism. 
 
4.7.1 Metformin counteracts mitochondrial dysfunction in DS-HFFs 
Metformin treatment increases the expression of mitochondria related genes 
To understand the impact of Metformin on the activation of the signaling 
pathway of PGC-1α, two DS-HFF cell lines were treated with different 
concentrations of the drug (0.5 mM, 1 mM and 2 mM) for 72 hours. The 
analysis of PGC-1α  gene by qRT-PCR demonstrated that the expression levels 
increased in treated DS-HFF cells at Metformin concentrations of 0.5 mm and 
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1 mM (Fig. 32A). The treatment with 2 mM Metformin did not cause 
significant changes compared to untreated trisomic control (Fig. 32A). 
The expression of NRF1, the main TF of mitochondrial enzymes was 
significantly increased at all Metformin concentrations (Fig. 32B). 
To evaluate the effects of Metformin treatment on mitochondrial biogenesis, 
the expression of D-LOOP and ACTIN was measured by qRT-PCR (Fig. 32C). 
The expression values of mtDNA (calculated from the ratio of genes D-
LOOP/ACTIN) increased in treated DS-HFF at Metformin concentrations of 
0.5 mm and 1 mM, while the treatment with 2 mM Metformin did not cause 
significant changes compared to untreated trisomic control (Fig. 32C). 
The expression of TFAM, a mitochondrial transcription factor, was increased 
after treatment at concentrations of 0,5 mM and 1 mM Metformin (Fig. 32D). 
The treatment with 2 mM Metformin did not cause significant changes 
compared to untreated trisomic control. 
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Fig. 32 qRT-PCR analysis in Metformin treated DS-HFF cells for 72h. (A) The expression 
levels of PGC-1α increased in treated DS-HFF cells for 72h at different Metformin 
concentrations when compared to untreated controls. (B) The expression values of NRF1 
increased at all Metformin concentration. (C) mtDNA, calculated as the ratio of genes D-
LOOP/ACTIN, increased in treated DS-HFF cells at Metformin concentrations of 0.5 mM and 
1 mM, while the treatment with 2 mM Metformin did not cause significant changes compared 
to untreated trisomic controls. The values represent the mean ± determined SEM; analysis were 
performed in triplicate. (D) The expression levels of TFAM increased in treated DS-HFF cells 
at Metformin concentrations of 0.5 mM and 1 mM, while the treatment with 2 mM Metformin 
did not cause significant changes compared to untreated trisomic controls Values represent the 
average determination ± SEM for two DS-HFFs samples carried out in triplicate. *=p<0.05. P-
value expressed statistical significance for treated trisomic cells versus untreated trisomic cells. 
 
 
Metformin treatment increases OCR in DS-HFFs 
To verify whether the increase of PGC-1α and mtDNA in treated trisomic cells 
were associated with an improvement of mitochondrial function, the rate of 
OCR was assayed by XFe 96 Extracellular Flux Analyzer. DS-HFF cells 
treated for 72 hours with different Metformin concentrations showed an 
increase of OCR inversely proportional to the concentration of the drug used. 
Best results were obtained at 0.5 mM Metformin concentration with a more 
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than 50% increase in comparison to non treated controls. In contrast, OCR was 
decreased in DS-HFF cells treated with 2 mM Metformin (Fig. 33). 
 
Fig. 33 Measurement of OCR in DS-HFF cells treated with different Metformin 
concentrations for 72h. (A) XFe Analyzer detected an increase of OCR of about two times in 
DS-HFF cells treated with 0.5mm Metformin concentration when compared to untreated 
trisomic control. In contrast, a reduction of mitochondrial parameters was observed in DS-HFF 
treated at higher Metformin concentration (2 mM) when compared to untreated controls. (B) 
Quantification of OCR values in Metformin treated trisomic cells compared to untreated 
controls. The optimal concentration at which there was the best result was of 0.5 mM. Values 
represent the average determination ±SEM for two DS-HFF samples carried out in triplicate. 
*= p<0.05. P-value expressed statistical significance for treated trisomic cells versus untreated 
trisomic cells. 
 
 
Metformin treatment increases mitochondrial activity 
Mitochondrial function after Metformin treatment was assessed by 
MitoTracker Red, as previously described. Three trisomic cell lines were 
treated for 72 hours with Metformin at a 0.5 mM concentration. Confocal 
microscopy showed a 70% increase in red fluorescence in treated DS-HFFs 
(Fig. 34B) when compared with non treated DS-HFFs (Fig. 34A). The semi-
quantitative analysis of Mitotracker fluorescence by ImageJ software is shown 
(Fig. 34C). 
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Fig. 34 Mitochondrial activity was increased in DS-HFF cells treated with Metformin. 
Confocal microscopy live cell imaging of the Mitotracker fluorescence in treated DS-HFFs: 
(A) untreated controls and (B) cells treated at the concentration of 0.5 mM Metformin for 72h. 
The cells were randomly selected, fifty cells for each sample/experiment were analyzed. An 
increase in Mitotracker-related fluorescence was observed in DS-HFF cells treated with 
Metformin compared to untreated controls. (C) Semiquantitative analysis of the Mitotracker-
related fluorescence using ImageJ software, which showed an increase in fluorescence up to 
70% more in treated DS-HFF cells, compared to untreated trisomic controls. *=p<0.05. The P-
value expressed statistical significance for treated trisomic cells vs. untreated trisomic cells. 
 
 
Moreover, the analysis showed comparable fluorescence in untreated N-HFFs 
(Fig. 35A) and in DS-HFF treated with Metformin (Fig. 35B)  
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Fig. 35 Comparison of mitochondrial activity in DS-HFF treated with Metformin and 
euploid untreated controls.  Confocal microscopy live cell imaging of the Mitotracker 
fluorescence in treated DS-HFFs: (A) untreated euploid controls and (B) trisomic cells treated 
with 0.5 mM Metformin for 72h. The cells were randomly selected, fifty cells for each 
sample/experiment were analyzed. (C) Semiquantitative analysis of the Mitotracker-related 
fluorescence using ImageJ software. The comparison between treated DS-HFF and untreated 
euploid control (NT) showed a very similar fluorescence.  *=p<0.05. The P-value expressed 
statistical significance for treated trisomic cells vs. untreated euploid cells. 
 
4.7.2 Pioglitazone counteracts mitochondrial dysfunction in DS-HFFs 
Pioglitazone treatment increases cellular ATP content 
ATP production in DS-HFFs was assessed as described above in 2 DS-HFF 
cultures treated with Pioglitazone at different concentrations (100 nM, 1 µM  
and 2µM), for either 48 or 72 hours. ATP production was increased in treated 
cells in a dosage dependent way (Fig. 36). The increase was very significant at 
72 hours: the treatment with 1 µM Pioglitazone raised the ATP content up to 
the values observed in euploid cells. 
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Fig. 36 ATP concentration dosage in Pioglitazone DS-HFF cells. (A). DS-HFF cells treated 
with Pioglitazone at different concentrations for 48 hours showed an increase of up to 50% of 
mitochondrial ATP-dosage compared to untreated control. (B) DS-HFF cells treated with 
Pioglitazone at different concentrations for 72 showed an increase of ATP three times greater 
than trisomic untreated controls . *=p<0.05. The P-value expressed statistical significance for 
trisomic treated cells vs. untreated cells. 
 
 
Pioglitazione treatment affects mitochondrial network in DS-HFFs 
Pioglitazone is a drug that acts as an agonist of PPARγ, therefore able to affect 
the biogenesis and mitochondrial function. To evaluate the effects of 
Pioglitazone on mitochondrial morphology, DS-HFF cells were infected with 
the addition of an adenovirus mtGFP in the culture medium, incubated for the 
next 72 hours, and subjected to treatment with 1 µM Pioglitazone for 72h. As 
shown in Figure 37 the mitochondrial network is much less fragmented if 
compared to untreated trisomic control.  
More experiments are needed to plot data and to analyze statistical 
significance. 
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Fig. 37 Mitochondrial network in Pioglitazone DS-HFF treated at concentration of 1 µM. 
(A) Confocal microscopy images showed mitochondrial network in a euploid cell. (B) 
Mitochondrial network in a trisomic untreated cell. (C) Mitochondrial network in a trisomic 
cell treated with 1 µM Pioglitazone for 72h. Confocal microscopy images obtained with Nikon 
Eclipse Ti showed that the mitochondrial network in DS-HFF cells is much less fragmented as 
a result of treatment with the drug. 
 
 
Pioglitazone treatment increases the expression of mitochondria related genes 
To understand the impact of Pioglitazone on the activation of PGC-1α 
signaling pathway, two DS-HFF cell lines were treated with different 
concentrations of the drug (100 nM, 1 µM and 2 µM) for 72 hours. The 
analysis of PGC-1α gene expression by qRT-PCR demonstrated that the 
expression levels increased in treated DS-HFF cells at all Pioglitazone 
concentrations (Fig. 38). 
Also the expression of PPARγ, the direct target of Pioglitazone, was 
significantly increased at all the concentrations (Fig. 38). 
To evaluate the effects of Pioglitazone treatment on mitochondrial biogenesis, 
the expression of D-LOOP and ACTIN was measured by qRT-PCR (Fig. 38). 
The expression values of mtDNA (calculated from the ratio of genes D-
LOOP/ACTIN) increased in treated DS-HFFs at Pioglitazone concentrations of 
1 µM and 2 µM, while treatment with 100 nM Pioglitazone did not cause 
significant changes if compared to untreated trisomic controls. 
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Fig. 38 qRT-PCR analysis in Pioglitazone treated DS-HFF cells for 72h. The expression 
levels of PGC-1α increased in treated DS-HFF cells for 72h at different Pioglitazone 
concentrations when compared to untreated controls. Also PPARγ expression increased at all 
Pioglitazone concentrations tested. The expression of mtDNA, calculated as the ratio of genes 
D-LOOP/Actin, increased in treated DS-HFF cells at Pioglitazone concentrations of 1 µM and 
2 µM, while the treatment with 100nM Pioglitazone did not cause significant changes 
compared to untreated trisomic controls. Values represent the average determination ± SEM 
for two DS-HFFs samples carried out in triplicate. *=p<0.05. P-value expressed statistical 
significance for treated trisomic cells versus untreated trisomic cells. 
 
 
Pioglitazone treatment increases OCR in DS-HFFs 
To verify whether the increase of PGC-1α , PPARγ and mtDNA in treated 
trisomic cells were associated with an improvement of mitochondrial function, 
the rate of OCR was assess by XFe 96 Extracellular Flux Analyzer. DS-HFF 
cells treated for 72 hours with different Pioglitazone concentrations showed an 
increase of OCR. Best results were obtained at 2 µM Pioglitazone 
concentration with an increase of about 60% in comparison with non treated 
controls (Fig. 39). 
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Fig. 39 Measurement of OCR in DS-HFF cells treated with different Pioglitazone 
concentrations for 72h. (A) XFe Analyzer detected an increase of OCR in DS-HFF cells 
treated at all Pioglitazone concentrations when compared to untreated trisomic control. (B) 
Quantification of OCR values in Pioglitazone treated trisomic cells compared to untreated 
controls. The optimal concentration at which there was approximately 60% of OCR increase 
was 2 µM Pioglitazone. Values represent the average determination ±SEM for two DS-HFF 
samples carried out in triplicate. *=p<0.05. P-value expressed statistical significance for treated 
trisomic cells versus untreated trisomic cells. 
68 
 
5. DISCUSSION 
Since 2005, the research group in which I have been working has been 
committed at unraveling the molecular consequences of TS21 on the 
development of specific DS phenotypic traits. The first strategy was to 
compare the overall gene expression profile of hearts from human fetuses with 
and without TS21. The analysis showed that most Hsa21 genes were 
approximately 1.5 fold upregulated and 441 non-Hsa21 genes were 
dysregulated in all trisomic samples (Conti et al. 2007). 
Functional analysis of differentially expressed genes revelead both a 
prevalence of NEMGs, among downregulated genes, and a prevalence of ECM 
genes among the upregulated ones (Conti et al. 2007). As a consequence of 
that, the corresponding protein levels and enzymatic activities may be 
dysregulated in DS subjects. It has been proposed that NEMG hypoexpression 
might be the cause of the molecular, functional and morphological alterations 
found in mitochondria from DS cells and tissues.  
Indeed, abnormal mitochondrial cristae morphology, reduced oxygen 
consumption, increased ROS production and increased levels of intra-
mitochondrial calcium (Piccoli et al. 2013) have been demonstrated in skin 
fibroblasts from fetuses with TS21. They also showed an abnormal 
mitochondrial distribution, with smaller and more numerous mitochondria than 
euploid fetal fibroblasts. The global mitochondrial mass was not significantly 
different. 
The pro-oxidative state observed in DS-HFFs (Piccoli et al. 2013) led us to test 
the hypothesis that NEMGs regulation might be under the control of one 
regulatory gene affected by trisomy of Hsa21. 
Many Hsa21 genes have been proposed as possible candidates for 
mitochondrial abnormalities, such as APP (Askanas et al. 1996), the 
transcription factor GABPA (O'Leary et al. 2004), the copper-zinc superoxide 
dysmutase SOD1 (Shin et al. 2004), DYRK1A, DSCR1/RCAN1 (Bushdid et al. 
2003) and NRIP1. The analysis of expression profiling of cells in which each 
of these genes was induced (De Cegli et al. 2010), clearly demonstrated that 
only NRIP1 gene is able to cause NEMG downregulation, when overexpressed, 
and that no other Hsa21 gene tested exerts such an effect.  
NRIP1 is a corepressor for nuclear receptors and transcription factors 
controlling energy homeostasis in white adipose tissue (Powelka et al. 2006), 
muscle (Seth et al. 2007), and heart (Fritah et al. 2010). It links nuclear 
receptors to chromatin remodeling enzymes, including the HDAC enzymes, 
involved in chromatin condensation and transcriptional repression, and this 
function is modulated by post translational modifications which include 
phosphorylation and methylation (White et al. 2008). NRIP1 is also target of 
acetylation, which inhibits the recruitment of the C-terminal binding protein 
(CtBP) (Vo et al. 2001). The upregulation of  NRIP1 in adipocytes inhibited a 
panel of PGC-1α target genes through its partners, such as PPARs, ERRs and 
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NRFs (Hallberg et al. 2008) (Fig. 40). mRNA expression analysis revealed that 
ERRα, PPARα, PPARβ, NRF1, as well as some of their target genes, were 
repressed by NRIP1 and induced by PGC-1α in a dose dependent manner in 
neonatal rat cardiomyocytes (Chen et al. 2012). 
 
Fig. 40 Corepressor function of NRIP1 in regulating target gene transcription. NRIP1 acts 
as a transcriptional corepressor for PPARs, blocking UCP1 promoter activation through the 
recruitment of DNA methyltransferase (Dnmt), C terminal binding protein (CtBP), histone 
methyltransferase (HMT) and histone deacetylase (HDAC) (Seth et al. 2007). 
 
 
This highly conserved gene shows a 1.5- to 4-fold upregulation both in the 
heart and fibroblasts from DS subjects (Piccoli et al. 2013; Conti et al. 2007). 
The upregulation of NRIP1 protein was also demonstrated in DS hippocampus 
(Gardiner, 2006) together with the upregulation of SUMO3, another gene 
mapping to Hsa21, which might modulate NRIP1 repressive activity. Indeed, 
the lysines located in NRIP1 repression domain 3 and 4 represent a SUMO3 
attachment consensus region and they are evolutionary conserved across 
vertebrates (Rytinki and Palvimo, 2009). The simultaneous upregulation of 
both Hsa21 genes might exert a synergistic effect.  
The analysis of genes, which possibly may affect mitochondrial function, 
highlighted that PGC-1α transcription and activity are negatively regulated by 
NRIP1 (Scarpulla et al. 2011) (Fig. 41).  
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Fig. 41 Regulatory network governing mitochondrial functions orchestrated by PGC-1α. 
Interactions among some key participants in the transcriptional network regulating 
mitochondrial biogenesis are depicted schematically. The diagram summarizes the regulation 
of PGC-1α by transcriptional and post-transcriptional pathways and its interactions with some 
of its target transcription factors involved in metabolic regulation. Potential suppression of 
glycolysis through NRF-1 control of VHL expression and negative control by the 
NRIP1/RIP140 co-repressor are also shown (Scarpulla et al. 2011). 
 
 
 
Powelka et al, (2007) demonstrated that NRIP1 significantly affects oxidative 
metabolism and mitochondrial biogenesis, and Seth et al, (2007) demonstrated 
that NRIP1 overexpression represses nuclear mitochondrial genes involved in 
all respiratory chain complexes. Moreover NRIP1 affects also the genes 
encoding enzymes within the glycolytic, TCA cycle, fatty acid oxidative 
pathways which were upregulated in response to NRIP1 depletion. 
Even a mild NRIP1 overexpression is able to repress NEMGs involved in all 
respiratory chain complexes (Seth et al. 2007).  
NRIP1 is known to suppress both oxidative metabolism and mitochondrial 
biogenesis through ERRα (Powelka et al. 2006). It engages in a direct 
interaction with PGC-1α in suppressing the ERRα and NRF1 dependent 
expression of CIDEA, a gene involved in both programmed cell death and 
metabolism (Hallberg et al. 2008). Thus, PGC-1α utilizes a network of positive 
and negative transcriptional regulators to establish and modulate metabolic 
functions (Fig. 41).  
The lists of genes regulated by NRIP1 and PGC-1α largely overlap each other 
and to the list of NEMGs hypoexpressed in DS fetal hearts (Fig. 19, Table S1, 
appendix 1). 
To biologically validate the results deriving from the bioinformatic strategy, 
we verified the potential role of NRIP1 in mitochondrial dysfunction in a cell 
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model of DS in which NRIP1 is upregulated. When NRIP1 was transiently 
attenuated in human trisomic fibroblasts, an inverse correlation between NRIP1 
and PGC-1α expression was demonstrated. Accordingly, this attenuation 
induced the upregulation of genes controlled by both NRIP1 and PGC-1α. 
Moreover, NRIP1 siRNA-mediated attenuation in DS-HFFs, and the 
consequent PGC-1α and NRF1 upregulation, elicited a significant increase in 
mtDNA.  
A functional analysis of mitochondrial activity was performed in NRIP1 
silenced DS-HFFs vs control scrambled cells. ROS production decreased, and 
mitochondrial activity increased, in silenced cells demonstrating that the 
induction of NEMG expression counteracts mitochondrial impairment and 
partially rescues mitochondrial function. Notably, NRIP1 silencing also 
increased cellular ATP content. These results, together with the finding that 
NRIP1 attenuation by siRNA leads to an increase in the adenine nucleotide 
translocators ANT1/SLC25A4 and ANT2/SLC25A5, suggest that a more 
efficient exchange of ATP is induced.  
It is known that NRIP1 also directly inhibits a panel of PGC-1α related genes 
through its transcriptional partners (Hallberg et al. 2008). In particular, the 
transcription factors NRF1 and ERRα, as well as their targets, are repressed by 
NRIP1 and induced by PGC-1α in a dose dependent manner, in neonatal rat 
cardiomyocytes (Chen et al. 2012). PGC-1α null mice (Mitra et al. 2012; 
Leone et al. 2005), as well as knock-in NRIP1 mice (Seth et al. 2007), show 
reduced expression of mitochondrial genes in multiple tissues.  
The role of NRIP1 in DS might extend to several phenotypic aspects. The 
NRIP1-dependent repression of genes involved in mitochondrial function is 
closely linked with post-natal impaired cardiac function. Indeed, the most 
obvious phenotype of mice expressing exogenous NRIP1 is the impaired 
postnatal heart function (Fritah et al. 2010). The transgenic mice are 
characterized by rapid onset of cardiac hypertrophy and ventricular fibrosis 
resulting in increased mortality. These data suggest that NRIP1 might play a 
role in DS in postnatal heart defects such as cardiac hypertrophy, but also 
embryo heart development might be affected, as congenital heart defects have 
been associated to a more severe pro-oxidative state in DS fetuses (Piccoli et 
al. 2013).  
NRIP1 and PGC-1α are also involved in glucose uptake and therefore in the 
physiopathology of diabetes through the regulation of the insulin sensitive 
glucose transporter GLUT4 expression and its subcellular localization (Fritah et 
al. 2012). These findings might correlate with the fact that cardiac hypertrophy 
and diabetes are two important post-natal complications of DS.  
It is known that mitochondria play a central role in many neurodegenerative 
diseases such as Alzheimer, Parkinson, Amyotrophic Lateral Sclerosis and 
Huntington diseases. Impaired energy metabolism, defect of mitochondrial 
enzymes activities, abnormalities of mitochondrial respiration, mtDNA 
mutations and oxidative stress are common characteristics of these 
neurodegenerative conditions (Petrozzi et al. 2007). The similarity of 
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neurodegenerative processes between DS and AD and the high prevalence of 
AD in DS patients suggest that AD and DS share common brain alterations 
possibly due to similar molecular pathways involved in the pathogenesis, such 
as mitochondrial dysfunction and oxidative stress (Dumont and Beal, 2011).  
It is interesting to note that the bioinformatic functional analysis indicated that 
many genes regulated by both NRIP1 and PGC-1α, and dysregulated in DS, 
characterize the mitochondrial dysfunction pathways described in 
neurodegenerative diseases such as AD and Parkinson’s disease [KEGG 
Pathways http://www.genome.jp/kegg/ (Kanehisa et al. 2000)].  
This suggests that the pathway regulated by the NRIP1/PGC-1α axis may be 
the target of a potential pharmacological strategy to counteract mitochondrial 
dysfunction and consequently mitigate the DS phenotype. 
Therapeutic protocols have already been used in the past to counteract the 
oxidative stress observed in DS. Several clinical studies have tested the effects 
of antioxidant nutrients and vitamins (Lott et al. 2012; Tiano et al. 2011; Ellis 
et al. 2008; Miles et al. 2007). They concluded that the intake of these agents 
did not improve cognitive performance, nor prevented dementia in DS. Better 
results were obtained on learning and memory in the mouse model Ts65Dn 
using pentylenetetrazole, Memantine, Fluoxetine, Lithium, Epigallocatechin-3-
gallate (EGCG) and antioxidants such as vitamin E, (Gardiner, 2014) but the 
clinical trials have not yielded the expected results.  
To counteract mitochondrial dysfunction in DS we searched for drugs that 
interfere on the pathways regulated by NRIP1/ PGC-1α. Even though drugs 
capable of modulating the activity of PGC-1α are already used for the 
treatment of metabolic diseases and neurodegenerative diseases, such as AD, 
they have never been used in clinical trials in DS patients. 
Two drugs were evaluated in the present study: Metformin, an activator of 
PGC-1α and Pioglitazone, an agonist of PPARγ. 
Metformin is a drug commonly used as a hypoglycemic agent in type 2 
diabetes because it inactivates gluconeogenesis (Caton et al. 2010). Metformin 
activates AMPK in the liver and muscles causing the phosphorylation and thus 
activation of PGC-1α, and upregulates SIRT1 that in turn activates PGC- 1α by 
deacetylation (Fig. 42). 
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Fig. 42 Representation of the mechanism of action of Metformin. The drug activates 
AMPK, which in turn phosphorylates PGC-1α. Metformin also activates SIRT1 that in turn 
deacetylates PGC-1α activating it. 
 
 
By activating the PGC-1α pathway, Metformin can affect mitochondrial 
biogenesis and function, slowly permeating into mitochondria. All the tests of 
mitochondrial function we performed showed increased expression levels of 
PGC-1α and a global improvement of mitochondrial activity at Metformin 
concentrations of 0.5-1 mM. Correspondingly, analysis by XFe 96 Extracellular 
Flux Analyzer showed an increase of OCR of about two times.  
Since it is known that Metformin also has an inhibitory effect on the activity of 
mitochondrial complex I, one of the aims of the research was to identify 
concentrations that had effect on the activation of PGC-1α but not on the 
inhibition of respiratory activity.   
At 2mM Metformin concentration (the highest that has been analyzed) there 
was a significant OCR decrease with a consequent reduction of mitochondrial 
activity. At this drug dose also PGC-1α transcription was decreased. 
The therapeutic dosage of the hypoglycemic agent Metformin is 50µM which 
corresponds to a blood concentration from 0.05 to 1 mM. This dosage should 
be optimal to obtain maximum effect on mitochondrial function without 
inhibition of respiratory activity. 
The second drug we tested, Pioglitazone, is a high affinity ligand for the 
nuclear receptor PPARγ, a downstream gene of the PGC-1α pathway. The 
binding with the drug activates the PPARγ receptor, which forms a heterodimer 
with the retinoid-X receptor leading to transcription of adipogenic genes (Fig. 
43).  
The treatment of type 2 diabetes with Pioglitazone significantly reduces insulin 
resistance (Fullert et al. 2002), and has beneficial effects on plasma lipid 
profile leading to a lower risk of acute myocardial infarction, stroke or heart 
failure (Goldberg et al. 2005; Aronoff et al. 2000). However, the clinical use of 
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Pioglitazone is also limited by the occurrence of certain adverse events, 
including weight gain, fluid retention, and possibly bladder cancer (Cariou et 
al. 2012; Hirose et al. 2002). 
The therapeutic dosage of the drug as a hypoglycemic agent ranges from 15 to 
30 mg/day, which should correspond to a blood concentration of 3-5 µM. 
The aim of this study was therefore to evaluate if the mitochondrial function 
might be improved at dosages that have limited side effects. 
 
 
Fig. 43 Representation of mechanism of action of Pioglitazone. The drug binds to the 
PPAR-γ receptor that forms a dimer with RXR receptor leading to transcription of downstream 
genes. 
 
 
We evaluated he therapeutic effect of Pioglitazone treatment on mitochondrial 
phenotype in vitro for 48-72 hours, at concentrations from 100 nM to 2 µM. 
All concentrations showed an impact on the phenotype as assessed by 
mitochondrial ATP production and organization of the mitochondrial network. 
The trisomic cell lines treated with Pioglitazone for 72 hours showed a less 
fragmented mitochondrial network, with a reduced number of isolated 
mitochondria and a greater average mitochondrial volume if compared to non-
treated controls.  
In the last part of the study, we looked for a regulator of ECM genes that maps 
to Hsa21 and that is upregulated in DS samples, by virtue of a gene dosage 
effect. To this aim, we re-analyzed the same GEO series discussed above (De 
Cegli et al. 2010). Our analysis demonstrated that only one gene is able to 
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cause the overexpression of 32 ECM genes, when overexpressed, and that no 
other Hsa21 tested gene exerts such an effect. This gene is RUNX1 that is 
included in the smallest critical region recently identified for CHDs in DS (Liu 
et al. 2013). 
The protein encoded by this gene represents the alpha subunit of CBF, a 
transcription factor involved in the development of normal hematopoiesis. The 
association of RUNX1 with ECM genes regulation is supported by experiments 
that demonstrated that ectopic expression of RUNX1 in 3T3 fibroblasts induced 
deep alterations in the distribution of N-cadherin, an increased expression of 
Integrin β5, and increased survival at confluence (Wotton et al. 2008).  
Furthermore, transcription factor-binding site (TFBS) analysis of ECM genes 
upregulated in DS fetal hearts identified RUNX1 as the transcription factor with 
the highest specificity of binding. About 60% of ECM genes overexpressed in 
DS hearts showed consensus sequences for RUNX1 (Tab. 6).  
Our interest in ECM proteins is justified by the role they play in cardiac 
morphogenesis. Since 1984 it is known that cells derived from endocardial 
cushions and outflow tract of DS fetuses are more adherent in vitro when 
compared with controls (Wright et al. 1984).  
ECM proteins are widely represented among the upregulated genes in DS fetal 
hearts (Conti et al. 2007). Since DS is a major cause of congenital heart 
defects, their dysregulation may represent a key pathological mechanism. 
Specific changes in the expression and accumulation of ECM components have 
been observed during human cardiomiocyte differentiation from human 
embryonic stem cells (Chan et al. 2010). Heart valvulogenesis is initiated in the 
atrioventricular junction and outflow tract by signaling events originating in the 
myocardium that induce endocardial cells to undergo an epithelial to 
mesenchymal transformation (EMT) and to migrate into cardiac jelly. This is 
an acellular and extracellular matrix-rich space that separates the myocardial 
and endocardial cell layers in the primitive heart during the early steps of heart 
development (Wirrig et al. 2007). As a result of EMT, endocardial cushions are 
formed that are composed of highly proliferative, undifferentiated, 
mesenchymal valve progenitor cells embedded in an unorganized ECM. The 
cushions will then elongate and undergo ECM remodeling in order to form 
functionally mature valves with decreased proliferation of endocardial cushions 
cells and increased organization and complexity of the ECM. The process by 
which endocardial cushions develop into mature valve leaflets is marked by the 
expression of specific ECM proteins and remodeling enzymes. Proteoglycans 
(aggrecan and versican/VCAN) and hyaluronan play critical role in heart 
development. Normal development of the heart requires synyhesis, deposition 
and degradation of the ECM components versican and hyaluronan. 
Fetal heart transcriptome profiling that we performed demonstrated that VCAN 
and Cartilage link protein 1 (Crtl1; also known as Hyaluronan and 
Proteoglycan Binding Protein 1- Hapln1), an ECM protein that stabilizes the 
interaction between hyaluronan and VCAN, are upregulated in DS fetal hearts 
in comparison to control fetal hearts. Intriguingly, we found that VCAN, 
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CRTL1 and ADAMTSs, crucial genes implicated in the embryonic development 
and in particular in the heart morphogenesis, are among the genes with 
consensus sequence for RUNX1.  
VCAN is a chondroitin sulfate proteoglycan abundantly expressed within the 
extracellular matrix compartment of the developing and mature cardiovascular 
system. It binds to a number of other ECM components, as well as to cellular 
receptors, to influence cell adhesion, proliferation, migration and survival. It is 
necessary for cardiac cushion formation, atrioventricular valve development, 
ventricular septation, and outflow tract development (Chan et al. 2010). 
Alterations in its expression have been associated with vascular diseases 
(Wight and Merrilees, 2004). Analysis of Vcan transgenic mice has established 
the requirement for versican in cardiac development and its role in 
skeletogenesis. The ADAMTS family includes several versican-degrading 
proteases that are active during remodeling of the embryonic provisional 
matrix, especially during sculpting of versican-rich tissues. Versican is cleaved 
at specific peptide bonds by ADAMTS proteases, and the cleavage products are 
detectable by neo-epitope antibodies. Myocardial compaction, closure of the 
secondary palate (in which neural crest derived cells participate), endocardial 
cushion remodeling, myogenesis and interdigital web regression are 
developmental contexts in which ADAMTS-mediated versican proteolysis has 
been identified as a crucial requirement (Nandadasa et al. 2014). 
VCAN dysregulation can induce changes in the distribution of periostin, 
another important molecule of the heart cushion extracellular matrix, and then 
may affect the developing valves by altering the structural integrity of the ECM 
through altered interaction with other molecules such as fibronectin, collagen 
and other proteoglycans (Norris et al. 2007). These molecules were found 
dysregulated in our data as well. Additionally, since it interacts directly with 
integrins, attachment-dependent signaling may be altered thus affecting cell 
migration and EMT in the cushion primordia of the septa and valves (Yan and 
Shao, 2006). 
Crtl1 is a glycoprotein found in the extracellular matrix. It is expressed in 
endocardial and endocardially-derived cells in the developing heart, including 
cells in the atrioventricular (AV) and outflow tract (OFT) cushions (Binette et 
al. 1994). Crtl1 is involved in the formation and stabilization of proteoglycan 
and hyaluronan aggregates (Matsumoto et al. 2006) and is important for 
preventing aggregate degradation by proteases, such as members of the 
ADAMTS and MMP families (Miwa et al. 2006). Alteration in the expression of 
Crtl1 results in impairment of growth and development of several tissues, 
including the cartilage, heart, and central nervous system (Wirrig et al. 2007). 
Craniofacial abnormalities and shortened long bones are important phenotypic 
traits of DS subjects. Crtl1 null mice are characterized by craniofacial 
abnormalities and shortened long bones, possibly due to a reduction of 
aggrecan within the cartilage, resulting in an inability of chondrocytes to 
undergo differentiation and hypertrophy (Watanabe et al. 1999). Cardiac 
malformations seen in Crtl1 knockout mice include muscular ventricular septal 
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defects, atrioventricular septal defects, and thin myocardium (Wirrig et al. 
2007).  
The role of RUNX1 in regulating ECM proteins and the role of ECM 
overexpression in the pathogenesis of DS-CHD will be elucidated by future 
experiments in which we plan to modulate RUNX1 expression in iPSCs from 
DS fibroblasts induced to cardiac differentiation. 
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6. CONCLUSIONS 
 
This study was aimed to identify Hsa21 genes responsible for either NEMG or 
ECM dysregulation; to develop strategies to counteract mitochondrial 
dysfunction in  DS; to investigate how NEMG downregulation or ECM 
upregulation might affect cardiac phenotype. 
The results we obtained indicate that the Hsa21 gene NRIP1 plays a key role in 
the NEMG downregulation observed in DS, and suggest that the NRIP1-PGC-
1α axis represents a potential therapeutic target for restoring altered 
mitochondrial function in this syndrome. This provides the basis for clinical 
trials aimed at alleviating and preventing some DS pathologies, including 
neurodegeneration, diabetes, obesity, and hypertrophic cardiopathy, thus 
providing a better quality of life for DS individuals and their families. Few 
therapeutic approaches have been undertaken in this direction mainly based on 
the use of antioxidants and nutraceutics with poor results.  
We have here demonstrated that in vitro treatments with Metformin, a PGC-1α 
activator, or Pioglitazone a PPARγ agonist, were both able to induce an 
improvement of mitochondrial function and morphology in DS cells. At lower 
concentrations than those commonly used for the diseases for which they are 
registered, these drugs caused an increase of OCR and ATP production and a 
decrease in the oxidative status of the cells. 
Mitochondrial dysfunction play a central role in many neurodegenerative 
diseases such as AD, Parkinson's disease (PD), Huntington's diseases (HD), 
and Amyotrophic Lateral Sclerosis (ALS) (Petrozzi et al. 2007), which share 
with DS the NEMG dysregulation.  This open new frontiers for the use of these 
drugs in other diseases, including neurodegenerative diseases.  
Last, we have investigated which Hsa21 gene may be responsible for the 
upregulation of ECM proteins observed in DS and how this upregulation might 
affect the heart development. The mechanisms governing regulation of ECM 
protein expression during heart development are complex and involve many 
signaling pathways (Combs et al. 2009). We have identified in the Hsa21 gene 
RUNX1 a possible candidate for ECM regulation and also we have focused our 
attention on 2 important non-Hsa21 genes, VCAN and CTRL1, upregulated in 
DS hearts (Conti et al. 2007), which play a key role in regulating ECM 
distribution during the cardiogenesis. 
Of course mitochondrial dysfunction and ECM alterations are just two 
potential mechanisms responsible for the DS phenotypic traits. Recently, it has 
been proposed that the variable phenotypic expression in DS might be caused 
by epigenetic modifications. Altered patterns of DNA methylation have been 
observed in DS tissues (Jones et al. 2013). Several genes that map on Hsa21, 
such as DNA methyltransferase III, or transcriptional regulators HMGN1 and 
NRIP1, could be important for epigenetic modifications, as histones bind and 
regulate the configuration of chromatin (Dekker et al. 2014). New experiments 
are needed also in this direction. 
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7. FUTURE PERSPECTIVES 
 
The results of this study lay the bases for future investigations. We are 
planning to test other drugs, namely Resveratrol, which activates PGC-1α 
acting on SIRT1, bezafibrate, a PPAR pan-agonist, and AICAR, on 
mitochondrial dysfunction. We will also test the effect drug associations. 
We are producing stem cells (iPSCs) directly induced from human fetal 
fibroblasts with TS21. Recent studies of the transcriptome of DS-iPSC cells 
have shown that genes related to mitochondria are dysregulated in both 
undifferentiated stem cells and in differentiated neuronal cells (Weick et al. 
2013). These demonstrations make iPSC a good cell model for the study of 
mitochondrial phenotype during differentiation and for drug testings directly 
on cell lines at various stages of differentiation without the use of any animal 
models. We plan also to induce iPSCs to differentiate into cardiomyocites, in 
order to perform a molecular and functional study to evaluate the effects of 
RUNX1 modulation on ECM gene expression. 
Gene therapy in DS is opening new scenarios. RNAi is a useful tool to silence 
specific genes in biological systems. Its efficacy was demonstrated in the 
treatment of several diseases in vivo, but its therapeutic use in treating 
neurological diseases has been hampered by the lack of an efficient way to 
deliver siRNA across the blood brain barrier (BBB). Initial attempts using 
intracranial injections of lentiviral vectors turned out to be inadequate (Zabel, 
2013; Fillat and Altafaj, 2012). Alternative delivery with the Adeno associated 
(AAV) virus system gave encouraging results (Fillat and Altafaj, 2012; 
McCown, 2011; Worgall et al. 2008;). AAV vectors were used indeed to 
correct DYRK1A-induced motor defects in DS (Ortiz-Abalia et al. 2008).  
Despite the capacity of AAV vectors to cross the BBB, the use of non viral 
systems, based on cationic lipids, polymers, dendrimers or different types of 
nanoparticles, seems more attractive as these vectors are demonstrating to be 
non immunogenic, easy to prepare and non expensive (Alvarez-Erviti et al. 
2011). 
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APPENDIX 1 
 
TABLE S1 List of genes encoding mitochondrial proteins downregulated in DS fetal 
hearts. 
 
Affymetrix Probe 
ID DSH/NH ratio Gene Name Genbank ID 
214274_s_at 0.647 ACAA1 AI860341 
215210_s_at 0.548 ACADM S72422 
205412_at 0.756 ACAT1 NM_000019 
208967_s_at 0.757 AK2 U39945 
201322_at 0.739 ATP5B NM_001686 
208972_s_at 0.739 ATP5G1 AL080089 
211715_s_at 0.554 BDH1 BC005844 
205295_at 0.699 CKMT2 NM_001825 
209746_s_at 0.721 COQ7 AF032900 
203858_s_at 0.74 COX10 NM_001303 
218057_x_at 0.738 COX4NB BC001472 
201597_at 0.764 COX7A2 NM_001865 
201633_s_at 0.727 CYB5B AW235051 
208905_at 0.702 CYCS BC005299 
209759_s_at 0.729 DCI BC002746 
211150_s_at 0.568 DLAT J03866 
204824_at 0.638 ENDOG NM_004435 
201931_at 0.698 ETFA NM_000126 
202942_at 0.692 ETFB NM_001985 
213133_s_at 0.713 GCSH AW237404 
221415_s_at 0.545 GJA10 NM_030772 
200947_s_at 0.758 GLUD1 NM_005271 
208813_at 0.671 GOT1 BC000498 
203745_at 0.678 HCCS AI801013 
200691_s_at 0.645 HSPA9B NM_004134 
210046_s_at 0.743 IDH2 U52144 
202070_s_at 0.709 IDH3A NM_005530 
210418_s_at 0.751 IDH3B AF023265 
200955_at 0.704 IMMT NM_006839 
36830_at 0.711 MIPEP U80034 
219527_at 0.701 MOSC2 NM_017898 
218027_at 0.716 MRPL15 NM_014175 
203781_at 0.741 MRPL33 NM_004891 
218890_x_at 0.745 MRPL35 NM_016622 
204331_s_at 0.735 MRPS12 AA587905 
220864_s_at 0.638 NDUFA13 NM_015965 
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202077_at 0.748 NDUFAB1 NM_005003 
218201_at 0.669 NDUFB2 NM_004546 
201226_at 0.663 NDUFB8 NM_005004 
201966_at 0.62 NDUFS2 NM_004550 
201740_at 0.72 NDUFS3 NM_004551 
201757_at 0.763 NDUFS5 NM_004552 
202941_at 0.76 NDUFV2 NM_021074 
218455_at 0.712 NFS1 NM_021100 
202780_at 0.705 OXCT1 NM_000436 
200980_s_at 0.598 PDHA1 BF739979 
214225_at 0.677 PIN4 BE674061 
203649_s_at 0.657 PLA2G2A NM_000300 
205241_at 0.724 SCO2 NM_005138 
201093_x_at 0.591 SDHA NM_004168 
202675_at 0.744 SDHB NM_003000 
202004_x_at 0.722 SDHC NM_003001 
203340_s_at 0.688 SLC25A12 AI887457 
217961_at 0.705 SLC25A38 NM_017875 
202825_at 0.607 SLC25A4 NM_001151 
216841_s_at 0.734 SOD2 X15132 
218119_at 0.634 TIMM23 NM_006327 
203092_at 0.612 TIMM44 AF026030 
220415_at 0.635 TNNI3K NM_015978 
209077_at 0.74 TXN2 AL022313 
201903_at 0.75 UQCRC1 NM_003365 
200883_at 0.716 UQCRC2 NM_003366 
208909_at 0.744 UQCRFS1 BC000649 
217140_s_at 0.637 VDAC1 AJ002428 
217249_x_at 0.68 WUGSC:H_RG162B04.1 AC004544 
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TABLE S2 List of genes encoding ECM proteins overespressed in DSH.  
Affymetrix Probe 
ID  DSH/NH ratio Gene name GenBank ID 
222162_s_at 1.93 ADAMTS1 AK023795 
219935_at 1.5 ADAMTS5 NM_007038 
220706_at 2.24 ADAMTS7 NM_014272 
214953_s_at 1.668 APP X06989 
219087_at 1.829 ASPN NM_017680 
220988_s_at 1.466 C1QTNF3 NM_030945 
219025_at 1.342 CD248 NM_020404 
211809_x_at 1.721 COL13A1 M59217 
203477_at 1.413 COL15A1 NM_001855 
209081_s_at 1.57 COL18A1 AF018081 
202310_s_at 1.546 COL1A1 K01228 
202403_s_at 1.596 COL1A2 NM_000089 
212489_at 1.595 COL5A1 AI983428 
212091_s_at 1.927 COL6A1 AI141603 
209156_s_at 2.391 COL6A2 AY029208 
213622_at 1.434 COL9A2 AI733465 
204724_s_at 1.6 COL9A3 NM_001853 
207420_at 4.268 COLEC10 NM_006438 
209335_at 1.73 DCN BC005322 
213661_at 1.516 DKFZP586H2123 AI671186 
206101_at 1.554 ECM2 NM_001393 
202994_s_at 1.716 FBLN1 Z95331 
204359_at 1.522 FLRT2 NM_013231 
209220_at 1.685 GPC3 L47125 
206766_at 1.378 ITGA10 AF112345 
216190_x_at 3.591 ITGB1 AA215854 
204989_s_at 2.269 ITGB4 BF305661 
221462_x_at 3.113 KLK15 NM_017509 
202202_s_at 1.591 LAMA4 NM_002290 
203417_at 1.434 MFAP2 NM_017459 
203877_at 1.673 MMP11 NM_005940 
201069_at 1.586 MMP2 NM_004530 
205907_s_at 1.961 OMD AI765819 
202465_at 1.482 PCOLCE NM_002593 
218585_s_at 1.48 RAMP AK001261 
218452_at 1.859 SMARCAL1 NM_014140 
205236_x_at 1.372 SOD3 NM_003102 
208606_s_at 2.534 WNT4 NM_030761 
In bold are shown Hsa21 ECM genes. 
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Mitochondrial dysfunction,which isconsistentlyobserved inDownsyndrome (DS)cells and tissues,might con-
tribute to the severity of theDSphenotype.Our recent studiesonDS fetal hearts andfibroblasts havesuggested
that one of the possible causes of mitochondrial dysfunction is the downregulation of peroxisome proliferator-
activated receptor gamma, coactivator 1 alpha (PGC-1a or PPARGC1A)—a key modulator of mitochondrial
function—and of several nuclear-encoded mitochondrial genes (NEMGs). Re-analysis of publicly available
expression data related tomanipulation of chromosome21 (Hsa21) genes suggested the nuclear receptor inter-
acting protein 1 (NRIP1 orRIP140) as a good candidate Hsa21 gene for NEMGdownregulation. Indeed,NRIP1 is
known to affect oxidative metabolism and mitochondrial biogenesis by negatively controlling mitochondrial
pathways regulated by PGC-1a. To establish whether NRIP1 overexpression in DS downregulates both PGC-
1a and NEMGs, thereby causing mitochondrial dysfunction, we used siRNAs to decrease NRIP1 expression
in trisomic human fetal fibroblasts. Levels of PGC-1a and NEMGs were increased and mitochondrial function
was restored, as shown by reactive oxygen species decrease, adenosine 5′-triphosphate (ATP) production
andmitochondrial activity increase. These findings indicate that the Hsa21 geneNRIP1 contributes to themito-
chondrial dysfunctionobserved inDS. Furthermore, they suggest that theNRIP1-PGC-1a axemight represent a
potential therapeutic target for restoring altered mitochondrial function in DS.
INTRODUCTION
Data from several studies show that trisomy of chromosome 21
(TS21) affects both mitochondrial function and reactive oxygen
species (ROS) production. Lower levels of the mitochondrial
complexes I, III and V have been observed in the cerebellar
and brain regions of subjects affected by Down syndrome (DS)
(1). Moreover, reduced mitochondrial redox activity and mem-
brane potential have been observed inDS astrocytes and neuron-
al cultures (2,3). Further evidence formitochondrial dysfunction
was found in the Ts1Cje mouse model for DS that shows
decreased levels of ATP production (4). Similarly, fetal DS
fibroblasts showbothadecreased efficiencyof themitochondrial
energy production apparatus, involving adenine nucleotide
translocators, ATP synthase, and adenylate kinase and a select-
ive deficit of complex I,whichmight contribute toROSoverpro-
duction by DSmitochondria. These events were correlated with
changes in the cAMP/PKA signaling pathway (5,6). Similar re-
search conducted on human primary lines of fibroblasts (HFFs)
fromTS21 fetuses has revealed thatTS21disruptsmitochondrial
morphology, decreases oxygen consumption, increases mtCa2+
load and ROS production (7).Moreover, by analyzing mitochon-
drial defects according to the cardiac phenotype, a more severe
mitochondrial dysfunctionwasevidenced incardiopathic-derived
TS21 fibroblasts (7). A possible interpretation of these results is
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that a more pronounced pro-oxidative state might contribute to
generating a more severe cardiac phenotype—a concept that
might be extended to other phenotypic traits. Studies of genome-
wide expression analysis in DS have demonstrated that nuclear-
encoded mitochondrial genes (NEMGs) represent the main
downregulated category in fetal TS21 heart samples (8).Downre-
gulation isalsomanifest inDSfetal brains (9).These observations
led us to hypothesize that NEMG dysregulation is likely a cause
ofmitochondrial dysfunction inDS (8).Among the dysregulated
genes, the peroxisome proliferator-activated receptor gamma,
coactivator 1 alpha (PGC-1a/PPARGC1A) has been found
hypo-expressed at the transcriptional and protein levels in
TS21 HFFs (7). PGC-1a is indeed known to play a central role
in regulating mitochondrial biogenesis and respiratory function
through the interaction with transcriptional partners, such as
NRF1, ERRa, PPARs and YY1 (10).
A known repressor ofPGC-1a activity is the nuclear receptor
interacting protein 1 (NRIP1/RIP140) (11–13). This protein is
coded by a highly conserved chromosome 21 (Hsa21) gene
with consistent dosage effect in many studies on DS samples
(14). NRIP1 acts as a scaffold protein recruiting regulatory
factors, such as histone deacetylases (15), COOH terminal
binding protein (16) and histone metyltransferases (17), to
exert its co-repressive function. Furthermore, NRIP1 directly
interacts with some nuclear receptors including PPARs, ERRs
and ERs (18–20). More specifically,NRIP1 negatively controls
the expression and the activity of PGC-1a as well as the expres-
sion of its targets. Indeed, in PGC-1a null mice (21,22), as well
as in knock-inNRIP1mice (23),NEMGexpression is decreased.
Likewise, NRIP1 is always upregulated by 1.5- to 4-fold in the
heart (8) and fibroblasts (7) from DS fetuses. NRIP1 protein is
also increased in the hippocampal tissue from DS subjects (24).
Thus, building upon previous research, in this study, we endea-
vored to provide new insights into the transcriptional changes
influencing the molecular mechanisms associated with mito-
chondrial dysfunction in DS. In particular, we first investigated
whether Hsa21 gene overexpression causes NEMG downregula-
tion by focusing on those Hsa21 genes, transcription factors,
and kinases that have the highest probability of affecting the ex-
pression of many genes. To this aim, we analyzed the public ex-
pression data related to the manipulation of Hsa21 genes to
investigate their effects on NEMG downregulation. These ana-
lyses led us to the identification of NRIP1 as a good candidate
for the downregulation of mitochondria-related genes in DS.
Then, to determine whether NRIP1 downregulation can
effectively counteract mitochondrial dysfunction and some of
its pathophysiological effects, we attenuated NRIP1 expression
in human fibroblasts from DS fetuses (DS-HFFs).
Understanding the molecular correlation between NRIP1 ex-
pression levels, NEMG regulation, and mitochondrial function
could lay the basis for the development of new therapeutic pro-
tocols for DS.
RESULTS
Analysis of public expression data suggests that NRIP1
affects NEMG expression
Several Hsa21 genes can possibly interfere with NEMG expres-
sion. For instance, DYRK1A and DSCR1/RCAN1 play key roles
in the calcineurin/NFAT pathway, which affects mitochondrial
activity and morphology during heart development (25). Two
more genes, NRIP1 (23) and GABPA/NRF2 (26) are also
involved in mitochondrial pathways.
To identify which Hsa21 gene might possibly downregulate
NEMG expression, we screened the Gene Expression Omnibus
(27) repository (http://www.ncbi.nlm.nih.gov/geo) for gene ex-
pression data related to the modulation of Hsa21 genes. We
selected the GEO GSE 19836 experiment (28), a set of data
derived from a mouse embryonic stem cell (ESC) bank in
which several orthologs of Hsa21 genes, with potential regula-
tory role, are individually overexpressed in an induciblemanner.
Expression data were available for 13 transcription factors (in-
cludingNRIP1,RCAN1 andGABPA), the transcriptional activa-
tor RCAN1 and six protein kinases (including DYRK1A) (for
details see Materials and Methods). We re-analyzed this series
of data by focusing on the mitochondria-related categories and
pathways dysregulated by the overexpression of each gene look-
ing for Hsa21 genes that when overexpressed would induce
NEMG downregulation. Among the 20 analyzed Hsa21 genes,
only NRIP1, one of the seven genes that are considered ‘effect-
ive’ for the expression perturbation in the manipulated cells
(28), was able to cause NEMG downregulation when overex-
pressed.Our analysis showed thatNRIP1 overexpression caused
a significant enrichment of NEMGs among 298 downregulated
genes. The ‘Mitochondrion’ was the most affected Cell Compo-
nent Gene Ontology (GO) category (P , 0.0001) (Table 1 and
Supplementary Material, Fig. S1), with a cluster of 37 downre-
gulated genes.Motif enrichment analysis, by clustering downre-
gulated genes on the basis of their promoter regions, revealed a
significant enrichment (P , 0.005) in genes with the ERRa
motif.Twenty-fivedownregulatedgenes, insteadof the expected
10, showed promoter regions around the transcription start site
containing the ERRamotif.
Neither DYRK1A, nor RCAN1, nor GABPA, all considered
‘silent’ genes (28), causedNEMGdownregulationwhenoverex-
pressed.
Modulation of NRIP1 and PGC-1a expression dysregulates
the same NEMGs downregulated in DS fetal hearts
To investigate whether the sets of genes regulated byNRIP1 and/
or PGC-1a showed any overlapping to the NEMGs downregu-
lated inDSfetal hearts (8),weperformedameta-analysis compar-
ing three sets of gene expression data, SET1, SET2 and SET3.
SET1 included 123 genes which were both upregulated after
NRIP1 silencing and downregulated after NRIP1 re-expression
in mouse adipocytes (29). SET2 included 129 genes which were
upregulated after PGC-1a induction in SAOS2 cells (human
osteoblast-like cells) (30). SET3 included the70genesdownregu-
lated inDSfetal heart tissues (8) belonging to the ‘mitochondrion’
GO category (Supplementary Material, Table S1). The compari-
son was aimed at identifying genes consistently dysregulated
across these studies.
The Venn Diagram shows that NEMGs in SET3, which were
downregulated in DS fetal hearts, overlap with both SET1 and
SET2 (Fig. 1A). The three sets of genes overlap each other for
at least 25 genes. Fifteen genes are consistently dysregulated
across all three experiments (Fig. 1B). Most of these genes are
included in the electron transport chain, mainly in complex I,
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Table 1. Gene Ontology categories affected by NRIP1 overexpression in GSE 19836 series with a P-value ,0.05
Biological process GO category Genes in category Observed Expected O/R ratio P-value
Carboxylic acid metabolic process GO:0019752 630 20 7.51 2.66 0.0089
Cellular carbohydrate metabolic process GO:0044262 198 11 2.36 4.66 0.0089
Monocarboxylic acid metabolic process GO:0032787 339 14 4.04 3.47 0.0089
Carboxylic acid catabolic process GO:0046395 139 8 1.66 4.83 0.0100
Organic acid catabolic process GO:0016054 139 8 1.66 4.83 0.0100
Regulation of transmembrane receptor protein
serine/threonine kinase signaling pathway
GO:0090092 137 8 1.63 4.9 0.0100
Carbohydrate metabolic process GO:0005975 527 17 6.28 2.71 0.0100
Lipid metabolic process GO:0006629 881 23 10.5 2.19 0.0100
Oxoacid metabolic process GO:0043436 667 20 7.95 2.52 0.0100
Organic acid metabolic process GO:0006082 680 20 8.1 2.47 0.0100
Molecular function
Kinase activity GO:0016301 736 21 9.07 2.32 0.0219
Transferase activity GO:0016740 1574 34 19.4 1.75 0.0328
Transferase activity. transferring
phosphorus-containing groups
GO:0016772 857 21 10.56 1.99 0.0511
Cofactor binding GO:0048037 244 9 3.01 2.99 0.0602
Cellular component
Mitochondrion GO:0005739 1480 37 17.7 2.09 0.0009
Mitochondrial envelope GO:0005740 446 17 5.34 3.19 0.0010
Mitochondrial membrane GO:0031966 424 16 5.07 3.15 0.0013
Organelle inner membrane GO:0019866 330 13 3.95 3.29 0.0036
Mitochondrial part GO:0044429 548 17 6.56 2.59 0.0043
Mitochondrial inner membrane GO:0005743 312 12 3.73 3.22 0.0047
Organelle envelope GO:0031967 671 18 8.03 2.24 0.0122
Envelope GO:0031975 683 18 8.17 2.2 0.0133
Mitochondrial outer membrane GO:0005741 111 6 1.33 4.52 0.0174
Organelle outer membrane GO:0031968 125 6 1.5 4.01 0.0277
The ‘Mitochondrion’ is the category most affected by NRIP1 upregulation (enrichment ¼ 37 observed genes instead of 17.7 expected genes with P , 0.001).
Figure 1. Comparison of NEMGs downregulated in DS fetal hearts with those dysregulated by NRIP1 and/or PGC-1a. (A). Venn diagram showing overlapping
among the three sets of data. Out of the 70 mitochondrial genes that are downregulated in DS fetal hearts (SET3) (8), 25 overlap the list of NRIP1 regulated genes
(SET1) (29) and 29 overlap the list ofPGC-1a regulated genes (SET2) (30). (B) List ofmitochondria-related genes overlapping in the three sets of data. The complete
lists of genes are in Supplementary Material, Table S1.
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and in oxidative phosphorylation pathways. It is also interesting
to note that 42 genes overlap between the sets of genes inversely
regulatedbyNRIP1 andPGC-1a (SET1andSET2), in agreement
with the antagonistic functions of the two coregulators (19).
NRIP1 attenuation by siRNA affects NEMG expression
in DS-HFFs
We previously demonstrated that NRIP1 is upregulated in DS-
HFFs in which Hsa21 trisomy negatively regulates NEMGs
and impairs mitochondrial function (7).
To test the hypothesis that NRIP1 overexpression perturbs
mitochondrial function and that this effect is associated with
PGC-1a downregulation, we performed silencing experiments
of NRIP1 gene in DS-HFFs. In brief, after re-analyzing all
DS-HFF lines used for silencing experiments, we demonstrated
thatNRIP1 is significantly upregulated in all trisomic samples if
compared with euploid controls (Fig. 2A). Seventy-two hours
after transfection of a specific SMART pool of siRNAs in
DS-HFFs, an inverse correlation between NRIP1 and PGC-1a
expression, in a siRNA dosage-dependent way, was demon-
strated by qRT–PCR (Fig. 2B). By immunofluorescence ana-
lysis, we demonstrated that the NRIP1 protein localizes to the
cell nucleus, as expected for a corepressor protein, both in
euploid and in trisomic fibroblasts (Fig. 3). Fluorescent signal
was more intense over nuclei of DS-HFFs (Fig. 3B) with
respect to euploidHFFs (Fig. 3A), indicating a higher concentra-
tion of the NRIP1 protein in trisomic cells. In these cells, some
fluorescent signal was also present over the cytoplasm (Fig. 3B)
likely due to the overexpression of the NRIP1 protein. In DS-
HFFs treated with siRNAs to attenuate NRIP1 mRNA expres-
sion, NRIP1 fluorescent signal was significantly decreased in a
siRNA dosage-dependent way (Fig. 3). Quantitative evaluation
of fluorescence intensities in euploid, trisomic and siRNA trans-
fected cells (Fig. 3F) indicated that siRNA transfection reduces
NRIP1 protein levels of trisomic cells down to the range of
diploid cells or even lower (Fig. 3D and E).
To determine the effects of NRIP1 attenuation by siRNA on
other mitochondria-related genes, we compared the expression
of seven genes in silenced versus scrambled cells using qRT–
PCR. Three genes, i.e. COX5A, NDUFA1 and NDUFS3, were
chosen from the list of 15 genes that resulted consistently dysre-
gulated across the three sets compared in the meta-analysis
(Fig. 1). The fourth gene, NRF1, which is downregulated in
DS hearts (8) and fibroblasts (7), was chosen because of its
role both as a PGC-1a partner and as its target. Finally, three
other genes, i.e. ANT1/SLC25A4, ANT2/SLC25A5 and ANT3/
SLC25A6, which are downregulated in DS fetal fibroblasts
(our unpublished data), were also chosen as PGC-1a targets
(SET2, Supplementary Material, Table S1) (30). ANT1/
SLC25A4 is downregulated in SET3 and after NRIP1 overex-
pression in the De Cegli’s dataset (28). The expression ratio of
thesegenes inNRIP1-silencedDS-HFFsversus scrambled trans-
fected DS-HFFs demonstrated that five out of seven analyzed
genes were significantly upregulated after NRIP1 attenuation
by siRNA (Fig. 4).
Furthermore, to verify the effect of NRIP1 attenuation and
consequent PGC-1a upregulation on the mitochondrial biogen-
esis, we used qRT–PCR to quantify D-LOOP and ACTIN gene
expression in scrambled and silenced cells, as mitochondrial
and nuclear markers, respectively. The average of the
D-LOOP/ACTIN ratio increased by 2.5-fold in silenced trisomic
cells (Fig. 5), thereby suggesting that mtDNA content does in-
crease after NRIP1 attenuation by siRNA and consequent
PGC-1a overexpression.
Mitochondrial function is improved in DS-HFFs
after NRIP1 attenuation by siRNA
WeverifiedwhetherNRIP1 attenuation by siRNA, alongwith the
consequent increases in PGC-1a and other mitochondrial genes,
might counteract the mitochondrial dysfunction in trisomic
cells. For this study, intracellular ROS production, mitochondrial
activity, mitochondrial calcium and ATP content were evaluated
in DS-HFFs after transient NRIP1 siRNA-mediated attenuation.
ROS production was measured by confocal microscopy
imaging of cells treated with the redox-sensitive fluorescent
Figure 2. NRIP1modulates PGC-1a expression in HFFs. (A) NRIP1mRNA ex-
pression level in euploid cells (N1-N5), and in trisomic (DS1-DS8)HFF lines used
for silencing experiments. For each sample, values represent the average
determination+SEM for three qRT–PCR experiments. A pool of euploid cells
was used as a calibrator. ∗∗P, 1024. P-values express statistical significance
for euploid versus trisomic comparisons. (B) NRIP1 and PGC-1a expression
levels in trisomic cells transfected with a scrambled siRNA and with a NRIP1-
specific SMART pool of siRNAs. A decrease in theNRIP1 expression level corre-
sponds to an increase of PGC-1a expression level in a siRNA-dependent way.
Values represent the average determination+SEM for eight NRIP1-silenced
DS-HFFs carried out in triplicate. ∗P, 0.05, ∗∗P, 0.01.P-values express statis-
tical significance for NRIP1-silenced versus scrambled comparisons.
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probe dichlorofluorescein (DCF). Seventy-twohours after trans-
fectionwithNRIP1 siRNA,DCF-relatedfluorescencewas lower
with respect to scrambled DS-HFFs. Semi-quantitative analysis
of fluorescent signals demonstrated that, on an average basis, the
ROS-related DCF fluorescence decreased up to 50% in a siRNA
dosage-dependent manner (Fig. 6).
We then establishedwhether decreases inROS could depend on
a rescue of respiratory chain complex activities. To this aim, we
incubatedsilencedDS-HFFswith thespecificmitochondrial super-
oxide indicator,MitoSOXRed.This reagent is a live-cell permeant
that is rapidly and selectively targeted tomitochondria.Once in the
mitochondria, MitoSOX Red reagent is oxidized by superoxide
andexhibits redfluorescence. Inexperimentsperformed inNRIP1-
silenced DS-HFFs, a reduction of the MitoSOX Red signal was
demonstrated thus suggesting that the decrease inROSwaspartial-
ly associated with mitochondrial activity (Fig. 7).
Then, to confirm even further that NRIP1 attenuation by
siRNA improvesmitochondrial function, we incubated trisomic
silenced cellswith theMitoTrackerReddye, a reagent that stains
mitochondria in live cells and whose accumulation is dependent
Figure 3.NRIP1 immunofluorescence inNRIP1-silencedDS-HFFs.Representative images ofNRIP1 immunofluorescence analysis in (A) euploid cells, (B) trisomic
cells and trisomic cells transfected (C) with a scrambled siRNA, (D) with 5 nM NRIP1 siRNA and (E) 20 nM NRIP1 siRNA. (F) Semi-quantitative analysis of the
immunodetected signals, by the ImageJ software (means+SEM of three assayed samples). Fifty randomly selected, different cells for each sample/experimental
condition were analyzed. A decrease of the fluorescent signal is observed in silenced versus scrambled DS-HFFs. Signal from 5 nM NRIP1 siRNA transfected
cells is comparablewith euploidHFFs. Statistical significance: ∗∗P , 0.01 for trisomic versus euploid comparisons; #P , 0.05 forNRIP1-silenced versus scrambled
comparisons.
Figure 4. Mitochondria-related gene expression in NRIP1-silenced DS-HFFs.
Relative mRNA expression of seven mitochondria-related genes was measured
in NRIP1-silenced DS-HFFs versus scrambled transfected DS-HFFs. Five out
of the seven genes show a significant increase in their expression level. Values
represent the average determination+SEM for three DS-HFF samples carried
out in triplicate. A pool of scrambled transfected euploid cells was used as cali-
brator. ∗P , 0.05. P-value expresses statistical significance for NRIP1-silenced
versus scrambled comparisons.
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upon membrane potential. A significant 50% increase of the
MitoTracker Red-related fluorescence was observed in NRIP1-
silenced cells when compared with scrambled controls, thus
indicating an increase in respiratory activity (Fig. 8).
NRIP1 attenuation by siRNA does not affect
mitochondrial Ca21 homeostasis
In DS-HFFs, the mitochondrial Ca2+ concentration is signifi-
cantly greater than that of euploid fetal fibroblasts (7). Many
extracellular stimuli exert their effect through an increase in
cytosolic Ca2+ concentration ([Ca2+]c) mediated by the influx
of extracellular Ca2+ and/or the release of Ca2+ from intracellu-
lar stores, predominantly the endoplasmic reticulum(ER).When
[Ca2+]c increases, mitochondria undergo a major rise in the
matrix Ca2+ concentration ([Ca2+]m). The amplitude of this
rise largely exceeds that observed in the cytosol thanks to elec-
trochemical potential across the cation-impermeant inner mito-
chondrial membrane that provides the driving force for
mitochondrial Ca2+ accumulation (31).
Variations in [Ca2+]mweremeasured as previously described
(7). In brief, DS-HFFs were transfected with a mitochondrially
targeted aequorin (32) and then stimulated with histamine.
This agonist elicited the production of inositol 1,4,5 trispho-
sphate (IP3) and the consequent release of Ca2+ from the ER,
through the IP3 receptor.
We found no significant differences in the mitochondrial
[Ca2+]m uptake in NRIP1-silenced DS-HFFs compared with
control cells transfected with the non-targeting scrambled
siRNA (42.0+ 2.6 versus. 38.7+ 3.9 mM, P ¼ 0.5) (Fig. 9).
NRIP1 attenuation by siRNA strongly increases cellular
ATP content
Levels of phosphorylated adenosine nucleotides, including the
universal energy carrier ATP, define the energy state in living
cells and depend mainly on mitochondrial function (33). In
NRIP1-silenced DS-HFFs, we investigated the intramitochon-
drial ATP concentration ([ATP]m). For this purpose, we used a
chimera of theATP-sensitive photoprotein luciferase specifical-
ly targeted to mitochondria (mtLuc) to obtain a dynamic moni-
toring of [ATP]m. Luciferase has been widely employed to
measure ATP content both in isolated mitochondria and in
intact cells; its reactionwith luciferin produces a flash of yellow-
green lightwith apeakemissionat 560 nm, the intensityofwhich
is proportional to the amount of substrates in the reaction
mixture.
We found that silenced DS-HFFs showed a very strong in-
crease (+50%, P ¼ 1024) in basal ATP content, calculated by
the luminescence values of the plateau generated after the
Figure 5. mtDNA content in NRIP1-silenced DS-HFFs. Ratio between the
mtDNA marker D-LOOP and the nuclear DNA marker ACTIN indicates an in-
crease afterNRIP1 attenuation by siRNA.The ratiowas calculated upon normal-
ization to a reference gene (ABELSON) by qRT–PCR. Values represent the
average determination+SEM for three NRIP1-silenced trisomic samples
carried out in triplicate. ∗P, 0.05. P-value expresses statistical significance
for NRIP1-silenced versus scrambled comparisons.
Figure 6. ROS decrease in NRIP1-silenced DS-HFFs. A confocal microscopy live cell imaging of the DCF fluorescence in transfected DS-HFFs: (A) scrambled,
(B) 5 nM NRIP1 siRNA and (C) 20 nM NRIP1 siRNA. (D) Semi-quantitative analysis of the DCF-related fluorescence, by the ImageJ software (means+SEM of
three assayed samples). Fifty randomly selected, different cells for each sample/experimental condition were analyzed. A significant decrease of DCF-related fluor-
escence is observed afterNRIP1 attenuation in a siRNA-dependent way. ∗∗P , 1024.P-value expresses statistical significance forNRIP1-silenced versus scrambled
comparisons.
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addition of luciferin (Fig. 10). Since basal ATP content is highly
dependent on the abundance of transfected luciferase, we deter-
mined the exact amount of the luciferase transduced under our
experimental conditions through an immunoblot assay. We
found that the levels of luciferase protein transduced in NRIP1-
silenced DS-HFFs were comparable with those detected in
control cells transfected with the non-targeting scrambled
siRNA (Fig. 11).
In parallel, NRIP1-silenced cells were slightly decreased in
mitochondrial ATP production 72 h after transfection. This
was calculated by subtracting the basal cellular luminescence
plateau, generated after the addition of luciferin, from the lumi-
nescence values of the second plateau, generated after the add-
ition of the Ca2+mobilizing agent histamine (Fig. 10).
DISCUSSION
This study originates from previous analyses demonstrating a
global mitochondrial dysfunction in several DS models (1–4)
Figure 7. Intra-mitochondrial superoxide decrease in NRIP1-silenced DS-HFFs. Confocal microscopy live cell imaging of theMitoSOXRed fluorescence in trans-
fected DS-HFFs: (A) scrambled and (B) 20 nM NRIP1 siRNA. Note that the distribution of MitoSOX Red signal resembles the mitochondrial network. (C) Semi-
quantitative analysis of the MitoSOX-related fluorescence, by the ImageJ software (means+SEM of three assayed samples). Fifty randomly selected, different
cells for each sample/experimental condition were analyzed. A reduction of the fluorescent signal over the mitochondrial network is detected. ∗∗P , 0.01.
P-value expresses statistical significance for NRIP1-silenced versus scrambled comparisons.
Figure 8.Mitochondrial activity in DS NRIP1-silenced DS-HFFs. Confocal microscopy live cell imaging of the Mitotracker fluorescence in transfected DS-HFFs:
(A) scrambled and (B) with 20 nMNRIP1 siRNA. (C) Semi-quantitative analysis of theMitotracker-related fluorescence, by the ImageJ software (means+SEM of
fiveassayed samples). Fifty randomly selected, different cells for each sample/experimental conditionwere analyzed.An increaseofMitotracker-relatedfluorescence
is observed in NRIP1-silenced DS-HFFs. ∗∗P , 0.005. P-value expresses statistical significance for NRIP1-silenced versus scrambled comparisons.
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and a significant dysregulation of NEMGs in the heart (8), brain
(9) and fibroblasts (7) from human fetuses with DS. From these
studies, it emerged that genes and transcription factors respon-
sible for the activity of respiratory complexes andmitochondrial
biogenesis are globally repressed. Thus,we speculated thatmost
of the underexpressed NEMGs might be under the same regula-
tory control and that this controlmight be affected by the trisomy
of Hsa21. In the present study, we looked for a regulator of
NEMGs that maps to Hsa21 and that is upregulated in DS
samples, by the virtue of a gene dosage effect. To this aim, we
re-evaluated the expression data from the GEO repository
(http://www.ncbi.nlm.nih.gov/geo) by focusing on an experi-
ment in which regulatory genes mapping to Hsa21 were indi-
vidually overexpressed in mouse ESCs (28). Our analysis
demonstrated that only one gene is able to cause NEMG down-
regulation and that no other Hsa21 tested gene exerts such an
effect. This gene is NRIP1 which encodes for a corepressor
protein. Although the mean dysregulation of each NEMG eli-
cited by NRIP1 overexpression was not very strong, the
number of affected genes was significantly enriched (P,
0.001). The role of NRIP1 in mitochondrial dysfunction is sup-
ported by previous findings demonstrating that both in cellular
and in animal models NRIP1 silencing upregulates the expres-
sion of genes responsible for mitochondrial biogenesis and oxi-
dative phosphorylation, whereas NRIP1 re-expression
downregulates them (29,23). Experiments of NRIP1 manipula-
tion, performed in transgenicmice and human cells, have actual-
ly demonstrated that even mild variations in NRIP1 expression
can significantly affect oxidativemetabolism andmitochondrial
biogenesis (11,23,29,34).
We also considered the possible effects of the overexpres-
sion of other Hsa21 genes that have previously been implicated
in the regulation of mitochondrial function such as DYRK1A,
DSCR1 and GABPA, but none of these genes turned out to
regulate per se NEMG expression. GABPA, in particular, is a
nuclear respiratory factor that would be expected to downregu-
late mitochondria-related genes when it is downregulated.
However, GABPA is never downregulated in DS samples.
Indeed it was normoregulated in DS fetal hearts (8), upregulated
in DS fetal fibroblasts (7) and inconsistently dysregulated in
Vilardell’s meta-analysis (14).
On the other hand, the effect of NRIP1 on NEMG expression
could be further reinforced by another Hsa21 gene, SUMO3, as
sumoylation modulates NRIP1 activity (35). We thus speculate
that the simultaneous upregulation of both NRIP1 and SUMO3
exerts a synergistic effect on mitochondrial dysfunction.
NRIP1 is supposed to exert a repression of mitochondrial bio-
genesis by either interacting with nuclear receptors (19,18) or
Figure9.Mitochondrial calciummeasurement. (A)Thebarplotof the [Ca2+]m in
scrambled and NRIP1 siRNA transfected DS-HFFs. The light signal was col-
lected and calibrated into [Ca2+] values, as described in Materials and
Methods. Results are shown as the average of measurements from four different
NRIP1-silenced DS-HFFs+SEM. (B) Effect of histamine on [Ca2+]m. The
traces show the average [Ca2+]m in DS-HFFs transfected with the mitochond-
rially targeted aequorin.Where indicated, the cells were treatedwith 100 mMhis-
tamine added to KRB. No significant variation in [Ca2+]m is observed in the two
conditions.
Figure 10. Mitochondrial ATP measurement. (A) The barplot of the mitochondrial ATP content and of the basal ATP content in scrambled and NRIP1 siRNA-
transfected DS-HFFs. (B) The traces show mitochondrial [ATP]m changes elicited by mitochondrial [Ca
2+] increase in cells perfused with 100 mM histamine as
agonist. mtLuc luminescence data are expressed as a percentage of the initial value+SEM (n ¼ 4). The traces are representative of four independent experiments.
∗P ¼ 0.05, ∗∗P ¼ 1024. P-values express statistical significance for NRIP1-silenced versus scrambled comparisons.
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regulatingPGC-1a activity (10,12,13).PGC-1a knockout mice
show not only a decreased number of mitochondria but also a
decreased respiratory capacity in skeletal muscle (21). In par-
ticular, under physiological conditions, PGC-1a, by coactivat-
ing several transcription factors, including nuclear receptors
suchasPPARg,PPARaandERRa, promotesmitochondrial bio-
genesis and regulates mitochondrial respiratory efficiency
(10,21,36). Interestingly, among the 37 NEMGs downregulated
after NRIP1 induction in the GEO GSE 19836 experiment (28),
we observed an enrichment both of genes involved in PPARs
pathways (8 genes) and of genes containing the ERRa motif in
their promoter regions (25 genes) (P, 0.0005). Notably, the
known targets of PGC-1a, namely, CIDEA (12) and ANT1/
SLC25A4 (30), are included in the list of genes that are downre-
gulated following NRIP1 overexpression (28).
Moreover, to investigate whether the NEMGs repressed by
NRIP1 and induced by PGC-1a corresponded to the NEMGs
downregulated genes in DS fetal hearts (8), we performed a
meta-analysis by comparing our microarray data with the
results of two experiments in which the gene expression of
NRIP1 or PGC-1a was modulated. We found that the corres-
pondence between the three sets of genes was remarkably
high, considering that they all derived from different species,
tissues and experimental approaches. The high number of over-
lapping genes in SET1 and SET2 is in agreement with previous
research indicating an interrelationship between PGC-1a and
NRIP1 activity on mitochondrial pathways (11).
These results, combinedwith the data from previous research,
finally led us to verify the potential role of NRIP1 in mitochon-
drial dysfunction in DS. When we transiently attenuated
NRIP1 in trisomic fibroblasts, we demonstrated an inverse cor-
relation between NRIP1 and PGC-1a expression. Accordingly,
we found that this attenuation induced the upregulation of five
out of seven genes randomly chosen in SET3, all of which over-
lapped with the lists of genes regulated byNRIP1 (SET1) and/or
PGC-1a (SET2). Moreover, NRIP1 siRNA-mediated attenu-
ation in DS-HFFs, and the consequent PGC-1a andNRF1 upre-
gulation, elicited a significant increase in mtDNA. This result
fully corroborates similar experiments performed in cardiomyo-
cytes (11).
In the same trisomic fibroblasts, ROS production was
decreased and mitochondrial activity was increased, demon-
strating that the induction of NEMG expression in silenced
DS-HFFs counteracts mitochondrial impairment and partially
rescues mitochondrial function. However, no significant altera-
tions ofmitochondrial [Ca2+]were observed afterNRIP1 attenu-
ation by siRNA. A possible explanation to this phenomenon is
either that 72 h is not a sufficient time to determine detectable
differences in Ca2+ uptake or that many other mechanisms
affect calcium uptake in TS21 cells, e.g. the trisomy of genes
Figure 11.Luciferase expression followingNRIP1 attenuation by siRNA. (A) Representative immunoblot of luciferase protein in threeNRIP1-silenced or scrambled
DS-HFFs transfectedwith a luciferase-encoding plasmid specifically targeted tomitochondria (mtLuc) and cultured in completemedium for 72 h. (B) Quantification
of luciferase accumulation by the LUCIFERASE/GAPDH ratio.
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involved in the calcineurin pathway (DYRK1A andDSCR1) (25).
Other Ca2+ regulators could play a role.
Interestingly, in NRIP1-silenced trisomic cells, we found a
significant 50% increase in the basal ATP content. These
results, together with the finding that NRIP1 attenuation by
siRNA leads to an increase in the adenine nucleotide transloca-
torsANT1/SLC25A4 andANT2/SLC25A5 (Fig. 4), suggest that a
more efficient exchange of ATP is induced, thus benefitting the
mitochondrial activity and function of these cells, as demon-
strated by the reduction in ROS production at the mitochondrial
level (Fig. 7).
Supporting evidence for the opposite effects of NRIP1 and
PGC-1a on mitochondrial function and NEMG regulation is
that in neonatal rat cardiomyocytesNRIP1mediates an antagon-
istic role versus PGC-1a in the regulation of mitochondrial
energy metabolism (11). Indeed, overexpressed NRIP1 abro-
gates PGC-1a-mediated induction of mitochondrial membrane
potential and mitochondrial biogenesis (11). Furthermore, the
NRIP1-dependent repressionof genes involved inmitochondrial
function is closely linked with post-natal impaired cardiac func-
tion as a result of reducedmitochondrial electron-transport chain
activity and oxygen consumption.NRIP1 hyperexpressing mice
are indeed affected by cardiac hypertrophy (34).
NRIP1 and PGC-1a are also involved in glucose uptake and
therefore in the physiopathology of diabetes through the regula-
tion of the insulin sensitive glucose transporter GLUT4 expres-
sion and its sub-cellular localization (37). These findings
correlate with the fact that cardiac hypertrophy and diabetes
are two important post-natal complications of DS.
Mitochondrial dysfunctionmight also contribute to determin-
ing DS mental retardation and other DS-associated post-natal
pathologies, such as Alzheimer’s disease (AD) and obesity. It
is known that mitochondria also play a central role in many neu-
rodegenerative diseases such as AD, Parkinson’s disease, Hun-
tington’s disease and amyotrophic lateral sclerosis. Impaired
energymetabolism, defectivemitochondrial enzymatic activity,
abnormal mitochondrial respiration, mutated mtDNAs and oxi-
dative stress are all common features of these neurodegenerative
conditions (38).
It is interesting to note that the bioinformatic functional ana-
lysis of the 25 genes overlapping SET1 (genes regulated by
NRIP1) and SET3 (genes downregulated in DS fetal hearts)
showed that 16 out of 25 genes characterized the mitochondrial
dysfunction pathways described in neurodegenerative diseases
such as AD and Parkinson’s disease [KEGG Pathways http
://www.genome.jp/kegg/ (39)]. However, given that there is a
high prevalence ofAD inDSpatients,we cannot neglect the pos-
sibility that the overexpression of the Hsa21 gene APP might
have a main role in the development of AD in DS patients.
Taken all together our study indicates thatNRIP1 is a key gene
in the regulation of the mitochondrial pathways and that it is
linked to mitochondrial dysfunction in DS. Accordingly, this
should be taken into account when planning therapeutic
approaches aimed at improving functions and cognitive per-
formance in DS mouse models. Many of these models are
indeed inadequate since they are not trisomic for all Hsa21
genes and may also have duplications of regions non-syntenic
to Hsa21. This is true, for instance, for the very popular
Ts65Dn mouse that, among other Hsa21 genes, is not trisomic
for either NRIP1 or SUMO3. Thus, preclinical models of
Ts65Dn will be unable to address all phenotypic problems and
we speculate that clinical trial oftentimes fails because the over-
expression of important genes such as NRIP1 is not taken into
account.
Our results do highlight thatNRIP1 plays a relevant role inDS
mitochondrial dysfunction, as evidenced by the ability ofNRIP1
inhibition to counteract mitochondrial dysfunction. However,
we cannot rule out the likelihood that other genes may, in fact,
be involved. A case in point is that the DS mouse model
Ts1Cje manifests mitochondrial dysfunction even though it is
not trisomic for either NRIP1 or for SUMO3. Thus, further
studies are indeed warranted to identify additional genes pos-
sibly responsible for DS mitochondrial alterations.
Finally, these results provide the basis for clinical trials aimed
at restoring mitochondrial function in DS subjects to counteract
specific phenotypic features such as neurodegeneration, cardiac
hypertrophy, diabetes and obesity. Such therapeutic approach
would be highly desirable considering that the very few thera-
peutic approaches undertaken so far in this direction using anti-
oxidants and nutraceutics have yielded either poor or discordant
outcomes (40,41).
Thus, we speculate that a possible therapeutic approach in DS
could be based either on PGC-1a activators, which have been
tested inotherdiseasemousemodels (42–45), or onPPARgago-
nists, which attenuate mitochondrial dysfunction in AD mouse
models (46–51). Such drugs are already routinely used in clinic-
al practice for the treatment of metabolic syndromes, type 2 dia-
betes, and neurodegenerative diseases such as AD (52–54).
In conclusion, our study has provided further insights into the
transcription factors that influencemitochondrial dysfunction in
DS.Our findings could indeed pave theway for the development
of new andmore effective drugs capable of selectively targeting
the intricate set of molecular mechanisms underlying the patho-
genesis of this disease.
MATERIALS ANDMETHODS
Analysis of public expression data
A set of expression data from GSE 19836 series (28) was
obtained from Gene Expression Omnibus repository GEO
(http://www.ncbi.nlm.nih.gov/geo). This set of datawas derived
from the analysis of a mouse ESC bank in which 32 orthologs of
human chromosome 21 genes, including transcription factors
and protein kinases, were individually overexpressed in an indu-
cible manner. A set of clones individually overexpressing 20
of the 32 genes, namely 13 transcription factors (Aire, Bach1,
Erg, Ets2, Gabpa, Nrip1, Olig1, Olig2, Pknox1, Runx1, Sim2,
ZFP295, 1810007M14Rik), one transcriptional activator (Dscr1-
Rcan1) and six protein kinases (DYRK1A, SNF1LK,Hunk, Pdxk,
Pfkl, Ripk4), was transcriptionally profiled under inducing and
non-inducing conditions with Affymetrix Gene Chip Mouse
430_2. Specifically, RNAs from three induced mouse ESCs
and three controls were profiled for each inducible Hsa21 gene
(28). In our analysis, we used GeneSpring software vers. 11.5
Multi–OmicAnalysis (Agilent technologies, Inc.) for data inter-
pretation; however, our criteria were different from those used
by the authors of the gene expression dataset, focusing on down-
regulated genes. We considered genes differentially expressed
with a Fold change (LogFC) .0.3 and ,20.3 with P , 0.05,
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thus producing two lists of dysregulated genes: 511 upregulated
genes and 298 downregulated genes. Gene ontology (GO) func-
tional class scoring of all the lists of significantly upregulated or
downregulated genes was performed using theWeb-basedGene
SetAnalysisToolkitV2 (http://bioinfo.vanderbilt.edu/webgestalt/)
(55,56). Special attention was given to mitochondria-related
categories and pathways.
Meta-analysis
We compared three sets of gene expression data from different
experiments, to identify genes consistently dysregulated across
the three studies. The first set, SET1, included genes dysregu-
lated by Nrip1 modulation in mouse adipocytes (29). The
second set, SET2, included genes upregulated after PGC-1a in-
duction in SAOS2 cells (human osteoblast like cells) (30). The
third set included mitochondria-related genes, downregulated
inDS fetal heart tissue (8). The three sets were filtered according
to the GO cell component category ‘mitochondrion’ with the
above-mentioned Web-based Gene Set Analysis Toolkit V2.
The resulting genes—123 genes in SET1, 129 in SET2 and 70
in SET3 (SupplementaryMaterial, Table S1)—were intersected
using the R software (http://www.R-project.org/). A Venn
diagram was built, which shows overlapping genes across the
three sets.
Ethics statement
HFFswere obtained from the ‘TelethonBank of Fetal Biological
Samples’ at theUniversity ofNaples.All experimental protocols
were approved by the local Institutional Ethics Committee.
Samples
Eight skin biopsies were explanted from human fetuses with
trisomy of Hsa21 (DS-HFF) after therapeutic abortion at 18–
22 gestational weeks. Fibroblasts from biopsies were cultured
in T25 flasks (BD Falcon) with Chang medium B + C (Irvine
Scientific) supplemented with 1% penicillin/streptomycin
(Gibco) at 378C in 5% CO2 atmosphere; all the analyses
described throughout this study were carried out at cell culture
passages 4–5.
Transfection protocol
NRIP1 was transiently silenced in eight DS-HFF lines using
a pool of specific NRIP1-siRNAs (ON-TARGETplus SMART-
pool, Dharmacon), with negative (ON-TARGETplus SMART-
pool Non-targeting siRNAs control, Dharmacon) and positive
controls (ON-TARGETplus SMARTpool, GAPDH siRNAs,
Dharmacon). Interferin transfection reagent (Polyplus transfec-
tion)was used. Cellswere plated on 12-well plates (50 000 cells/
well) forRNAcollection, on 35 mmdiameter plateswith 20 mm
slides (Delchimica) (50 000 cells/well) for ROS production
analysis and on 24-well plates (30 000 cells/well) (BD Falcon)
for immunofluorescence and mitochondrial activity assays.
DS-HFFs were transfected with 5 and 20 nM siRNA according
to themanufacturer’s protocol (Polyplus transfection). Seventy-
two hours after transfection, the effects of NRIP1 siRNA-
mediated attenuation were evaluated.
NRIP1 immunofluorescence
For the evaluation of NRIP1 protein by immunofluorescence,
30 000 cells were plated in 24-well plates on 12-mm diameter
round glass coverslips. Cells were fixed in 3 : 1 methanol: acetic
acid for 15 min, washed twice with PBS and then incubated
twice in 0.1 M borate buffer pH 8.5 for 10 min to neutralize the
pH. After two washes with PBS, the cells were incubated with
DNase 1 : 10 in RDD buffer (Qiagen) at 378C for 1 h and then
treated with 2% BSA in PBS to block non-specific protein–
protein interactions. The cells were then incubated with the
antibody anti-NRIP1 (30 mg/ml, ab42126 Abcam, Cambridge
Science Park, Cambridge, UK) overnight at +48C. The second-
ary antibody (green) was Alexa Fluorw 488 goat anti-rabbit IgG
(H + L) used at a 1/200 dilution for 1 h (57). Cells were finally
mounted in 50% glycerol in PBS. Immunofluorescence analysis
wasperformedat a confocal laser scanningmicroscopeLSM510
(Zeiss, Gottingen, Germany) equippedwith anArgon ionic laser
whoselwas set at 488 nm, and anHeNe laser whoselwas set at
633 nm. Emission of fluorescence was revealed by a BP 505–
530 band pass filter for Alexa Fluor 488 and by a 615 long pass
filter for DRAQ5. Images were acquired at a resolution of
1024 × 1024 pixels. Analysis of data was performed with the
ImageJ software, version 1.37 (58). Fifty random single cells
were analyzed for each imaging analysis.
Laser scanning confocal microscopy live cell imaging
of ROS production
For the evaluation of ROS production afterNRIP1 siRNA trans-
fection, 50 000 cells were plated on 25-mmdiameter round glass
coverslips in anAttofluor cell chamber (Molecular Probe, Leiden,
the Netherlands). Seventy-two hours later, the cells were incu-
bated for 15 min at 378C with 10 mM of 2,7-dichlorofluorescin
diacetate (DCF-DA) which is converted to DCF by intracellular
esterases, for detection of H2O2, or with 5 mM of MitoSOX
TM
Red reagent (Life Technologies, Molecular Probes), which is a
live-cell permeant and is rapidly and selectively targeted to the
mitochondria. Once in the mitochondria, MitoSOXTM Red rea-
gent is oxidized by superoxide and exhibits red fluorescence.
After incubation, cells were washed three times with medium
without serum. To maintain the cells alive during observation
and to create the proper environmental conditions, the specimen
was placed in anOko Lab (Na, Italy)Water Jacket Top Stage In-
cubator, kept at 378C,underhumidifiedconditionof 5%CO2and
95% air by means of temperature controllers, gas mixers and
humidifiers right on the microscope.
Theanalysis of immunofluorescencewasperformedwith a con-
focal laser scanner microscopy Zeiss LSM 510 (Carl Zeiss, Got-
tingen, Germany), equipped with Argon ionic laser whose l was
set at 488 nm, anHeNe laserwhoselwas set at 546 nmand an im-
mersion oil objective 63×/1.4f. Emission of fluorescence was
revealed by BP 505–530 band pass filter for DCF and 560 Long
Pass for MitoSOX Red. Images were acquired in the green or in
the red channels and then saved in TIFF format to prevent the
loss of information. They were acquired with a resolution of
1024 × 1024 pixel with the confocal pinhole set to one Airy unit.
Analysis of data was performed with the ImageJ software,
version 1.37. Fifty random single cells were analyzed for each
imaging analysis.
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Mitotracker immunofluorescence
For the evaluation of mitochondrial activity, MitoTrackerwRed
CMXRos (Molecular Probes)was chosen.MitoTrackerw probes
passivelydiffuse across theplasmamembraneandaccumulate in
actively respiring mitochondria. Thirty-thousand cells were
plated on 24-well plates on 12 mm diameter round glass cover-
slips and then incubated with 150 nM of Mitotracker Red for
30 min. After incubation cells were fixed for 20 min in PBS con-
taining 4% paraformaldehyde (Sigma) and then washed once
with PBS 1×. Nuclei were stained with the DNA intercalant
DRAQ5 (Bio status, Alexis Corporation). Cells were finally
mounted in 50% glycerol in PBS. Immunofluorescence analysis
was performed with a confocal laser scanning microscope LSM
510 (Zeiss, Gottingen, Germany). The lambda of the two HeNe
lasers was set at 546 and at 633 nm. Fluorescence emission was
revealedbyBP560–615bandpassfilter forMitotrackerRedand
by a 615-long pass filter for DRAQ5. Double staining immuno-
fluorescence images were acquired separately in the red and in-
frared channels at a resolution of 1024 × 1024 pixels, with the
confocal pinhole set to one Airy unit, and then saved in TIFF
format. Fifty random single cells were analyzed for each
imaging analysis using the ImageJ version 1.37.
RNA extraction and quantitative real-time PCR
Total RNA from each sample was extracted using TRIzol
reagent (Gibco/BRL Life Technologies, Inc., Gaithersburg,
MD) and was reverse transcribed using the iScript cDNA Syn-
thesis kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Real-time PCR was performed using iQ Supermix SYBR
Green 2× on aBio-Rad iCycler according to themanufacturer’s
protocols. PCR reactions were performed in triplicate. Primer
pairs (MWG Biotech, Ebersberg, Germany) were designed
using the Primer 3 software (http://frodo.wi.mit.edu/primer3)
to obtain amplicons ranging from 100 to 150 base pairs. Expres-
sion valueswere normalized either versus scrambled transfected
cells or versus scrambled transfected euploid cells. ABELSON
and GAPDH housekeeping genes were chosen as reference
genes.
mtDNA quantification
To quantify the mtDNA content, we selected two genes:
D-LOOP as the mitochondrial target and ACTIN as the nuclear
target. Both targets were quantified by qRT–PCR using cDNA
reverse-transcribed fromRNAof threeNRIP1-silenced trisomic
samples and scrambled control. Normalization of gene expres-
sion was obtained using the ABELSON gene as housekeeping.
The ratio between D-LOOP and ACTIN expression under each
condition (NRIP1-silenced or scrambled trisomic cells) was cal-
culated.
Aequorin measurement
A chimeric aequorin targeted to the mitochondria (mtAEQmut)
was used as a probe. For the experiments with mtAEQmut, cells
were incubated with 5 mM coelenterazine (Fluka, 7372) for 1–
2 h in DMEM supplemented with 1% FBS. A coverslip with
transfected cells was placed in a perfused thermostated chamber
located in close proximity to a low-noise photomultiplier with
a built-in amplifier/discriminator. All aequorin measurements
were performed in KRB supplemented with 1 mM CaCl2.
Agonist was added to the same medium as specified in figure
legends. The experiments were terminated by lysing cells with
100 mM digitonin in a hypotonic Ca2+-containing solution
(10 mMCaCl2 in H2O), thus discharging the remaining aequorin
pool. The output of the discriminator was captured by a Thorn
EMI photon-counting board and stored in an IBM-compatible
computer for further analyses. The aequorin luminescence data
were calibratedoffline into [Ca2+] values using a computer algo-
rithm based on the Ca2+ response curve of mutant aequorins.
Immunoblotting
For immunoblotting, cellswere scraped into ice-cold phosphate-
buffered saline and lysed in a modified 10 mM Tris buffer, pH
7.4, containing 150 mM NaCl, 1% Triton X-100, 10% glycerol,
10 mMEDTAandprotease inhibitor cocktail.After 30 minof in-
cubation on ice, the lysates were cleared via centrifugation at
12 000g at 48C for 10 min. Protein concentrations were deter-
mined by the Lowry procedure. Protein extracts (18 mg) were
separated on 4–12% Bis-Tris acrylamide Gel (Life Technolo-
gies, NP0323) and electron-transferred to PVDFor nitrocellulose
membrane according to standardprocedures.Unspecific binding
sites were saturated by incubatingmembranes with TBS-Tween
20 (0.05%) supplemented with 5% non-fat powdered milk for
1 h.Next, themembraneswere incubatedovernightwithprimary
antibodies [GAPDH (Cell Signaling, 2118); LUCIFERASE
(Invitrogen, 356700)] and the detection was assessed by appro-
priate HRP-labeled secondary antibodies [Santa Cruz, sc-2004
(goat anti-rabbit) and sc-2005 (goat anti-mouse)] plus a chemi-
luminescent substrate (ThermoScientific, 34080).Equal loading
of lanes was confirmed by incubation with an anti-GAPDH
antibody.
Luciferase measurements
Cells were seeded on glass coverslips (13 mm in diameter) for
single sample luminescence measurements and allowed to
grow until 50% confluence. The cells were then transfected
with a cytosolic (untargeted) firefly luciferase and a mtLuc
(59,60).
Cell luminescence was measured in the same purpose-built
luminometer used for the aequorin measurements, constantly
perfused with KRB, supplemented with 1 mM CaCl2 and
20 mM luciferin. The light output of a coverslip of infected
cells was in the range of 1000–10 000 counts per second (cps)
versus a background ,10 cps. All compounds employed in
the experiments were tested for non-specific effects on the lumi-
nescence, but none was observed.
Statistics
The ANOVA test, with a Bonferroni post hoc correction in case
of multiple comparisons, was applied to evaluate the statistical
significance of differences measured throughout the datasets
presented. The threshold for statistical significance (P-value)
was set at 0.05.
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SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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Large duplication of the short arm of chromosome 5 is a rare condition normally associated to severe
phenotype anomalies including heart and brain malformations.
We report a prenatal case of a large 5p duplication with sub-telomeric deletion in a foetus with very
mild phenotypic abnormalities. Foetal ultrasonographic examination at 22 weeks of gestation showed
short femur, clubfeet, pielectasy, and facial dysmorphisms.
Chromosome investigations revealed an inverted duplication of the short arm of chromosome 5 from
5p13.1 to 5p15.33 and a 800 kb deletion at 5pter.
The absence of severe anomalies such as cardiac and cerebral defects, observed so far in all large 5p
duplications, and the comparison to previous cases described both in literature and in DECIPHER data-
base suggest that the critical region for the severe phenotype in 5p duplication syndrome might be
smaller than that previously described, excluding half of the 5p13 band. This might help in prenatal
genetic counselling.
 2011 Elsevier Masson SAS. All rights reserved.1. Clinical description
A 26-year-old Caucasianwoman, gravida 3, para 2, at 22weeks of
gestation, was referred to our unit for prenatal diagnosis because of
foetal malformations. The family history of both themother and the
father was unremarkable, and their karyotypes were normal. Foetal
ultrasonographic examination showed intrauterine growth retar-
dation, short femurs (2nd percentile), 3rd grade bilateral clubfoot,
pielectasy, inter-hemispheric cyst and broad anterior fontanelle
(Fig. 1AeC). Foetus biometry was as follows: biparietal diameter,
5.14 cm; occipitofrontal diameter, 6.44 cm; head circumference,
18.15; abdominal circumference, 15.87 cm; and femur length,
2.94 cm. Tridimensional sonography showed facial dysmorphisms
including low-set ears, exophthalmos and a sloping forehead
(Fig. 1D). The association of multiple soft markers suggested the
opportunity for foetal karyotyping; therefore, cordocentesis was
performed. Due to the foetal malformations and preliminary
anomalous results from a BACs-on-Beads assay, the couple decided
to terminate the pregnancy. An autopsy conﬁrmedmild phenotypic: þ39 081 7463656.
on SAS. All rights reserved.abnormalities and facial dysmorphisms. No cardiac or cerebral
defects were observed.
2. Methods of detection
2.1. Cytogenetics and FISH
Chromosomal analysis was performed from foetal blood by stan-
dard G-banding technique at the 400-band level. Fluorescent in situ
hybridisation (FISH) analysis was performed with the commercial
probe LSI D5S23 for the cri-du-chat syndrome critical region 5p15.2
and for whole chromosome 5 (wcp5; Vysis) according to the manu-
facturer’s protocols. The 5p15.33 region was hybridised with the
Bacterial Artiﬁcial Chromosome (BAC) clone RP11-94J21. The BAC
location was mapped according to the UCSC Genome Bioinformatics
group (http://genome.ucsc.edu, GRCh37/hg19 assembly). The BAC
clone was extracted using standard methods [1], labelled by random
priming with CY3-dCTP and hybridised as for the LSI probe. Thirty
metaphases per probe were analysed.
2.2. Array-CGH
The proband’s DNA was isolated using MasterPure DNA Puri-
ﬁcation Kit (EPICENTRE Biotechnologies, USA).
Fig. 1. Ultrasonographic images of the foetus showing clubfeet (A), pielectasy (B) and broad anterior fontanelle (C). Tridimensional sonography shows facial dysmorphisms such as
low-set ears, exophthalmos and sloping forehead (D).
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formed using the oligonucleotide-based CytoChip ISCA 4  44K
BlueGnome (Technogenetics-Bouty, Italy) with a mean 130-kb
resolution according to the manufacturer’s instructions
(http://www.chitochip.com). Fluorescent images were collected
using the Perkin Elmer microarray laser scanner ScanRI. The
hybridisation data were analysed by BlueFuse Multi software V2.2
(BlueGnome, UK). The control genome was that of a standard
female (Promega, USA).
2.3. BACs-on-Beads assay
A BACs-on-Beads assay (BoBs, Perkin Elmer, USA), based on
Luminex xMAP technology (Multi-Analyte Proﬁling beads), was
used as the ﬁrst rapid diagnostic test. Selected BAC probes
are immobilised on colour-coded beads and hybridised to the
proband’s DNA to analyse gains and losses in targeted chromo-
some regions in order to detect (within 48 h) aneuploidies of
chromosomes 13, 18, 21, X and Y, as well as frequently occurring
microdeletion/duplication syndromes including WolfeHirschhorn,
cri-du-chat, WilliamseBeuren, LangereGiedion, PradereWilli,
Angelman, MillereDieker, SmitheMagenis and DiGeorge. One male
and one female control genomes were used as reference samples.
The BoBs assay was performed according to the manufacturer’s
instructions. Data were analysed using BoBsoft software (Perkin
Elmer, USA).
2.4. Chromosomal anomaly
The BoBs assay revealed that the whole cri-du-chat syndrome
region was duplicated (Fig. 2). Eight independent BAC probes wereincluded in the BoBs panel for chromosome 5p, spanning 7.7 Mb,
from 5p15.2 to 5p15.33. The foetal karyotype showed additional
material on the short arm of chromosome 5 (Fig. 3A). Array-CGH
analysis using the oligonucleotide-based CytoChip ISCA 4  44K
BlueGnome (Technogenetics-Bouty, Italy) with a mean 130-kb
resolution, showed a de novo 40.5 Mb duplication of the 5p arm
from 5p13.1 to 5p15.33 (from 943,000 to 41,584,000), with a 5pter
deletion spanning approximately 870 Kb (Fig. 3B). The 5p deleted
region is not represented by any BoBs probe.
2.5. Method of conﬁrmation
The whole chromosome painting for chromosome 5 demon-
strated that the additional material was derived from chromosome
5 only. No additional hybridisation signals were seen on other
chromosomes (Fig. 3C). Dual FISH using both a cri-du-chat unique
sequence mapping to the p15.2 region of chromosome 5 and the
BAC clone mapping to p15.33 demonstrated that the duplication
was inverted (Fig. 3D).
2.6. Causative of the phenotype
Parental chromosomal analysis revealed normal karyotypes
without any chromosomal aberrations. These ﬁndings suggested
that the abnormality detected in the foetus was de novo and
causative of the phenotype.
3. Discussion
We have characterised the ﬁrst prenatal case of inverted
duplication of a large part of the chromosome 5 short arm with
Fig. 2. BACs-on-Beads (BoBs) proﬁle showing a male karyotype with duplication of BAC clones in 5p15 (cri-du-chat CDC probes 1e8). The normal ratio for BoBs probes is
approximately 1.0. The normal ratio range is outlined by the vertical lines from 0.8 to 1.2. In this case, the ratios for all 5p probes higher than 1.2, compared both to normal females
(red dots) and to normal males (blue dots), demonstrate a duplication of all tested 5p regions.
A. Izzo et al. / European Journal of Medical Genetics 55 (2012) 140e144142sub-telomeric deletion, presenting with very mild ultrasono-
graphic anomalies. This rearrangement does not involve other
chromosomes. FISH and aCGH analyses demonstrated that the
duplication, which spans 40.5 Mb from 5p13.1 to 5p15.33, is
inverted and includes the critical region for cri-du-chat syndrome.
The terminal deletion was of approximately 870 kb.
The use of a new xMAP technology, BoBs, allowed us to detect
the chromosome duplication in less than 48 h. This informationFig. 3. A. G-banding karyotype and ideogram of the derived chromosome 5 from foetal
chromosome 5. B. aCGH proﬁle of chromosome 5 showing a de novo 40.5-Mb duplication
41,584,000) and a 5pter deletion spanning approximately 870 kb (red dots on the left side).
painting for chromosome 5 demonstrates that the additional material derives from chromos
ﬂuorescent in situ hybridisation, using both a cri-du-chat unique sequence (Vysis) (green
ﬂuorescent green signals on the abnormal 5p (white arrow) with a double red signal in bewas helpful to the couple that had to decide what to do about the
pregnancy. The technique is quite powerful in prenatal diagnosis
because of the rapidity by which not only the most frequent
aneuploidies but also frequently occurring micro-deletion/micro-
duplication syndromes can be detected.
Trisomies of the short arm of chromosome 5 are uncommon
abnormalities. Less than 50 subjects with complete or partial
5p duplications have been described so far. For the majority oflymphocytes showing the presence of additional material on the short arm of one
(green line on the right side) of the 5p arm from 5p13.1 to 5p15.33 (from 943,000 to
Control genome was that of a standard female (Promega, USA). C. Whole chromosome
ome 5 only. No additional hybridisation signals are seen on other chromosomes. D. Dual
signal) and the RP11-94J21 BAC clone mapping to 5p15.33 (red signal), shows two
tween, which demonstrates that the duplication is inverted.
Table 1
Comparison of clinical ﬁndings among cases of partial or complete trisomy 5p.
Study Portion of 5p
duplicated
Brain
abnormalities
Facial
dysmorphisms
Clubfeet Congenital
heart defects
Low-set
ears
Enlarged anterior
fontanelle
Present study 5p13.1-p15.33  þ þ  þ þ
Sreekantaiah et al., 1999 [11] 5p14-p15.3  þ    
Grosso et al., 2002 [12] 5p10-pter þ þ   þ þ
Cervera et al., 2005 [13] 5p13.3-p15.3 þ þ   þ þ
Wang et al., 2008 [14] 5p14.3-p15.31  þ    
Loscalzo et al., 2008 [3] 5p11-p13.3 þ þ  þ þ 
Vetro et al., 2008 [4] 5p11-p14.1 þ þ þ þ þ 
Patient 4119 from DECIPHER database 5p12-p15.31  þ  þ  
Patient 1227 from DECIPHER database 5p12-p13.2  þ  þ  
Patient 1 from Yan et al., 2009 [6] 5p13.2 þ þ   þ 
Patient 2 from Yan et al., 2009 [6] 5p13.2  þ   þ 
Patient 3 from Yan et al., 2009 [6] 5p13.2  þ    
Patient 4 from Yan et al., 2009 [6] 5p13.2 þ þ   þ 
Patient 5 from Yan et al., 2009 [6] 5p13.2  þ    
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chromosomal rearrangements or due to chromosome markers.
Various clinical features have been associated with segmental
aneusomy on chromosome 5p [2e4]. Patients with duplications
spanning from 5p13.3 to 5p15.3 showmild and relatively indistinct
phenotypes, including facial dysmorphisms, clubfeet and low-set
ears, while with the occurrence of complete 5p trisomy as well as
duplications of the 5p10-5p13.1 segment, the anomalies are more
severe, including macrocephaly, hydrocephalus, dilated cerebral
ventricles, cardiac defects and other severe clinical features.
In order to establish genotypeephenotype correlations, we
compared the proband’s phenotype with previously reported
phenotypes of inv dup 5p subjects, with or without terminal
deletion (Table 1). We have excluded reciprocal translocations
because the imbalance of different chromosomes could inﬂuence
the phenotype. We have also excluded chromosome markers [5]
because of possible epigenetic silencing of phenotypic traits.
In the present study, the proband, with 5p duplication extend-
ing from 5p13.1 to 5p15.33, shares mild phenotypic features with
smaller duplications starting from 5p14. Unfortunately, some clin-
ical features often found in these patients, such as hypotonia,
speech delay and mental retardation, are not assessable in prenatal
diagnosis.
Severe phenotypic signs that are associated with duplications
involving chromosomal regions from the centromere to 5p13.3,
such as congenital heart defects and brain abnormalities, were not
observed in the present case.
The gene NIPBL, mapping to 5p13.1, was thought to be respon-
sible for heart defects because its haploinsufﬁciency can cause
cardiopathy in Cornelia de Lange type 1 Syndrome [6,7]. Table 1
shows that heart defects are never observed in patients with 5p
duplications spanning from 5pter to the position 41,584,000
including NIPBL gene, while heart defects are present in the patient
referred to as DECIPHER 1227 with a 5p duplication from the
genome positions 36,240,080 to 42,862,390.
Therefore it is possible to hypothesise that NIPBL overexpression
is not responsible for cardiac abnormalities and that the critical
region for heart defects in the 5p13 syndrome is possibly included
within the 1.3 Mb from the centromeric end of the duplication
we have described and the centromeric end of the DECIPHER
1227 duplication from position 41,584,000 to 42,800,000 (Build
NCBI36/hg18). Nine RefSeq genes map to this trait; only 3 of them
are highly expressed in the heart tissue: SEPP1, a selenoprotein
involved in extracellular antioxidant defence; GHR, the growth
hormone receptor; and the OXCT1 gene, which encodes a member
of 3-oxoacid CoA transferase.Inverted duplication with terminal deletion has been hypoth-
esised to arise by different mechanisms, all involving the formation
of a dicentric chromosome that subsequently breaks duringmeiosis
to form a monocentric duplicated and deleted chromosome.
The existence of two different couples in tandemwith low-copy
repeats (LCRs) spanning at least 30 kb, with similarities higher than
95% located close the breakpoint region at 5p15.33, supports the
hypothesis that the mechanism of this inv dup del 5p is likely
consistent with the Non-allelic Homologous Recombination model
[8,9]. As suggested by Gorinati et al. [10], a paracentric micro-
inversion in one parent may be present. The single copy region
predicted by such a model, spanning less than 50 kb between LCRs
in 5p15.33, could not be identiﬁed at the resolution of the aCGH
that we used.
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